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CHAPTEIR 1 
GENERAL INTRODUCTION 
Host defense against bacterial infections 
Antimicrobial defenses in the immunocompetent host 
The host possesses a variety of specific and nonspecific defense mechanisms against 
invasion of potentially pathogenic bacteria (115, 140, 183,206,219-221). The skin and mucosa 
form the first line of defense. The intact skin is not penetrable to most bacteria. The glandular 
secretions contain lactic acid and fatty acids that inhibit bacterial growth. At the mucosal 
level, a variety of physical and biochemical mechanisms prevent colonization of pathogenic 
bacteria. Antibodies found on mucosal surfaces are able to neutralize bacterial toxins and 
prevent attachment of bacteria to the epithelium. In the respiratory tract the movement of 
cilia, coughing and sneezing are important for removing bacteria. In the alimentary tract 
lysozyme containing saliva, low pH of gastric acid, proteolytic enzymes, and movement of 
intestinal contents are important. A low pH and regular voiding prevent the invasion of 
pathogenic bacteria in the urogenital tract as does the microflora resident in the skin, 
alimentary tract and the urogenital tract. In addition, the lysozyme and lactoferrin in tears and 
saliva display antibacterial activity. 
If bacteria succeed in passing the first line of defense, the second line of defense, 
consisting of humoral and cellular defense mechanisms, is needed for elimination of the 
invaders. 
Humoral antimicrobial factors can be either nonspecific (lysozyme, lactoferrin and 
transferrin, complement, fibronectin, interferon, C-reactive protein, and tuftsin) or specific 
(antibodies) (115, 140,206,220,221). Lysozyme and complement are able to kill bacteria. 
Lactoferrin and transferrin bind to iron, thereby depriving bacteria of the iron necessary for 
their growth. Complement, fibronectin, C-reactive protein and antibodies are able to facilitate 
the uptake of bacteria by phagocytic cells (opsonization). 
The cellular defense mechanism against bacteria consists of granulocytes, monocytes and 
macrophages, which take up bacteria and usually will kill them (115,206,220,221). In 
addition, after phagocytosis of bacteria by monocytes or macrophages, bacterial antigens are 
processed and are exhibited on the surface of the cell together with an HLA-class !I molecule, 
and specific T- and B-cells can then be activated. Some bacterial strains are only effectively 
killed by the monocytes or macrophages after these cells have been activated by cytokines 
produced by specific T-cells. 
Antimicrobial defenses in the immunocompromised host 
The antimicrobial defense mechanisms not always act optimally. This decreased defense 
can be caused by several factors. Host defense disorders can be classified as primary 
(congenital) or secondary (acquired) (195). Primary immunodeficiencies are rare and manifest 
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TABLE 1.1 Factors impairing the host defense (195,206) 
catheters, prostheses, foreign bodies 
burns 
protein-calorie malnutrition 
age 
neoplastic diseases 
chemotherapeutic therapy 
irradiation 
immunosuppressive treatment 
splenectomy 
infections (mostly viral) 
some chronic diseases 
stress 
themselves as impaired granulocyte or monocyte function, antibody or complement production 
or cell mediated immunity. Acquired disturbances of the host defense are more common and 
an overview of factors leading to this is given in Table 1.1. Catheters, prostheses, foreign 
bodies and burns disrupt the skin and mucous membrane (195). Protein-calorie malnutrition 
results in damaged skin and mucous membrane barriers with decreased lysozyme 
concentrations and, in addition, T-cell function is also weakened (195,206). In neonates, the 
humoral and cellular host defense mechanisms are immature while, in the elderly, the quality 
of the first line of defense is decreased, the humoral responses are reduced and the T-cell 
function is impaired (195,206). Neoplastic diseases are associated with impaired humoral or 
cellular host defenses. Chemotherapeutic therapy results in leukopenia and deranged T-cell 
and B-cell immune functions while irradiation affects all rapidly proliferating cells, such as 
epithelium cells of the gastro-intestinal tract (195,206). Immunosuppressive treatment 
particularly affects the cellular host defenses: cyclosporin A weakens T-cell function while 
monocyte and granulocyte function may be impaired by glucocorticosteroids (195,206). 
Splenectomy results in a decreased clearance of bacteria from the blood and an impaired 
humoral defense (195,206).lnfections with viruses (e.g. Epstein Barr virus, cytomegalovirus, 
human immunodeficiency virus) or bacteria (e.g. Mycobacterium spp, Brucella spp) 
contribute to suppression of the cellular host defenses (195,206). In addition, some chronic 
diseases such as diabetes mellitus or hepatic cirrhosis are associated with an impaired second 
line of defense (195,206), while stress is also linked with immune dysfunction (195). 
Stimulation of nonspecific antimicrobial defenses 
The rationale for stimulation of nonspecific antimicrobial defenses 
From clinical experience it is known that, in immunocompromised patients severe 
infections frequently occur and are a continuing threat to patients. Antibiotic treatment of 
these infections is not always successful despite the use of new and potent antibiotics 
(8,169, 195). Several factors may contribute to the failure of antibiotic treatment. One factor 
is an impaired host defense system unable to provide adequate support for antibiotic therapy 
(8,169). For the potentiation of treatment of severe infections different approaches are 
available. One method is the intensification of antibiotic treatment by developing new dosing 
regimens or developing rational delivery systems for antibiotics. The use of antibiotic delivery 
systems such as liposomes should result in increased antibiotic concentrations either in the 
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infected tissues or intracellularly in the infected cells and a reduced toxicity of potentially 
toxic antibiotics. 
Another approach for the potentiation of treatment of severe infections is stimulation of 
the nonspecific resistance of the host. Since the mononuclear phagocyte system (MPS) plays 
a major role in the nonspecific host defense against infection, stimulation of the MPS may 
be of great value. It is expected that this not only leads to an increased resistance against 
infections involving the MPS, but also against infections in general. lmmunocompromised 
patients are often leukopenic, resulting in development of septicemia from a local infection 
at an early stage. For these patients maximal blood clearance capacity of the MPS is of great 
importance. Cells of the MPS can be stimulated by immunomodulators. 
Stimulation of nonspecific antimicrobial defenses by immunomodulators 
Irnmunomodulators are agents that can stimulate cells of the immune system. Experi-
mental studies in animals have demonstrated that administration of various immunomodulators 
can enhance the nonspecific resistance against bacterial infections (Table 1.2). In the first 
studies immunomodulators of bacterial origin were used. Since these agents are potent 
inducers of cytokines, more recently these cytokines themselves were investigated for their 
capacity to enhance antibacterial resistance. To this aim models of bacterial, fungal, viral and 
protozoal infections were used. In most cases the percentage survival of infected animals was 
used as parameter for therapeutic efficacy. The immunomodulators were administered in the 
free form, via several routes (subcutaneously, intraperitoneally, intravenously, intranasally). 
Usually a single dose was given. 
In this thesis the effects of a lipophilic muramyl dipeptide derivative, muramyl tripeptide 
phosphatidylethanolamide (MTPPE), as a representative of immunomodulators of bacterial 
origin, and of interferon--y (IFN-')'), as a representative of cytokines, are investigated. It is 
known that these agents have the capacity to stimulate the cells of the MPS to tumorcytotoxic 
activity (95, 196,202). In clinical studies MTPPE and IFN--y are at present under investigation 
in cancer patients with respect to their capacity to stimulate the nonspecific resistance in the 
removal of metastases (56,70,125). 
The basic molecule ofMTPPE is muramyl dipeptide, which is part of the peptidoglycan 
of the cell wall of bacteria and is the minimum active compound in Freund's complete 
adjuvant. It can be synthetically produced and modifications can be made to reduce toxic side 
effects (53). Muramyl dipeptide and its derivatives have many effects on macrophages in 
terms of morphological and biochemical changes, enzyme and monokine production and 
macrophage-mediated tumorcytotoxicity ( 61,65, 134, 172, 181). In addition, it has been shown 
that treatment of animals with muramyl peptides led to resistance against infections with 
intracellular as well as extracellular micro-organisms. Exposure of macrophages to muramyl 
peptides in vitro results in killing of intracellular micro-organisms. A summary of the studies 
of the antimicrobial resistance enhancing effects of muramyl peptides in vivo, in the 
immunocompetent and immunocompromised host, as well as in vitro is given in Table 1.3. 
IFN--y is a cytokine produced by activated T -lymphocytes which exerts a broad spectrum 
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TABLE 1.2 Immunomodulators with antimicrobial resistance enhancing properties 
Immunornodulator Micro-organism References 
bacterial origin 
lipopolysaccharide Candida albicans 212b 
Klebsiella pneumoniae 72 
lipid X Escherichia coli 79 
monophosphoryl lipid A Staphylococcus epidennidis 23 
trehalose dimycolate Klebsiella pneumoniae 126 
Toxoplasma gondii 121 
Trypanosoma cruzi 121 
muramyl peptides various micro-organisms Table 1.3 
cytokines 
interleukin-1 Candida albicans 16b 
Escherichia coli 38 
Listeria monocytogenes 39,40,93 
Klebsiella pneumoniae !59 
Plasmodium berghei 38 
Pseudomonas aeruginosa 159,207c 
Salmonella typhimurium 139 
Streptococcus pneumoniae 207c 
Toxoplasma gondii 25 
herpes simplex virus 93 
cytomegalovirus 208 
Sendai virus 93 
interleukin-2 Candida albicans 212ab 
Escherichia coli 83 
Listeria monocytogenes 83 
Klebsiella pneumoniae 94 
Mycobacterium avium 91b 
Toxoplasma gondii 190 
herpes simplex virus 214 
interleukin-4 Leishmania major n•b 
Listeria monocytogenes 44ab 
interleukin-6 Listeria monocytogenes 44ab 
colony stimulating factor (CSF) 
G-CSF Candida albicans 131,181"b 
Escherichia coli 131 
Listeria monocytogenes 186 
Pseudomonas aeruginosa 131 
Serratia marcescens 131 
Staphylococcus aureus 13lb,179 
M-CSF Candida albicans 24 
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Immunomodulator Micro-organism 
Histoplasma capsulatum 
Listeria monocytogenes 
Mycobacterium avium 
GM-CSF Candida albicans 
Histoplasma capsulatum 
Mycobacterium lepraemurium 
Pseudomonas aeruginosa 
Salmonella typhimurium 
Staphylococcus aureus 
Streptococcus pneumoniae 
tumor necrosis factor Candida albicans 
Klebsiella pneumoniae 
Legionella pneumophila 
Listeria monocytogenes 
Mycobacterium lepraemurium 
Plasmodium falciparum 
Streptococcus pneumoniae 
Toxoplasma gondii 
Trypanosoma cruzi 
cytomegalovirus 
interferon-a herpes simplex virus 
Toxoplasma gondii 
interferon-£ simian varicella-like virus 
Toxoplasma gondii 
interferon-/' various micro-organisms 
a no antimicrobial resistance enhancing effects are found 
b in vitro studies 
c immunocompromised host 
References 
149 
102 
184a 
133 
149 
43b 
133 
81 
133 
216 
16,100 
88 
14 
44b 
43b 
116 
168 
45 
45,141b 
208 
175 
5ab 
55 
5ab 
Table L4 
of biological activities, such as antiviral activity and action on B-lymphocytes, natural killer 
cells and macrophages (95). IFN-y stimulates macrophages to increase the production of its 
enzymes and monokines, as well as enhancing their tumoricidal activity in vitro as well as 
in vivo (13,95). In addition, it has been shown that in animals treated with IFN-y, a 
resistance against microbial infections was found (87,132). Also after in vitro exposure to 
IFN-y, macrophages show increased microbicidal activity. A summary of the studies of the 
antimicrobial resistance enhancing effects of IFN-'Y in vivo, in the immunocompetent and 
immunocompromised host, as well as in vitro is given in Table 1.4. Most studies were in 
vitro studies, performed in monolayers or suspensions of macrophages. 
To stimulate the MPS by administration of irnmunomodulators in immunocompromised 
patients who are prone to infections during a prolonged period of time, repeated 
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administration of these agents is anticipated. This may result in toxic side effects 
(18,55,117,188). To reduce the toxicity of these immunomodulating agents a less toxic 
formulation of these agents, such as encapsulation in liposomes, may be of importance. It is 
clearly demonstrated that conventional liposomes are taken up preferentially by the cells of 
the MPS. These liposomes can therefore be used in targeting immunomodulators to stimulate 
the MPS (162). 
Liposornes as carriers of irnrnunornodulators 
Why /iposomes? 
Liposomes are microscopic vesicles consisting of one or more lipid bilayers surrounding 
an internal aqueous compartment (Figure 1.1). A variety of agents can be entrapped in 
liposomes, hydrophobic agents in the lipid bilayers and hydrophilic agents in the inner 
aqueous space. Depending on the method of production, liposomes can vary widely in size 
and in number of lamellae (unilamellar or multilamellar vesicles) and in their physicochemical 
characteristics. A vast body of literature is available describing the different physicochemical 
and biopharmaceutical aspects of these vesicular structures (63,99,123,200,215). The 
pharmacokinetics of liposomes in animals has gained extensive attention. Liposomes are quite 
similar to natural membranes and, as a result, they can be safely administered and are 
biodegradable. Data in humans are now rapidly becoming available. Central to any 
therapeutic use is the pattern of biodistribution of the liposomes after intravenous 
administration, and the ability to manipulate this biodistribution in order to target the 
liposomes selectively. The disposition of liposomes after parenteral administration strongly 
FIGURE 1.1 A liposome (multilamellar vesicle) (82) 
14 
o Water :.oluble molecules I Lipid soluble molecules 
YWaler :.oluble molecul.es with hydrophobic moiety penetrating lipid pl1ase 
TABLE 1.3 Micro-organisms studied with respect to the antimicrobial resistance enhancing effects of muramyl peptide derivatives 
Micro~organism 
in vivo studies 
Candida albicans 
Escherichia coli 
Klebsiella pneumoniae 
Listeria monocytogenes 
Mycobacten·um leprae 
Naegleria fowleri 
Pseudomonas aeruginosa 
Salmonella enteritidis 
Stapylococcus aureus 
Trypanozoma cruzi 
Toxoplasma gondii 
Friend leukemia virus 
herpes simplex virus 
influenza A,B 
murine hepatitis virus 
parainfluenza 
Rift Valley fever virus 
in vitro studies 
Listeria monocytogenes 
human immunodeficiency virus 
Muramyl peptide derivative 
MDP, abuMDP, MTPPE 
MDP, L18-MDP,MDP-Lys(Ll8) 
L18-MDP 
MDP, LI8-MDP, 
murabutide, MDP-Lys(Ll8) 
MDP 
MDP, murabutide, MDP-Lys(L18) 
MDP 
MDP 
MDP 
MDP, norMDP, abuMDP 
MDP 
MDP 
MDP, norMDP, abuMDP, 
MDP-Lys(Ll8), L18MDP 
MDP, MDP-Lys(LI8) 
MDP, MDP-Lys(Ll8) 
Ll8MDP 
MDP 
MDP 
MDP, MTPPE 
MDP, MTPPE 
MDP, MTPPE, murabutide 
MDP, murametide 
MDP, MTPPE 
MDP, MTPPE 
MDP 
MDP 
a no antimicrobial resistance enhancing effects are found 
Immunocompromising factor 
irradiation or cyclophosphamide 
starvation 
neonatal 
cobra venom factor 
shock due to hypertonic glucose 
cyclophosphamide or hydrocortison 
cortison acetate 
myeloperoxidase deficiency 
References 
51,56 
130,154,158 
155 
29,130, 154",176, 178 
3,26, 158,165, 177 
73,74 
163,167 
33 
4 
75 
2,27,63",67, 154. 
114" 
121 
27,130,154,165 
153,157 
151,158 
152" 
154 
109,121 
121 
51 
51,112 
32,46,51 
128 
51 
51 
84 
129 
depends on their physicochemical characteristics, particularly the size, the bilayer, rigidity and 
the charge ( 63 ,94). 
Conventionalliposomes, when administered intravenously, rapidly accumulate in cells 
of the MPS, primarily those residing in the liver and spleen. These liposomes, therefore, tend 
to have a short half-life in blood (124,200). This natural behaviour of liposomes can be 
exploited in the treatment of infectious diseases in two ways. Firstly, liposomes can be used 
as carriers of antibiotics in treatment of infections involving the MPS. Secondly, since cells 
of the MPS play a major role in the nonspecific host defense against infections in general, 
TABLE 1.4 Microorganisms studied with respect to the antimicrobial resistance enhancing 
effects of interferon-)' 
Micro-organism 
in vivo studies 
Aspergillus fumigatus 
Candida albicans 
Klebsiella pneumoniae 
Listeria monocytogenes 
Mycobacterium tuberculosis 
Salmonella enteritidis 
Salmonella typhimurium 
Staphylococcus aureus 
Trypanosoma cruzi 
herpes simplex virus 
in vitro studies 
Blastomyces dennatitidis 
Candida albicans 
Chlamydia psiuaci 
Coccidioides immitis 
Legionella pneumophila 
Leishmania donovani 
Listeria monocytogenes 
Mycobacterium avium 
Mycobacterium bovis 
Mycobacterium microti 
Mycobacterium tuberculosis 
Pseudomonas aeruginosa 
Staphylococcus aureus 
Toxoplasma gondii 
Trypanosoma cruzi 
Immunocompromising factor 
chronic granulomatous disease 
neonatal 
a no antimicrobial resistance enhancing effects are found 
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references 
11 
104. 
86,87 
108,117,146, 
203.,204. 
31 
106 
77,132 
77,101,204. 
189 
180 
175 
138,142 
16,21 
143 
9,10 
12,98,110,148 
48,90,143 
104,107,170,179 
15. 
64 
107 
48. 
104 
77 
5 
141,142 
liposomes can be used for targeting of immunomodulators, giving an enhancement of 
nonspecific resistance in infections caused by a variety of organisms. Prolongation of the 
circulation time and partial avoidance of liposome uptake by the MPS is important for a wider 
application of liposomes used as carriers of agents required outside the MPS. This can be 
accomplished by manipulation of the liposome size and composition and thereby influencing 
the biodistribution of the liposomes after intravenous administration. 
Liposomes, therefore, seem to be useful as carriers of ~rugs because of their versatility. 
Through variation in size, number of bilayers, lipid composition, charge and surface 
characteristics, the cell specificity and the rate of intracellular degradation of liposomes can 
be manipulated and the therapeutic availability of the encapsulated agent can be increased. 
(8,62,99, 123,200,215) 
Liposomal encapsulation of immunomodu/ators 
The most important goal of liposomal encapsulation of immunomodulators is reduction 
of toxicity and the targeting of these agents to the cells of the MPS in the liver and spleen. 
It has been shown that liposomal encapsulation of MTPPE and IFN--y results in decreased 
TABLE 1.5 Liposome-encapsulated immunomodulators with antimicrobial resistance enhancing 
properties 
Immunomodulator 
LE•-MDP 
LE-abuMDP 
LE-MDP-GDP 
LE-MTPPE 
LE-IFN-6 
LE-IFN-r 
a LE=liposome-encapsulated 
b in vitro studies 
Micro-organism 
Candida albicans 
Listeria monocytogenes 
Rift Valley fever virus 
Candida albicans 
Pseudomonas aeruginosa 
Listeria monocytogenes 
Salmanella spp. 
Streptococcus pneumoniae 
Friend leukemia virus 
influenza virus 
herpes simplex virus 2 
Leishmania donovani 
Rift Valley fever virus 
simian varicella-like virus 
Leishmania donovani 
Toxoplasma gondii 
References 
54 
7b 
111 
54 
54 
171 
171 
97,171 
51 
76b 
51,112 
89 
105 
55 
89 
137 
17 
toxicity (58,90,188). Targeting of MTPPE and IFN--y to cells of the MPS may be 
accomplished by encapsulation in large negatively charged liposomes consisting of multiple 
bilayers ofphosphatidylcholine and phosphatidylserine (162, 199). Until now studies regarding 
the stimulation of the nonspecific resistance against bacterial infections by liposome-
encapsulated immunomodulators are limited (Table 1.5). 
Aim of the study and introduction to experimental work 
From the foregoing section it can be deduced that stimulation of the cells of the MPS 
by MTPPE or IFN--y might be promising in the treatment of infections in the immunocom-
promised host. The aim of this thesis was to obtain insight in the possibilities and 
restrictions of treatment with MTPPE and IFN--y in the free fonn or liposome-
encapsulated form. To this end, different models of infection in mice were used. 
In one experimental model infections were induced with Listeria monocytogenes, a 
bacterium that is rapidly taken up by cells of the MPS, but that can resist intracellular killing 
by escape from the phagosome into the cytoplasm. It was investigated whether the cells of 
the MPS, when stimulated by MTPPE or IFN--y are able to effectively kill L. monocytogenes. 
L. monocyto-genes infection was induced by intravenous (i.v.) inoculation, resulting in uptake 
of all bacteria from the blood, particularly by liver and spleen. Thereafter bacterial numbers 
increased rapidly in both organs, while the blood remained sterile. This increase was followed 
by a decrease at five days after inoculation. Eventually all mice survived. 
In other experimental models infections were induced with Klebsiella pneumoniae, a 
bacterium that, when it is not opsonized by specific antibodies, is poorly taken up by cells 
of the MPS. It is investigated whether in the non-immune host, the cells of the MPS, when 
stimulated by MTPPE, are able to effectively phagocytose K. pneumoniae. When K. 
pneumoniae infection was induced by i.v. inoculation about 80% of the bacteria were cleared 
from the blood by liver and spleen, resulting in death of all mice due to septicemia 
('artificially-induced septicemia'). In a more clinically relevant model of infection K. 
pneumoniae was inoculated intraperitoneally (i.p.). In this model multiplication of bacteria 
i.p. resulted in appearance of bacteria in the blood at regular intervals. Eventually all mice 
died due to septicemia ('naturally-induced septicemia'). 
It is known that genetic factors contribute to the susceptibility of man to infections. In 
this thesis it was investigated whether the difference in susceptibility is a restrictive factor 
in the usefulness of MTPPE and IFN--y to induce resistance against L. monocytogenes 
infection. Mouse strains differing in their innate resistance against L. monocytogenes were 
used. In these mice the different susceptibility is manifested by a different influx of 
leukocytes to the site of infection. The effects of MTPPE and IFN--y on bacterial numbers 
were investigated in relation to the recruitment of leukocytes (Chapters 2 and 3). 
Since in the immunocornprornised host protection against infections is needed for a 
prolonged period of time, it was investigated what the effects were of administration of 
immunomodulators in the less toxic liposome-encapsulated form. In the model of 
artificially-induced K. pneumoniae septicemia the efficacy of a single dose of MTPPE and 
LE-MTPPE was studied in relation to the appearance of bacteria in the blood (Chapter 4). 
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In the model of naturally-induced K. pneumoniae septicemia single dose treatment as well as 
repeated administration of MTPPE and LE-MTPPE were investigated (Chapter 6). 
Particularly in immunocompromised patients, enhancement of nonspecific resistance 
against infections by administration of imrnunomodulators may be of importance. These 
patients are often leukopenic. It was investigated what the relative roles were of the 
recruitment of leukocytes, on the one hand, and the activation of tissue macrophages, 
on the other hand, both of which are induced by LE-MTPPE (Chapter 5). 
To obtain more insight in which tissues and cell types are mainly involved in the by 
LE-MTPPE induced effects, the tissue and cellular distribution of liposomes encapsulating 
MTPPE were investigated (Chapter 7). 
When macrophages in vitro are exposed to both MTPPE and !FN-')' a synergistic effect 
in antibacterial resistance is found. The value of this synergistic effect for treatment of 
infections is questionable since exposure of macrophages to both immunomodulators 
simultaneously after i. v. administration of MTPPE and !FN-')' is expected to be minimal. 
However, this may be realized by administration of the immunomodulators co-encapsulated 
in the same liposome. It was investigated what the therapeutic effects were of MTPPE 
and IFN-I' co-encapsulated in liposomes (Chapter 8). This was studied in the model of L. 
monocytogenes infection. In this model the importance of the immunomodulator to lipid 
ratio on the antibacterial effects of LE-MTPPE and LE-IFN-y was also investigated. 
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CHAPTER2 
EFFECT OF MURAMYL TRIPEPTIDE PHOSPHATIDYL 
ETHANOLAMIDE ON LISTERIA MONOCYTOGENES INFECTION IN 
GENETICALLY RESIST ANT OR SUSCEPTIBLE MICE 
Pernella M.B. Melissen, Wim van Vianen, Monique A.M. Hofkens, and Irma A.J.M. 
Bakker-Woudenberg. 
Immunology and Infectious Diseases 1993: in press. 
Abstract 
The effect of the immunomodulator muramyltripeptide phosphatidylethanolamide 
(MTPPE) on the resistance against Listeria monocytogenes infection was investigated in mice 
which differed in their genetically determined innate resistance against this infection. It was 
shown that administration of MTPPE led to increased antibacterial resistance in terms of 
decreased numbers of bacteria in liver and spleen in so called resistant C57Bl mice but not 
in susceptible CBA mice. The effectiveness of MTPPE appeared to correlate with the 
MTPPE-induced capacity to recruit leukocytes from the bone marrow, since numbers of 
peripheral leukocytes were significantly increased in resistant mice but not in susceptible 
mice. Exposure of macrophages of resistant mice in vitro to MTPPE had no effect on the 
uptake and intracellular growth of L. monocytogenes, suggesting that besides the macrophage 
also other cell types play a role in the MTPPE-increased antibacterial resistance. 
Introduction 
From clinical experience it is well known that antibiotic treatment of severe infections 
especially in immunocompromised patients is not always successful. One of the factors which 
contribute to the lack of success of antibiotic treatment is the failure of the host defense to 
provide adequate support to antibiotic therapy. Administration of agents that stimulate the 
nonspecific antimicrobial resistance might prove beneficial in treatment of infections in the 
immunocompromised host (50, 150, 169). To this aim immunomodulatory agents such as 
muramyl peptides may be useful. 
Muramyl dipeptide (MDP) is the minimal essential structure of the bacterial cell wall 
of Mycobacteria that is required for adjuvant activity of Freund's complete adjuvans (53). 
Muramylpeptides (MDP or analogs) have many effects on macrophages in terms of morpholo-
gical changes (37, 120, 161), biochemical changes (50,217), enzyme production (96,120, 134), 
monokineproduction (30,28, 166) and macrophage-mediated tumoricidal activity (41, 172,174, 
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202). In addition, muramyl peptides are able to stimulate macrophages to an increased 
production of colony stimulating factor resulting in an increase in the number of leukocytes 
in the blood (41 ,158). It is also demonstrated that muramyl peptides administered by various 
routes to animals resulted in enhancement of the nonspecific resistance to infections caused 
by a variety of organisms (158,20,167). However the role of muramyl peptides in resistance 
to infections caused by Listeria monocytogenes is still controversial (27,67,92,154,158,165). 
Resistance to infection with L. monocytogenes in mice is genetically determined 
(127,185,192,198). Some strains of mice for example C57Bl mice are so called resistant to 
L. monocytogenes, whereas other strains among which CBA mice are susceptible. In suscepti-
ble mice the influx of leukocytes to the site of infection is delayed and less as compared to 
the influx in resistant mice (113,192,197,198). In the present study it was investigated 
whether treatment with the lipophilic derivative muramyltripeptide phosphatidylethanolamide 
(MTPPE) could increase the resistance against L. monocytogenes infection and whether the 
effect was related to the genetically determined resistance of the host against this infection. 
Because of the importance of peripheral leukocytes in the innate resistance against L. 
monocyrogenes infection, also the change in the numbers of peripheral leukocytes with time 
due to treatment with MTPPE was studied. 
Materials and methods 
Animals. Specific pathogen free, 11 to 13 weeks old female C57Bl/Ka and male 
CBA/Rij mice were used (ITR!-TNO, Rijswijk, The Netherlands). The experiments with 
animals are approved by the local ethical committee according to the rules regarding the use 
oflaboratory animals on the Erasmus University Rotterdam (1991, protocol no. 117.91.01). 
Reagents. N-acety 1-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-[1 ,2-dipalmitoyl-sn-
glycero-3-(hydroxy-phosphoryloxy)]ethanolamide (MTPPE) was a generous gift of Ciba Geigy 
(Basel, Switzerland). Dipalmitoyl phosphatidylethanolamine (DPPE) was obtained from Sigma 
(StLouis, Missouri, USA). All reagents were dissolved in phosphate-buffered saline (PBS). 
Bacteria. A strain of Listeria monocytogenes type 112 was used. Bacteria were grown 
for 16 hat 37°C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, England) and preserved on 
ice. Directly before the inoculation of mice, the bacteria were washed twice in PBS. The i.v. 
50% lethal dose (LD50) was 2.6xl04 CFU in C57Bl!Ka mice and 5.9xlo3 CFU in CBA/Rij 
mice. 
Experimental irifection caused by L. monocytogenes. Infections were induced by intrave-
nous inoculation of 2xl04 CFU (0. 75xLD50) L. monocytogenes into C57BI mice and 2xl04 
CFU (3.4xLD50) or 4.5xl03 CFU (0. 75xLD50) L. monocytogenes into CBA mice. At 
different intervals after inoculation blood samples were taken from the retroorbital plexus and 
twofold diluted in 3.8% sodium citrate (BDH Chemicals Ltd, Poole, England). Serial!O-fold 
dilutions in PBS were prepared and volumes of 0.2 ml of each dilution were spread on 
tryptone soya agar (TSA) plates (Oxoid Ltd, Basingstoke, England). Mice were then sacri-
ficed and spleen and liver were removed and homogenized in 20 ml of PBS for 30 s at 
10,000 rpm in a VirTis homogenizer (The VirTis Co. Inc., Gardiner, New York). Serial!O-
fold dilutions of homogenate in PBS were prepared. Volumes of 0.2 ml of each dilution and 
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2 ml volumes of the undiluted homogenate were spread on TSA plates. The remainder of the 
homogenate together with an equal volume of double concentrated TSA was poured in plastic 
plates. All plates were incubated for 48 h at 37°C. The number of viable bacteria recovered 
from liver, spleen and blood was used as a parameter of therapeutic efficacy. 
Quantitation of blood leukocytes. Bloodsamples (0.8 ml) were taken from the retroor-
bital plexus and collected in polypropylene tubes containing 1 mg dried EDTA (BDH 
Chemicals Ltd Poole, England). For total leukocyte counts blood was diluted 1:10 with Turk 
solution (0.1% crystal violet in 1% acetic acid) and numbers of leukocytes were determined 
in duplicate in a Bilrkers hemocytometer. The numbers of lymphocytes, granulocytes and 
monocytes were calculated from the total number of leukocytes and differential counts of 500 
leukocytes in cytocentrifuge preparations of buffycoats, obtained by centrifugation of blood 
samples for 30 min at 1500 x gin hematocrit tubes (Tamson B.V., Zoetermeer, The Nether-
lands). 
Mono/ayers of peritoneal macrophages infected with L. monocytogenes. Monolayers of 
3.5x!05 macrophages from CS7Bl mice were cultured at 3rC in chamber-slides (Miles 
laboratories Inc., Naperville, Illinois) in a humidified atmosphere of 7.5% C~ in air in 
culture medium containing Dulbecco modified Eagle medium (D-MEM, Flow Laboratories, 
Irvine, Scotland) with 1% glutamine and 15% fetal bovine serum (PBS, HyClone Laborato-
ries Inc., Logan, Utah, USA) for 48 h before incubation with bacteria. After the first 2 h of 
incubation fresh culture medium was added to the monolayer. The cells were exposed 24 h 
before incubation with bacteria to various non-toxic concentrations of MTPPE or to PBS. At 
zero time bacteria were added in a ratio of 16 bacteria per macrophage. After an uptake 
period of 30 min the noningested bacteria were removed by washing the monolayer three 
times with culture medium. The macrophages were reincubated for 6 h. At different time 
intervals during the period of incubation rnonolayers were washed with icy-cold culture 
medium and the macrophages were disrupted by quickly freezing and thawing and vigorously 
mixing of the cell suspension. This procedure had no effect on the viability of L. monocytoge-
nes. The intracellular numbers of viable bacteria were determined by preparing tenfold serial 
dilutions. Volumes of 0.2 ml of each dilution were spread on TSA plates. All plates were 
incubated for 48 h at 37°C. 
Statistical analysis. Statistical evaluation of differences in numbers of bacteria between 
MTPPE-treated and PBS-treated groups of animals was performed by using the Mann-
Whitney test. The Student-T test was used for evaluation of differences in numbers of 
leukocytes between MTPPE-treated and PBS-treated groups. 
Results 
Effect of dose and administration time of MTPPE on the course of L. monocytogenes 
infection in resistant C57Bl mice. Figure 2.1 shows that after i. v. inoculation of C57BI mice 
with 2xl04 CPU L. monocytogenes (0. 75x LD5o) within I h most bacteria were trapped in 
the liver and spleen. The number of bacteria in the liver and spleen increased until 72 h after 
bacterial inoculation followed by a stability in the liver and a decrease in the spleen. All mice 
survived (Table 1). Administration of 100 p.g MTPPE per mouse (5.2 mg/kg) at 24 h before 
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before bacterial inoculation appeared to be the minimal dose from a 2-fold dose range that 
resulted in a significant decrease in the number of bacteria in liver and spleen at 120 h after 
inocula-tion. At 1, 24, or 72 h after inoculation the number of bacteria was the same in 
MTPPE-treated mice as in control mice. The blood was always sterile. A dose of 50 l'g 
MTPPE per mouse (2.6 mg/kg) resulted in decreased numbers of bacteria in the spleen at 120 
h, but not in the liver. A dose of 25 l'g MTPPE per mouse (1.3 mg/kg) had no effect 
anymore on the numbers of bacteria in both the liver and spleen at 120 h. 
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FIGURE 2.1 Effect of MTPPE on the numbers of L. monocytogenes in liver and spleen of C57Bl 
mice. M-ice infected with 2xi04 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 100 l'g MTPPE per mouse (5.2 mg/kg) (- -), 50 l'g MTPPE (2.6 
mg/kg) (-- -), 25 l'g MTPPE (1.3 mg/kg) (------)or PBS(--). Each point represents the 
geometric mean for six mice. Significance: *p :;;0.05 ***p :;;0.001 versus PBS-treated mice. 
Effect of MTPPE on the number of leukocytes in the blood of resistant C57Bl mice. 
Figure 2.2 shows that in uninfected mice the numbers of total leukocytes fluctuated around 
3700 per mm3 blood. Numbers of monocytes, granulocytes and lymphocytes fluctuated 
around respectively 70, 200, and 3400 per mm3 blood. Administration of 100 l'g MTPPE per 
mouse (5.2 mg/kg), the lowest dose from the 2-fold dose range which was effective in L. 
monocytogenes infection, to uninfected mice at 24 h before zero time resulted in a 3-fold 
increase of monocytes and an almost 2-fold increase of granulocytes as well as lymphocytes. 
In mice infected with L. monocytogenes at zero time the numbers of monocytes, 
granulocytes and lymphocytes were significantly decreased at 48 h after bacterial inoculation 
to 35% of the numbers at 24 h after inoculation, followed by an increase. Pretreatment of 
infected mice with 100 l'g MTPPE per mouse (5.2 mg/kg) at 24 h before bacterial inoculation 
resulted in 3-fold increased numbers of monocytes at 24 h after inoculation, whereas the 
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numbers of granulocytes and lymphocytes remained stable until 24 h after inoculation. At 48 
h after bacterial inoculation numbers of monocytes, granulocytes and lymphocytes were 
significantly decreased to 25%, 50% or 45% respectively of the numbers at 24 h after 
inoculation. Hereafter numbers of monocytes, granulocytes and lymphocytes increased again. 
Effect of MTPPE on the uptake awl intracellular survival of L.monocytogenes in 
macrophages of C57Bl mice in monolayer. In Table 2.2 is shown that exposure of macropha-
ges in monolayer to 4-fold increasing concentrations of MTPPE ranging from 0.4 up to 100 
l'g/ml for 24 h before incubation with L. monocytogenes had no effect on the uptake and 
intracellular survival of the bacteria, except that exposure to 100 l'g MTPPE/ml or 25 l'g 
MTPPE/ml resulted in slightly but significantly increased numbers of intracellular surviving 
bacteria at 4 h after bacterial uptake. 
TABLE 2.1 Effect ofMTPPE treatment on survival of C57Bl mice and CBA mice fromL. monocyto-
genes infection 
Percentage survivalb 
C57Bl CBA CBA 
Treatment3 infected with infected with infected with 
( mg MTPPE/kg) 2.0xl04 CFU 2.0xl04 CFU 4.5xl03 CFU 
5.20 100 0 0 
2.60 100 ND ND 
!.30 100 ND 50 
0.64 ND ND 100 
0.32 ND 0 100 
0.16 ND 0 ND 
0 100 0 100 
a Mice i.v. infected with 2x104 or 4.5x103 CFU L. monocytogenes were i.v. treated with a single 
dose MTPPE from a twofold increasing dose range at 24 h before inoculation. 
b Survival was determined until 6 days after bacterial inoculation. 
Effect of dose awl administration time of MTPPE on the course of L. monocytogenes 
infection in susceptible CBA mice. Figure 2.3 shows that after i. v. inoculation of CBA mice 
with 2x104 CFU L. monocytogenes within l h most bacteria were trapped in the liver and 
spleen. This inoculum was the same inoculum as used in the experiments with resistant C57Bl 
mice (0.75xLD5o), however in susceptible CBA mice this inoculum is equivalent to 
3.4xLDso· Numbers of bacteria increased until the mice died at 96 h after bacterial 
inoculation (Table 2.1). Administration of a dose of 130 l'g MTPPE per mouse (5.2 mg/kg) 
at 24 h before bacterial inoculation resulted in a significant increase in numbers of bacteria 
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FIGURE 2.2 Effect of MTPPE on the numbers of total leukocytes, monocytes, granulocytes and 
lymphocytes in blood of C57Bl mice. Mice infected with 2xl<f CFU L. monocytogenes at zero time 
were treated i.v. at 24 h before bacterial inoculation with 100 llg MTPPE per mouse (5.2 mg/kg) 
(.a.---...,) or PBS (e.---e). Uninfected mice were treated i.v. at 24 h before zero time with 100 JLg 
MTPPE per mouse (5 .2 mg/kg) (1>.- -1>.) or PBS (<>-----<>). Each point represents the mean for six 
mice. Significance: *p s; 0.05 **p ::::;;Q.Ol ***p s; 0.001 versus uninfected PBS-treated mice. 
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TABLE 2.2 Effect of MTPPE on uptake and intracellular survival of L. monocytogenes in peritoneal 
macrophages of C57Bl mice in vitroa 
Concentration Log CFU L. monocytogenes per 106 macrophagesb at times (h) 
MTPPE (!<glml) after U£take of bacteria 
0 1 4 6 
100 5.57±0.03 5.76±0.08 6.18±0.09* 6.52±0.06 
25 5.66±0.04 5.72±0.05 6.28±0.07** 6.56±0.04 
6.2 5.57±0.05 5.56±0.08 5.86±0.10 6.29±0.04 
1.6 5.55±0.06 5.62±0.12 6.09±0.16 6.58±0.04 
0.4 5.50±0.06 5.58±0.12 6.07±0.07 6.41±0.08 
0 5.67±0.08 5.84±0.11 5.96±0.03 6.52±0.11 
a Before incubation with bacteria, macrophages in monolayer culture were exposed 24h to various 
concentrations of MTPPE. 
b Data represent the geometric mean ± SEM for six observations (control) or four observations 
(MTPPE). Significance: *p :s:; 0.05 **p :s:; 0.01 versus control. 
in the liver and spleen at 24 h after bacterial inoculation and in death of all mice at 48 h. 
Only in dead mice L. monocytogenes was recovered from the blood. From the 2-fold dose 
range of MTPPE 8.1 p.g MTPPE per mouse (0.32 mglkg) was the lowest dose that resulted 
in significant increased numbers of bacteria in the liver and spleen at 72 h after bacterial 
inoculation. A dose of 4 p.g MTPPE per mouse (0.16 mglkg) had no effect on the bacterial 
numbers compared to untreated control mice. Administration of MTPPE to susceptible 
BALB/c mice at 24 h before bacterial inoculation also resulted in significant increased 
bacterial numbers in liver and spleen, compared to numbers in untreated mice (data not 
shown). 
Figure 2.4 shows that after i.v. inoculation of CBA mice with 4.5x1o3 CFU L. monocy-
togenes (0.75xLD50) within 1 h most bacteria were trapped in the liver and spleen. Bacterial 
numbers in the liver and spleen increased till 72 h, followed by a decrease. All mice survived 
(Table 2.1). Administration of a dose of 130 p.g MTPPE per mouse (5.2 mglkg) at 24 h 
before bacterial inoculation resulted in a significant increase in numbers of bacteria in the 
liver and spleen at 24 h and 72 h and all mice died at 96 h. Only in dead mice bacteria were 
recovered from the blood. From the 2-fold dose range of MTPPE, 32.5 p.g MTPPE per 
mouse (1.3 mglkg) was the lowest dose that resulted in significant increased numbers of 
bacteria in liver and spleen at 24 h and at 72 h. A dose of 16.2 l'g MTPPE per mouse (0.64 
mglkg) resulted in increased numbers of bacteria at 24 h and 120 h in the liver, but not in 
the spleen. A dose of 8.1 p.g MTPPE per mouse (0.32 mglkg) had no effect anymore on the 
numbers of bacteria both in the liver and spleen at 120 h. 
Effect of DPPE on the course of L.monocytogenes infection in CBA mice. Figure 2.5 
shows that administration of 22 p.g DPPE per mouse (0.9 mg/kg, which is the equimolar a-
mount of 1.3 mg MTPPE/kg) at 24 h before inoculation with 4.5xl03 CFU L. monocytoges 
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FIGURE 2.3 Effect of MTPPE on the numbers of L. monocytogenes in liver and spleen of CBA 
mice. Mice infected with 2xl04 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 130 Mg MTPPE per mouse (5.2 mglkg) (- -), 8 Mg MTPPE per mouse 
(0.32 mg/kg) (- - -), 4 Mg MTPPE per mouse (0. 16 mg/kg)(-- --- -) or PBS (--). Each 
point represents the geometric mean for six mice. If mice died a geometric mean was not calculated. 
Significance: **p:::;O.Ol ***p::;O.OOl versus PBS-treated mice. 
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FIGURE 2.4 Effect of MTPPE on the numbers of L monocytogenes in liver and spleen of CBA 
mice. Mice infected with 4.5x103 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 130 l'g MTPPE per mouse (5.2 mg/kg) (-- -), 325 l'g MTPPE per 
mouse (L3 mg/kg) (- -), 16 l'g MTPPE per mouse (0.64 mg/kg)(--- --), 8 l'g MTPPE per 
mouse (0.32 mg/kg) (-------·--)or PBS (--). Each point represents the geometric mean for six 
mice. If mice died a geometric mean was not calculated. *pS:0.05 **p~O.Ol versus PBS-treated 
mice. 
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FIGURE 2.5 Effect ofDPPE on the numbers of L. monocytogenes in liver and spleen ofCBA mice. 
Mice infected with 4.5xi03 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 22 l'g DPPE per mouse (0.9 mg/kg) (----)or PBS(----). Each point 
represents the geometric mean for six mice. 
(0. 75xLD50) had no effect on the course of infection in the liver and spleen. 
Effect of MTPPE on the number of leukocytes in the blood of susceptible CBA mice. 
Figure 2.6 shows that in uninfected mice the numbers of total leukocytes fluctuated around 
5400 per mm3 blood. The numbers of monocytes, granulocytes and lymphocytes fluctuated 
around 200, 400 and 4800 per mm3 blood, respectively. Administration of 32.5 l'g MTPPE 
per mouse (1.3 mg/kg), the lowest dose from the 2-fold dose range which was effective in 
L. monocytogenes infection, to uninfected mice at 24 h before zero time had no effect on the 
number of leukocytes except from a significant lower number at 48 h after administration. 
In mice infected with 4.5xlo3 CFU L. monocytogenes (0. 75xLD50) at zero time the 
numbers of monocytes, granulocytes and lymphocytes were significantly decreased at 48 h 
after bacterial inoculation to 50% of the numbers at 24 h after inoculation, followed by an 
increase. Pretreatment with 32.5 l'g MTPPE per mouse (1.3 mglkg) at 24 h before bacterial 
inoculation resulted in a significant decrease of monocytes, granulocytes and lymphocytes 
until 50% of the mice died. 
Discussion 
In this study it is shown that administration of MTPPE led to an increased resistance 
against L. monocytogenes infection in C57Bl mice, which are genetically determined resistant 
for L. monocyrogenes. This protective effect appeared to be dependent on the dose of 
administration of MTPPE. An increased resistance against experimental infection by L. 
monocytogenes due to administration of muramyl peptides was also observed by other 
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FIGURE 2.6 Effect of MTPPE on the numbers of total leukocytes, monocytes, granulocytes and 
lymphocytes in blood of CBA mice. Mice infected with 4.5xl03 CFU L. monocytogenes at zero time 
were treated i.v. at 24 h before bacterial inoculation with 32.5 Jlg MTPPE per mouse (1.3 mg/kg) 
(A-----:4. . ) or PBS (e- --e). Uninfected mice were treated i.v. at 24 h before zero time with 32.5 
p.g MTPPE per mouse (1.3 mg/kg) (.o.- -A) or PBS (C>---<:>). Each point represents the mean for 
six mice. If mice died a mean was not calculated. Significance: *p$0.05 **p$0.01 ***p$0.001 
versus uninfected PBS-treated mice. 
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investigators (27,67,158,165). However some studies show that muramyl peptides had no 
effect on the course of L. monoeytogenes infection (63,92,154,164). Exposure of 
macrophages to MTPPE in vitro had no effect on the uptake and intracellular survival of L. 
monoeytogenes. This suggests that other cell types as well as macrophages are involved in 
the MTPPE-induced increased resistance against L. monoeytogenes. With respect to this it 
was observed in uninfected C57Bl mice that administration of MTPPE led to a threefold 
increase in numbers of monocytes and a twofold increase in numbers of granulocytes and 
lymphocytes in the blood. In infected C57Bl mice MTPPE pretreatment resulted in a more 
than threefold increased efflux of monocytes from the blood between 24 h and 48 h after 
bacterial inoculation compared to untreated infected mice which indicates that the MTPPE-
induced increased numbers of monocytes were also responsive. Yamaguchi et al. (218) also 
found that administration of a lipophilic muramyl peptide (MDP-Lys(Ll8)) to resistant mice 
resulted in increased numbers of leukocytes in the blood which was due to increased levels 
of CSF, a lymphokine which enhances the proliferation and differentiation of cells in the bone 
marrow (34). 
It has been shown that in genetically determined resistant mice, such as C57Bl mice 
resistance to L. monocytogenes infection is caused by the Lrr gene whose phenotype is 
manifested by a fast and great influx of monocytes to the site of infection (192,197,202) 
within 48 h after bacterial inoculation. Mice which are genetically determined susceptible 
such as CBA mice possess the Lrs gene and the influx of monocytes to the site of infection 
is delayed and less. In this study it is observed that administration of MTPPE to susceptible 
CBA mice infected with the same inoculum of L. monocytogenes as was used in resistant 
C57Bl mice did not result in an increased resistance against L. monocytogenes infection, 
however even resulted in a decreased resistance. Lowering the bacterial inoculum for 
susceptible CBA mice to an inoculum at the same ratio to LD50 (0. 75xLD5o) as used in 
resistant C57Bl mice did not change the effects of MTPPE in susceptible CBA mice. 
Regarding the observations on the effect of muramyl peptides in experimental L. monoeytoge-
nes infection in various mouse strains there is considerable discrepancy. Humphres et al. (92) 
demonstrated the ineffectiveness of MDP on L. monoeytogenes infection in susceptible CBA 
mice but he also found that administration of MDP had no effect on L. monoeytogenes 
infection in several other mouse strains among which resistant C57Bl mice. Fraser-Smith et 
al. (67) showed an increased survival from L. monoeytogenes infection after treatment with 
several hydrophilic muramyl peptides in susceptible CBA mice but not in ICR-SPF mice 
which are also susceptible for L. monoeytogenes. The MTPPE-induced decreased resistance 
in susceptible CBA mice observed in our study was probably caused by MTP since PE alone 
(DPPE) had no effect on the course of L. monoeyrogenes infection in these mice. In 
uninfected susceptible CBA mice, administration of MTPPE had no effect on the number of 
monocytes, granulocytes and lymphocytes except for a slight but significant lower number 
of monocytes and lymphocytes at 48 h after administration. The observations in resistant 
C57Bl mice and susceptible CBA mice on the effects of MTPPE in terms of resistance against 
L. monoeytogenes infection and the numbers of leukocytes in the blood suggests that the 
effectiveness of MTPPE correlates with the capacity to recruit leukocytes from the bone 
marrow. The observations in resistant C57Bl mice and susceptible CBA mice on the effects 
of MTPPE in terms of resistance against L. monocytogenes infection and the numbers of 
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leukocytes in the blood suggests that the effectiveness of MTPPE correlates with the capacity 
to recruit leukocytes from the bone marrow. Since the number of leukocytes in the blood of 
MTPPE-treated infected mice is a resultant of an increase due to MTPPE treatment and a 
decrease due to migration from the blood to the site of infection, in MTPPE-treated infected 
C57BI mice more leukocytes have migrated to the infected organs than in PBS-treated 
infected mice. The behaviour of leukocyte numbers in the infected organs is now under 
investigation. 
The observation described in this study that the effect of treatment with the immuno-
modulator MTPPE was related to the genetically determined resistance of the host against this 
infection, may be of importance with respect to the treatment of human patients. In man the 
genetically determined resistance against bacterial infections (e.g. Mycobacterium tuberculo-
sis) also may vary individually (22, 193). This effect may depend on which immunomodulator 
is used. Therefore, in future studies the importance of genetically determined resistance of 
the host in treatment with other immunomodulators, besides MTPPE, will be investigated. 
In summary, the protective effect in L. monocytogenes infection by MTPPE is dependent 
on the genetically determined resistance to L. monocytogenes. In resistant C57BI mice, 
administration of MTPPE results in increased resistance, in susceptible CBA mice it leads to 
a decreased resistance. The effectiveness of MTPPE appears to be correlated with the 
MTPPE-induced capacity of mice to recruit leukocytes from the bone marrow. MTPPE can 
not stimulate macrophages in vitro to inhibition of intracellular growth of L. monocytogenes. 
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CHAPTER 3 
EFFECT OF INTERFERON-GAMMA ON LISTERIA MONOCYTOGENES 
INFECTION IN GENETICALLY RESIST ANT OR SUSCEPTIBLE MICE 
Pernella M.B. Melissen, Wim van Vianen, and Irma A.J.M. Bakker-Woudenberg. 
This study is submitted for publication. 
Abstract 
The effect of the immunomodulator interferon--y (IFN--y) on the resistance against 
Listeria monocytogenes infection was investigated in mice which differed in their genetically 
determined innate resistance against this infection. It was shown that administ~ation of IFN-'Y 
led to increased antibacterial resistance in resistant as well as susceptible mice. This seemed 
not to be correlated with the capacity to recruit leukocytes from the bone marrow, since 
numbers of leukocytes were increased in resistant mice but not in susceptible mice. Exposure 
of macrophages of so called resistant C57Bl or susceptible CBA mice in vitro to IFN--y 
resulted in inhibition of intracellular growth of Listeria monocytogenes whereas exposure of 
macrophages of these mouse strains to MTPPE had no effect at all. 
Introduction 
It is well known from clinical experience that antibiotic treatment of severe infections 
especially in immunocompromised patients is not always successful. Several factors may 
contribute to the lack of success of treatment. One factor is the failure of the host defense to 
provide adequate support to antibiotic therapy. Administration of agents that stimulate the 
nonspecific antimicrobial resistance might prove benificial in treatment of infections in the 
immunocompromised host (50,150,169). To this aim immunomodulatory agents such as 
interferon--y may be useful. 
Interferon-gamma (IFN--y) is a lymphokine produced by activated T lymphocytes which 
exerts a broad spectrum of biological activities (95) such as antiviral activity and action on 
B lymphocytes, T lymphocytes, NK cells and macrophages (95). It is demonstrated that 
administration of IFN--y to animals resulted in enhancement of the nonspecific resistance to 
various microbial infections (142) including L. monocytogenes infection (31,108,117,146). 
Resistance to infection with L. monocytogenes in mice is genetically determined 
(127,185,192,198). Some strains of mice for example C57Bl mice are so called resistant to 
L. monocytogenes, whereas other strains among which CBA mice are susceptible. In suscepti-
ble mice the influx of leukocytes to the site of infection is delayed and less as compared to 
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the influx in resistant mice (113,192,197,198). In a previous study we have shown that the 
efficacy of the immunomodulator muramyl tripeptide phosphatidylethanolamide (MTPPE) 
against Listeria monocytogenes depended on the genetically determined innate resistance of 
the host against this L. monocytogenes. To investigate whether this is a general effect of 
immunomodulation, or only restricted to treatment with MTPPE, we have studied the effect 
of IFN-y, a cytokine very important in the innate resistance against L. monocytogenes 
(52, 147). 
Materials and methods 
Animals. Specific pathogen free, 11 to 13 weeks old female C57Bl!Ka and male 
CBA/Rij mice were used (ITRI-TNO, Rijswijk, The Netherlands). 
Reagents. Recombinant rat IFN-'Y with a specific activity of 4.4xl06 U/mg protein was 
kindly provided by Dr. P. van der Meide (!TR!-TNO, Rijswijk, The Netherlands) based on 
collaboration between the two laboratories. IFN-1 was dissolved in phosphate-buffered saline 
(PBS). 
Bacteria. A strain of Listeria monocytogenes type 1/2 was used. Bacteria were grown 
for 16 hat 37"C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, England) and preserved on 
ice. Directly before the inoculation of mice, the bacteria were washed twice in PBS. The 
intravenous 50% lethal dose (LD50) was 2.6xl04 CFU in C57Bl/Ka mice and 5.9xlo3 CFU 
in CBA/Rij mice. 
Experimental infection caused by L. monocytogenes. Infections were induced by 
intravenous inoculation of 2xl04 CFU (0. 75xLD50) L. monocytogenes into C57Bl mice and 
2xl04 CFU (3.4xLD50) L. monocytogenes into CBA mice. At different intervals after 
inoculation bloodsamples were taken from the retroorbital plexus and twofold diluted in 3.8% 
sodium citrate (BDH Chemicals Ltd, Poole, England). Serial 10-fold dilutions in PBS were 
prepared and volumes of 0.2 ml of each dilution were spread on tryptone soya agar (TSA) 
plates (Oxoid Ltd, Basingstoke, England). Mice were then sacrificed and spleen and liver 
were removed and each was homogenized in 20 ml of PBS for 30 sat 10,000 rpm in a VirTis 
homogenizer (The VirTis Co. Inc., Gardiner, New York). Serial 10-fold dilutions of 
homogenate in PBS were prepared. Volumes of 0.2 ml of each dilution and 2 ml volumes of 
the undiluted homogenate were spread on TSA plates. The remainder of the homogenate 
together with an equal volume of double concentrated TSA was poured in plastic plates. All 
plates were incubated for 48 h at 37°C. The number of viable bacteria recovered from liver, 
spleen and blood was used as a parameter of therapeutic efficacy. 
Quantitation of blood leukocytes. Bloodsamples (0.8 ml) were taken from the retroor-
bital plexus and collected in polypropylene tubes containing I mg dried EDTA (BDH 
Chemicals Ltd Poole, England). For total leukocyte counts blood was diluted 1:10 with Tiirk 
solution (0.1% crystal violet in 1% acetic acid) and numbers of leukocytes were determined 
in duplicate in a Biirkers hemocytometer. The numbers of lymphocytes, granulocytes and 
monocytes were calculated from the total number of leukocytes and differential counts of 500 
leukocytes in cytocentrifuge preparations of buffycoats obtained by centrifugation of blood 
samples for 30 min at 1500 x gin hematocrit tubes (Tamson B.V., Zoetermeer, The Nether-
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lands). 
Mono/ayers of peritoneal macrophages infected with L. monocytogenes. Monolayers of 
peritoneal macrophages from C57BI mice were cultured at 37°C in chamber-slides (Miles 
laboratories Inc., Naperville, Illinois) in an humidified atmosphere of 7.5% COz in air in 
culture medium containing Dulbecco modified Eagle medium (D-MEM, Flow Laboratories, 
Irvine, Scotland) with 1% glutamine and 15% fetal bovine serum (FBS, HyCione Laborato-
ries Inc., Logan, Utah, USA) for 48 h before incubation with bacteria. After the first 2 h of 
incubation fresh culture medium was added to the monolayer. The cells were exposed 24 h 
before incubation with bacteria to various concentrations of IFN--y, or to PBS. At zero time 
bacteria were added in a ratio of 16 bacteria per macrophage. After an uptake period of 30 
min the noningested bacteria were removed by washing the monolayer three times with 
culture medium. The macrophages were reincubated for 6 h. At different time intervals 
during the period of incubation monolayers were washed with icy-cold culture medium and 
the macrophages were disrupted by quickly freezing and thawing and vigorously mixing of 
the cell suspension. The intracellular numbers of viable bacteria were determined by prepa-
ring tenfold serial dilutions. Volumes of 0.2 ml of each dilution were spread on TSA plates. 
All plates were incubated for 48 h at 37°C. 
Statistical analysis. Statistical evaluation of differences in numbers of bacteria between 
IFN-y-treated and PBS-treated groups of animals was performed by using the Mann-Whitney 
test. The Student-T test was used for evaluation of differences in numbers of leukocytes 
between IFN-y-treated and PBS-treated groups. 
Results 
Effect of IFN-y on the course of L. monocytogenes infection in resistant C57Bl mice. In 
Figure 3.1 it is shown that administration of 1.25xHfl U IFN-y per mouse (6.4xlo5 U/kg) 
at 24 h before inoculation with 2x!04 CFU L. monocytogenes (0. 75xLD5o) was the minimal 
dose from a 2-fold dose range that resulted in a significant decrease in the number of bacteria 
in liver and spleen at 120 h after bacterial inoculation. All mice survived (Table 3.1). At 1, 
24 or 72 h after inoculation the number of bacteria was the same in IFN-y-treated mice as 
in control mice. The blood was always sterile. A dose of 6.2xl03 U IFN-y per mouse 
(3.2x!05 U/kg) had no effect on the number of bacteria in the liver and spleen at 120 h after 
bacterial inoculation. 
Effect of IFN-y on the number of leukocytes in the blood of resistant C57Bl mice. Figure 
3.2 shows that in uninfected mice the numbers of the total leukocytes fluctuated around 3700 
per mm3 blood. numbers of monocytes, granulocytes and lymphocytes fluctuated sround 
respectively 70, 200 and 3400 per mm3 blood. Administration of 1.25x!04 U IFN-y per 
mouse (6.4x!05 U/kg), the lowest dose from the 2-fold dose range which was effective in L. 
monocytogenes infection, to uninfected mice at 24 h before zero time resulted in a 1.5-fold 
increased number of lymphocytes from 24 h after zero time. Numbers of monocytes and 
granulocytes remained stable with time. 
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FIGURE 3.1 Effect of IFN-y on the numbers of L. monocytogenes in liver and spleen of C57Bl 
mice. Mice infected with 2x104 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 1.2x104 U IFN-y per mouse (6.4x lOS U/kg) (- -), 3.2x103 U IFN-r 
(1.2x105 U/kg)(-- -), or PBS (-- ). Each point represents the geometric mean for six mice. 
If mice died a geometric mean was not calculated. Significance: *p~0.05 **p::;O.Ol versus PBS-
treated mice. 
In mice infected with L. monocytogenes at zero time the numbers of monocytes, 
granulocytes and lymphocytes were significantly decreased at 48 h after bacterial inoculation 
to 35% of the numbers at 24 h after inoculation followed by an increase. Pretreatment of 
infected mice with 1.25x!04 U IFN-y per mouse (6.4x!o5 U/kg) at 24 h before bacterial 
inoculation resulted in 2-fold increased numbers of monocytes at 24 h after inoculation. 
Numbers of granulocytes and lymphocytes were not increased. At 48 h after bacterial 
inoculation numbers of monocytes, granulocytes and lymphocytes were significantly decreased 
to 60%, 75% and 60%, respectively, of the numbers at 24 h after inoculation. From 72 h, 
numbers of monocytes, granulocytes and lymphocytes increased again. 
Effect of IFN-y on the uptake and intracellular survival of L. monocytogenes in macro-
phages of C57Bl mice in monolayer. Table 3.2 shows that exposure of macrophages in 
monolayer to 1000 or 250 U IFN-y/ml for 24 h before incubation with L. monocytogenes 
resulted in significant lower numbers of intracellular surviving bacteria at 4 h and 6 h after 
bacterial uptake. Compared to bacterial numbers directly after phagocytosis, intracellular 
growth was inhibited by IFN-')'. A concentration of 62 U IFN-y/ml had no effect anymore 
on the number of bacteria at 6 h after bacterial uptake. 
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FIGURE 3.2 Effect of IFN-')' on the numbers of total leukocytes, monocytes, granulocytes and 
lymphocytes in blood of C57Bl mice. Mice infected with 2x104 CFU L. monocytogenes at zero time 
were treated i.v. at 24 h before bacterial inoculation with 1.25x104 U IFN-'Y per mouse (6.4xlo5 
U/kg) (A---...6..) or PBS (e------e). Uninfected mice were treated i.v. at 24 h before zero time with 
1.25x!04 U IFN-r per mouse (6.4xio5 U/kg) (A-----.~>) or PBS (o--o). Each point represents the 
mean for six mice. Significance: *p .::;::0.05 **p ~0.01 ***p ~0.001 versus uninfected PBS-treated 
mice. 
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TABLE 3.1 Effect of IFN-r treatment on survival of C57Bl mice and CBA mice from L. monocyto-
genes infection 
Treatment" 
(U IFN--y/kg) 
6.4x105 
3.2x105 
2.0x!04 
l.Ox104 
0 
Percentage survivalb 
C57Bl CBA 
infected with infected with 
2x104 CFU 2x104 CFU 
100 100 
100 ND 
ND 100 
ND 0 
100 0 
a Mice i.v. infected with 2x104 or 4.2x103 CFU L. monocytogenes were treated with a single dose 
MTPPE from a twofold increasing dose range at 24 h before inoculation. 
b Survival was determined until 6 days after inoculation. 
TABLE 3.2 Effect of IFN-r on uptake and intracellular survival of L. monocytogenes in peritoneal 
macrophages of C57Bl mice in vitroa 
Concentration log CFU L. monocytogenes per 106 macrophagesb at times (h) after 
of IFN--y (U/ml) uptake of bacteria 
0 4 6 
1000 5.58±0.04 5.52±0.04 5.51±0.09** 6.03±0.03** 
250 5.61±0.04 5.60±0.09 5.44±0.19** 6.13±0.05** 
62 5.60±0.06 5.74±0.04 5.74±0.05** 6.21±0.16 
15 5.55±0.03 5.85±0.04 5.9)±0.06 6.26±0.18 
0 5.67±0.08 5.84±0.11 5.96±0.03 6.52±0.11 
a Before incubation with bacteria, macrophages in monolayer culture were exposed 24 h to various 
concentrations of IFN-")'. 
b Data represent the geometric mean ± SEM for six observations (control) or four observations (IFN-
r). Significance: **p ~ 0.01 versus control. 
Effect of IFN--y on the course of L. monocytogenes infection in susceptible CBA mice. 
As shown in Figure 3.3 administration of 1.6x104 U IFN--y per mouse (6.4xl05 U/kg) at 24 
h before inoculation with 2x104 CFU L. monocytogenes (3.4xLD50) resulted in survival of 
all mice, whereas all control mice died at 96 h (Table 3.1). Only in dead mice bacteria were 
recovered from the blood. From a 2-fold dose range 5.0x102 U per mouse (2.0x1o4 U/kg) 
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was the lowest dose that resulted in survival of all mice and in significant decreased numbers 
of bacteria in liver and spleen at 72 h after bacterial inoculation. A dose of 2.5x!o2 U per 
mouse (I.Ox!04 U/kg) had no effect anymore on bacterial numbers in the liver and spleen 
compared to untreated control mice. 
Effect of IFN--y on the number of leukocytes in the blood of CBA mice. Figure 3.4 shows 
that in uninfected mice the numbers of total leukocytes fluctuated around 5400 per mm3 
blood. The numbers of monocytes, granulocytes and lymphocytes fluctuated around 200, 400 
and 4800 per mm3 blood, respectively. Administration of 5.0xl02 U IFN--y per mouse 
(2.0xl04 U/kg), the lowest dose from the 2-fold dose range which was effective in L. 
monocytogenes infection, to uninfected mice at 24 h before zero time resulted in 1.3 fold-
decreased numbers of granulocytes and lymphocytes at 24 h after zero time. From 48 h after 
zero time numbers of monocytes, granulocytes and lymphocytes remained stable with time, 
except from an significantly higher number of lymphocytes at 72 h after zero time. 
In mice infected with L. monocyrogenes at zero time the numbers of granulocytes were 
3.5-fold increased at 24 h 24 h after inoculation. Numbers of monocytes and lymphocytes 
were 2-fold and 3-fold decreased, respectively. From 48 h numbers of monocytes, granulo-
LIVER SPLEEN 
9 9 
8 8 
7 ~ '.::.:.:-..=~-==-:::=: 7 ~ 
:J 
lL 6 6 u 
Ol 5 5 
.Q 
4 4 
3 3 
2 2 
24 72 120 24 72 120 
Time (h) Time (h) 
FIGURE 3.3 Effect of IFN-')' on the numbers of L. monocytogenes in liver and spleen of CBA mice. 
Mice infected with 2x104 CFU L. monocytogenes at zero time were treated i.v. at 24 h before 
bacterial inoculation with 1.6x104 U IFN--y per mouse (6.4xlo5 U/kg) (- - ), 5.0x102 U IFN--y 
per mouse (2.0xl04 U/kg) (-- -), 2.5x102 U JFN--y per mouse (I.Oxl04 U/kg) (--- - -) or PBS 
(--). Each point represents the geometric mean for six mice. If mice died a geometric mean was 
not calculated. Significance: *p :s;Q.05 **p :s;O.Ol ***p :s;Q.OOl versus PBS-treated mice. 
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FIGURE 3.4 Effect of IFN-r on the numbers of total leukocytes, monocytes, granulocytes and 
lymphocytes in blood of CBA mice. Mice infected with 2.0x104 CFU L. monocytogenes at zero time 
were treated i.v. at 24 h before bacterial inoculation with 5.0x!02 U IFN-r per mouse (2.0xi04 U/kg) 
(A-- -A) or PBS ( ......... --e). Uninfected mice were treated i. v. at 24 h before zero time with 5.0x102 
U IFN., per mouse (2.0x104 U /kg)("- --6) or PBS (0--<l). Each point represents the mean for 
six mice. If mice died a mean was not calculated. Significance: *p.S:0.05 **p.S:O.Ol ***p~O.OOl 
versus uninfected PBS:-treated mice. 
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cytes and lymphocytes decreased further until all mice died. Pretreatment with 5.0x!02 U 
IFN-y per mouse (2.0xl04 U/kg) at 24 h before inoculation resulted in a 3-fold decrease in 
numbers of lymphocytes at 24 h after inoculation. Numbers of monocytes and granulocytes 
were not decreased. At 48 h after bacterial inoculation numbers of monocytes and lymphocy-
tes were significantly decreased to 60% and 30%, respectively of the numbers at 24 h after 
inoculation. From 72 h numbers of monocytes granulocytes and lymphocytes increased. 
Effect of IFN-y on the uptake and intracellular survival of L. monocytogenes in macro-
. phages of CBA mice in monolayer. Table 3.3 shows that exposure of macrophages in 
monolayer to 4-fold increasing concentrations of IFN-y ranging from 1.5 up to 1000 U/ml 
for 24 h before incubation with L. monocytogenes resulted in significant lower numbers of 
intracellular surviving bacteria at 4 h and 6 h after bacterial uptake. 
TABLE 3.3 Effect of IFN-y on uptake and intracellular survival of L. monocytogenes in peritoneal 
macrophages of CBA mice in vitroa 
Concentration log CPU L. monocytogenes per 106 macrophagesb at times (h) after 
of IFN-y (U/ml) uptake of bacteria 
0 I 4 6 
1000 5.95±0.11 5.63±0.06 5.39±0.06* 5.73±0.09* 
250 5.79±0.19 5.60±0.08 5.60±0.03* 5.84±0.04* 
62 5.89±0.16 5.57±0.04 5.39±0.07* 5.88±0.02* 
15 5.80±0.12 5.57±0.04 5.53±0.08 5.85±0.11* 
0 5.73±0.07 5.80±0.09 6.02±0.03 6.51±0.06 
a Before incubation with bacteria, macrophages in monolayer culture were exposed 24 h to various 
concentrations of IFN-')'. 
b Data represent the geometric mean ± SEM for four observations (IFN--y). Significance: *p :::;;: 0.05 
versus control. 
Discussion 
In this study it was shown that administration of IFN-y led to an increased resistance 
against L. monocytogenes infection in C57Bl mice as well as in CBA mice, mice which are 
genetically determined resistant or susceptible for L. monocytogenes, respectively. The 
protective effect appeared to be dependent on the dose of!FN-y administered. These findings 
are in contrast to the effect of administration of the immunomodulator MTPPE which resulted 
in increased resistance in C57Bl mice and a decreased resistance in CBA mice (Chapter 2). 
These observations on IFN-y are in agreement with those of other investigators who have also 
demonstrated an IFN-y-induced increased resistance against L. monocytogenes in various 
resistant mouse strains (31,108,117). However, Van Dissel and others (203) did not find an 
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antibacterial effect of IFN-y on L. monocytogenes infection in resistant C57BI mice or 
susceptible CBA mice. Actually their results are not in discrepancy with our data since in 
their study the effect of administration of IFN-y on numbers of bacteria in liver and spleen 
was only measured at 48 h after bacterial inoculation. In our study IFN-y treatment also did 
not result in decreased numbers of bacteria in liver and spleen at 48 h after bacterial inocula-
tion, however the effects were observed from 120 h after inoculation. Exposure of macropha-
ges to IFN-y in vitro resulted in stimulation of rnacrophages of both mouse strains to inhibit 
the intracellular growth of L. monocytogenes whereas MTPPE had no effect at all. Admini-
stration of IFN-y to uninfected C57Bl mice only led to an increase in the number of lympho-
cytes, not in the number of monocytes and granulocytes. Administration of IFN-y to uninfec-
ted CBA mice had no effect on the number of monocytes, granulocytes and lymphocytes 
except for a slight but significant lower number of granulocytes and a slight but significant 
higher number of lymphocytes at 48 h after administration. The efficacy of IFN-y in terms 
of increasing the resistance against L. monocytogenes infection seems not to be correlated 
with the capacity to recruit leukocytes from the bone marrow. In vitro we observed a growth 
inhibition of L. monocytogenes in macrophages exposed to IFN-')'. These in vivo and in vitro 
data suggest that other cell types besides the macrophage are of minor importance for the 
IFN-')'-induced resistance against L.monocytogenes infection. This is in contrast to the 
MTPPE-induced resistance for which other cell types were shown to be of major importance. 
Susceptible CBA mice seem to be more sensitive to IFN-y treatment than resistant 
CS7Bl mice in vivo as well as in vitro. In vivo in experimental infection in susceptible CBA 
mice the protective effect of IFN-'Y was obtained at a 32-fold lower dose compared to 
resistant C57Bl mice. In in vitro infected macrophages of susceptible CBA mice the effect 
of IFN-y was obtained at a 4-fold lower dose compared to resistant C57Bl mice. A possible 
explanation for this may be that macrophages of susceptible CBA mice are already in a 
primed state and therefore are able to respond more adequately on IFN-y stimulation. 
In summary, the protective effect in L. monocytogenes infection by IFN-7 is not 
dependent on the genetically determined resistance to L. monocytogenes. The effectiveness 
of!FN-y is not correlated with the IFN-y-induced capacity of mice to recruit leukocytes from 
the bone marrow. In addition IFN-y is able to stimulate macrophages in vitro to inhibition 
of intracellular growth of L. monocytogenes. 
42 
CHAPTER4 
FREE VERSUS LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE 
PHOSPHATIDYLETHANOLAMIDE IN TREATMENT OF 
EXPERIMENTAL INFECTION DUE TO KLEBSIELLA PNEUMONIA£ 
Pernella M.B. Melissen, Wim van Vianen, Yvonne Rijsbergen, and Irma A.J.M. Bakker-
Woudenberg. 
Infection and Immunity 1992;60:95-101 
Abstract 
The effect of free and liposome-encapsulated muramyl tripeptide phosphatidylethanol-
amide (MTPPE) on the resistance to Klebsiella pneumoniae infection was investigated in 
mice. It was shown that administration of MTPPE, at 24 h before bacterial inoculation, led 
to a dose-dependent antibacterial resistance in terms of increased clearance of bacteria from 
the blood and bacterial killling in various organs. The lowest effective dose of MTPPE was 
50 l'g per mouse. Administration of liposome-encapsulated MTPPE was also effective at a 
dose of 25 l'g per mouse. The time of administration of both free and liposome-encapsulated 
MTPPE, with respect to the appearance of bacteria in the blood, was very important and 
indicated that repeated administration is necessary to obtain protection for a prolonged period. 
In view of the toxicity of MTPPE it was an important observation that repeated administration 
of MTPPE in the liposome-encapsulated form also produced antibacterial resistance. Admi-
nistration of free and liposome-encapsulated MTPPE resulted in increased numbers of 
granulocytes, monocytes and lymphocytes in the blood of uninfected mice and prevented 
leukopenia in infected mice. 
Introduction 
It is well-known from clinical experience, that antibiotic treatment of severe infections, 
particularly in immunocompromised patients, is not always successful. Several factors may 
contribute to the lack of success of antimicrobial treatment. One factor is the failure of the 
host defense to provide adequate support to antibiotic therapy. Administration of agents that 
stimulate the nonspecific antimicrobial resistance might prove beneficial in treatment of 
infections in the immunocompromised host (50, 150, 169). To this aim the immunomodulating 
agent muramyl tripeptide phosphatidyl-ethanolamide (MTPPE) may be useful. 
MTPPE is a lipophilic derivative of muramyl dipeptide (MDP) which is the minimal 
active structure that can substitute for Mycobacteria in Freund's complete adjuvant (53). 
Muramyl dipeptide derivatives have many effects on macrophages in vitro such as morpholo-
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gical and biochemical changes, production of monokines and enzymes and macrophage-
mediated tumoricidal activity (2,29,120). It has also been demonstrated in animals, that 
muramyl dipeptide derivatives administered by various routes resulted in enhancement of the 
non-specific resistance to infections caused by a variety of organisms (20, 158, !66). 
Since immunocompromised patients are prone to infections during a prolonged period 
of time, it is expected that repeated administration of immunomodulating agents is needed. 
However, repeated administration of MTPPE has been shown to result in toxic side effects 
(18,58,188). Encapsulation ofMTPPE in liposomes may therefore be important since, in this 
form, a reduction in MTPPE toxicity has been found (58,188). The cells of the mononuclear 
phagocyte system (MPS) play a major role in the host defense system against infections, and 
targeting of macrophage modulators such as MTPPE by liposomal encapsulation can be 
effectively accomplished (35, 124). 
The aim of this study was to investigate the effect of MTPPE in the free form and 
liposome-encapsulated form on the clearance of Klebsiella pneumoniae from the blood after 
intravenous inoculation. In addition, the killing of bacteria in liver and spleen, organs rich 
in cells of the MPS, as well as bacterial killing in lung and kidney, organs containing fewer 
of the MPS, was investigated. 
Materials and methods 
Animals. Specific pathogen free, 11 to 13 weeks old female C57Bl!Ka mice were used 
(JTRI-TNO, Rijswijk, The Netherlands). 
Reagents. N-acetyl-muramy 1-L-alan y 1-D-isoglutaminyl-L-alanine-2-[ I, 2-dipalmitoyl-sn-
glycero-3-(hydroxy-phosphoryloxy)]ethanolamide (MTPPE) was kindly provided by Ciba-
Geigy (Basel,Switzerland). Liposomes containing MTPPE and placebo liposomes were a 
generous gift of Ciba-Geigy Ltd. (Basel, Switzerland). Liposomes were prepared from a dry 
Jyophilisate composed of 250 mg phosphatidylcholine and phosphatidylserine in a molar ratio 
of 7:3 (with or without I mg MTPPE) and shaken with 2.5 ml of phosphate buffered saline 
(PBS) (CGP 19835A lipid). The average diameter of the constituted liposomes was between 
2.0 and 3.5 I'm and at least 80% of the liposomes were larger than 1.5 I'm (205). 
Bacteria. A strain of K. pneumoniae capsular serotype 2 (ATCC 43816) was used. 
Bacteria were grown for 16 h at 37'C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, En-
gland) and preserved on ice. Directly before the inoculation of mice the bacteria were washed 
three times in PBS. 
Experimental infection caused by K. pneumoniae. Infections were induced by intrave-
nous inoculation of 103 CFU K. pneumoniae into C57Bl/Ka mice. At different intervals after 
inoculation blood samples were taken from the retroorbital plexus and twofold diluted in 
3.8% sodium citrate (BDH Chemicals Ltd, Poole, England). Serial tenfold dilutions were 
prepared and volumes of 0.2 ml of each dilution were spread on tryptone soya agar (TSA) 
plates (Oxoid Ltd, Basingstoke, England). Mice were then sacrificed and spleen, lungs, 
kidneys and liver were removed and homogenized in 20 ml of PBS for 30 s at 10,000 rpm 
in a VirTis homogenizer (The VirTis Co. Inc. Gardiner, New York). Serial!O-fold dilutions 
of homogenate in PBS were prepared. Volumes of 0.2 ml of each dilution and 2 ml volumes 
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of the undiluted homogenate, were spread on TSA plates. The remainder of the homogenate 
together with an equal volume of double concentrated TSA, was poured in plastic plates. All 
plates were incubated overnight at 26°C. The number of viable bacteria recovered from liver, 
spleen, lungs, kidneys and blood was used as a parameter for therapeutic efficacy. 
Quantitation of blood leukocytes. Blood samples (0.8 ml) were taken from the retroorbi-
tal plexus and collected in polypropylene tubes containing I mg dried EDTA (BDH Chemicals 
Ltd, Poole, England). For total leukocyte counts, blood was diluted 1:10 with Turk solution 
(0.1% crystal violet in I% acetic acid) and the number of leukocytes was determined in 
duplicate in a Blirkers hemocytometer. The numbers of lymphocytes, granulocytes and 
monocytes were calculated from the total number of leukocytes and the differential counts of 
500 leukocytes in cytocentrifuge preparations of buffycoats obtained by centrifugation of 
blood samples for 30 min at 1500 x gin hematocrit tubes (Tamson B.V., Zoetermeer, The 
Netherlands). 
Statistical analysis. Statistical evaluation of the differences in numbers of bacteria 
between MTPPE, liposome-encapsulated MTPPE-treated and PBS-treated groups of animals 
was performed by using the Mann-Whitney test. The Student-T test was used for the evaluati-
on of differences in numbers of leukocytes between test groups (MTPPE-treated or liposome-
encapsulated MTPPE-treated) and control (PBS-treated) groups in uninfected and infected 
animals. Differences in percentage survival were evaluated by using the Fisher-exact test. 
Results 
Effect of MTPPE on the course of K. pneumoniae infection. After i. v. inoculation of 
mice with 103 CFU K. pneumoniae most bacteria were trapped in the liver and spleen within 
1 h. Thereafter, the number of bacteria in liver and blood increased until the mice died at 72 
h after bacterial inoculation (Figure 4.1 and Table 4.1). Similar data were obtained in spleen, 
lung and kidney (data not shown). Administration of 50 l'g MTPPE per mouse at 24 h before 
bacterial inoculation appeared to be the minimal dose, from a twofold dose range, that 
resulted in significantly decreased numbers of bacteria in the organs from 24 h until 96 h 
after bacterial inoculation and also the survival of all mice. In these mice, the blood was 
sterile from 48 h after bacterial inoculation. A twofold lower dose of 25 l'g MTPPE per mou-
se also resulted in decreased numbers of bacteria in the organs at 24 h and at 48 h after 
bacterial inoculation however, only 50% of the mice survived. 
Effect of time of administration of MTPPE on the course of K. pneumoniae infection. 
Administration of 50 l'g MTPPE per mouse at 48 h before inoculation resulted in significantly 
decreased numbers of bacteria in liver and blood at 24 h and 48 h after bacterial inoculation 
(Figure 4.2). Thereafter, numbers of bacteria increased and all mice died (Table 4.1). Similar 
data were obtained in spleen, lung and kidney (data not shown). Administration of 50 l'g 
MTPPE per mouse at 1 h after bacterial inoculation also resulted in a significant lower 
number of bacteria in the organs and blood at 48 h after inoculation and with 50% of the 
mice surviving. Administration of 50 l'g MTPPE per mouse at 6 h after bacterial inoculation 
was not effective, the numbers of bacteria in the organs and blood being similar to those 
found in the untreated controls and all of the mice died. 
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FIGURE 4.1 Effect of MTPPE on the numbers of K. pneumoniae in liver and blood of mice. Mice 
i.v. infected with 103 CFU K. pneumoniae at zero time were treated i.v. at 24 h before bacterial 
inoculation with 50 ~g MTPPE per mouse (- -), 25 ~g MTPPE (-- -) or PBS ( --). 
Each point represents the geometric mean for six mice. If mice died a geometric mean was not 
calculated. Significance: *p :5:0.05 **p::::;; 0.01 versus PBS-treated mice. 
TABLE 4.1 Effect of time of administration of 50 J.l-g MTPPE on survival of mice from K. 
pneumoniae infectiona 
No. of surviving mice I no. of mice treated 
Time of administration day 7 day 14 
-48 h 0/6 0/6 
-24 h 6/6 6/6 
+lh 3/6 3/6 
+6 h 0/6 0/6 
control 0/6 0/6 
a Mice i.v. infected with to3 CFU K. pneumoniae at zero time were treated i.v. with 50 p,g MTPPE 
at several times before (-) or after ( +) inoculation. 
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Effect of liposome-encapsulated MTPPE on the course of K. pneumoniae infection. 
Figure 4.3 shows that administration of 25 l'g liposome-encapsulated MTPPE per mouse, at 
24 h before bacterial inoculation, appeared to be the minimal dose, from a twofold dose 
range, that resulted in significantly decreased numbers of bacteria in liver from 24 h until 96 
h after bacterial inoculation. Similar data were obtained for spleen, kidney and lung (data not 
shown). Eventually all mice survived (Table 4.2). The blood was sterile from 72 h after 
bacterial inoculation. A twofold lower dose of 12.5 l'g liposome-encapsulated MTPPE per 
mouse also resulted in decreased numbers of bacteria in the organs at 24 h and 48 h after 
bacterial inoculation however, only 17% of the mice survived. A dose of 6.25 mg placebo 
liposomes (which is equivalent to the amount of lipid in which 25 l'g of MTPPE is encapsula-
ted) had no effect on the course of the K. pneumoniae infection. 
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FIGURE 4.2 Effect of time of administration of MTPPE on the numbers of K. pneumoniae in liver 
and blood of mice. Mice i.v. infected with 103 CFU K. pneumoniae at zero time were treated i.v. 
with 50 J.tg MTPPE per mouse at 48 h before (- - -) or at 24 h before bacterial inoculation 
(- - ), or at I h after (-----) or at 6 h after inoculation ( .. · · · .. ), or with PBS ( ---) 
at 24 h before inoculation. Each point represents the geometric mean for six mice. If mice died a 
geometric mean was not calculated. Significance: *p ::::;;0.05 **p ::::;;0.01 versus PBS-treated mice. 
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FIGURE 4.3 Effect of liposome-encapsulated MTPPE on the numbers of K. pneumoniae in liver 
and blood of mice. Mice i.v. infected with 103 CFU K. pneumoniae at zero time were treated i.v. at 
24 h before bacterial inoculation with 25 J.l.g liposome-encapsulated MTPPE per mouse(--), 12.5 
l'g liposome-encapsulated MTPPE (-·-),placebo liposomes (----)or PBS (--).Each 
point represents the geometric mean for six mice. If mice died a geometric mean was not calculated. 
Significance: *p :s;0.05 **p :s; 0.01 versus PBS-treated mice. 
TABLE 4.2 Effect of time of administration of 25 p.g liposome-encapsulated MTPPE on survival of 
mice from K. pneumoniae infectiona 
No. of surviving mice I no. of mice treated 
Time of administration day 7 day 14 
-48 h 4/6 2/6 
-24 h 6/6 6/6 
+lh 0/6 0/6 
+6 h 0/6 0/6 
control 0/6 0/6 
a Mice i.v. infected with lo3 CFU K. pneumoniae at zero time were treated i.v. with 25 IJ.g 
liposome-encapsulated MTPPE at several times before(-) or after ( +) inoculation. 
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FIGURE 4.4 Effect of time of administration of liposome-encapsulated MTPPE on the numbers of 
K. pneumoniae in liver and blood of mice. Mice i.v. infected with 103 CFU K. pneumoniae at zero 
time were treated i. v. with 25 p,g liposome-encapsulated MTPPE per mouse at 48 h before (---) 
or at 24 h before bacterial inoculation(-- - ), or at 1 h after (---- ·) or at 6 h after inoculation 
( · · · · · · -), or with placebo liposomes (--- -) or with PBS (--) at 24 h before inoculation. Each 
point represents the geometric mean for six mice. If mice died a geometric mean was not calculated. 
Significance: *p ::;;0.05 **p ::;;0.01 versus PBS-treated mice. 
Effect of time of administration of liposome-encapsulated MTPPE on the course of K. 
pneumoniae irifection. When 25 p.g liposome-encapsulated MTPPE per mouse was 
administered at 48 h before inoculation, complete elimination of the bacteria from the organs 
was not found, and only 33% of the mice survived (Table 4.2 and Fig. 4.4). Administration 
of 25 p.g liposome-encapsulated MTPPE per mouse at 1 h or at 6 h after bacterial inoculation 
was not effective. The numbers of bacteria in the organs and blood were similar to or higher 
than those found in the untreated controls and all of the mice died. 
Effect of repeated administration of liposome-encapsulated MTPPE. Table 4.3 shows 
that all mice survived when a single dose of liposome-encapsulated MTPPE was administered 
at 24 h before bacterial inoculation. However, administration at 48 h before inoculation 
resulted in the survival of only 40% of the mice, but was increased to 80% when a second 
dose of liposome-encapsulated MTPPE was given at I h or 24 h after inoculation (ie. 48 h 
or 72 h after the first dose). When the second dose was given at 48 h after inoculation (ie. 
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96 h after the first dose) the survival rate was not increased. A single dose of 25 l'g 
liposome-encapsulated MTPPE administered at I h or at 24 h after inoculation had no 
significant therapeutic effect. 
Effect ofMTPPE and liposome-encapsu/ated MTPPE on the number of leukocytes in the 
blood. Figure 4.5 shows that, in uninfected mice, the number of granulocytes, monocytes and 
lymphocytes was around 200, 70, and 3400 per mm3 blood, respectively. Administration of 
50 l'g MTPPE or 25 p.g liposome-encapsulated MTPPE to uninfected mice at 24 h before 
zero time resulted in a 2.0-fold, 2.3-fold and a 1.5-fold increase in the number of 
granulocytes, monocytes and lymphocytes, respectively, compared to the numbers in 
uninfected PBS-treated mice. The rise in granulocytes and lymphocytes due to liposome-
encapsulated MTPPE was 24 h later compared to that due to MTPPE in the free form. 
Administration of placebo liposomes had no effect on the number of leukocytes. 
Figure 4.6 shows that, in mice infected with K. pneumoniae at zero time, the numbers 
of granulocytes, monocytes and lymphocytes in the blood were decreased to 40% of those in 
uninfected mice at 48 h qfter zero time. In infected mice treated with 50 l'g MTPPE or 25 
p.g liposome-encapsulated MTPPE at 24 h before bacterial inoculation the number of 
leukocytes in the blood did not change with time. Only the numbers of monocytes increased 
10-fold compared to those in infected PBS-treated mice. The numbers of granulocytes and 
lymphocytes remained stable throughout, except for a significant decrease at 1 h after 
bacterial inoculation. Pretreatment with placebo liposomes had no effect on the numbers of 
monocytes, granulocytes and lymphocytes compared to the numbers in infected PBS-treated 
mice. 
TABLE 4.3 Effect of repeated administration of25 f.Lg liposome-encapsulated MTPPE on survival of 
mice from K. pneumoniae infectiona 
No. of surviving mice I no. of mice treated 
Time of administration day 7 day 14 
-24 h 10/10 10/10 *** 
-48 h 6/10 4/10 * 
-48 h, + 1 h 8/10 6/10 ** 
-48 h, +24 h 8/10 8/10 *** 
-48 h, +48 h 4/10 4/10 * 
+lh 0/10 0/10 
+24 h 4/10 2/10 
control 0110 0110 
a Mice i.v. infected with lo3 CFU K. pneumoniae at zero time were treated i.v. with 25 p.g 
liposome-encapsulated MTPPE at several times before(-) and after ( +) inoculation. Significance: 
*p~0.05 **p$0.01 ***p$0.001 versus control mice. 
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FIGURE 4.5 Effect of MTPPE or liposome-encapsulated MTPPE on the numbers of leukocytes in 
blood of uninfected mice. Mice were treated i. v. at 24 h before zero time with 50 JLg MTPPE per 
mouse (----- ), 25 ~g liposome-encapsulated MTPPE (· · · · · ·), placebo liposomes (- ---)or 
PBS ( --- ). Each point represents the mean for six mice. Significance: *p ::;0.05 **p ::;:0.01 
***p ::;0.001 versus uninfected PBS-treated mice. 
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FIGURE 4.6 Effect of MTPPE or liposome-encapsulated MTPPE on the numbers of leukocytes in 
blood of infected mice. Mice i.v. infected with 103 CFU K. pneumoniae at zero time were treated i.v. 
at 24 h before bacterial inoculation with 50 p,g MTPPE per mouse (-- - - - ), 25 Jlg liposome-encap-
sulated MTPPE (·· · · · ···),placebo liposomes (---)or PBS(-- -- ). Uninfected mice were 
treated i.v. at 24 h before zero time with PBS (----- ). Each point represents the mean for six 
mice. If mice died a mean was not calculated. Significance: *p s:;.0.05 **psO.Ol ***p SO.OOl versus 
uninfected PBS-treated mice or +p :;;0.05, + +p :;;O.OI, + + +p :;;0.001 versus infected PBS-treated 
mice. 
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Discussion 
In this study, it was shown that administration of MTPPE led to an increased resistance 
against K. pneumoniae infection in mice in terms of clearance of bacteria from the blood and 
bacterial killing in various organs. This protective effect appeared to be dependent on the 
dose of MTPPE. An increased resistance against experimental infection with K. pneumoniae 
in mice due to administration of MDP or -derivatives was also observed by other investigators 
using either systemic infection or wound infection models with the survival of animals 
(29,75, 165, 177), or the decrease in bacterial numbers in the infected organs (3,75, 178), used 
as parameters for therapeutic efficacy. In addition, our study indicated that the protective ef-
fect of MTPPE was dependent on the time of administration of MTPPE with regards to the 
appearance of bacteria in the blood. Since the immunocompromised host is prone to infections 
during a prolonged period of time, repeated administration of immunomodulating agents is 
needed. It has been shown that repeated administration of MTPPE has toxic side effects 
(18,58, 188), the most prominent of which being vascular lesions due to cellular accumulation. 
These lesions often result in necrotic foci in several organs of rabbits, dogs and guinea pigs 
(18,58,188). Mice, however, could tolerate high doses of MTPPE (58). Schumann et al. 
(188) showed that the highest non-toxic dose of liposome-encapsulated MTPPE was 10-fo1d 
higher as the non-toxic dose of MTPPE in the free form. In addition Fidler et al. (58) found 
that, due to liposomal encapsulation, the same dose of MTPPE was not toxic anymore. 
This study shows that administration of MTPPE in the liposome-encapsulated form also 
led to antibacterial resistance, even at a 2-fold lower dose than MTPPE in the free form. This 
2-fold increased therapeutic efficacy is probably not related to an increased level ofliposome-
encapsulated MTPPE in the the main clearing organ, the liver, because Fogler et al. (66) 
showed that liposomal encapsulation did not result in increased distribution of MTPPE in the 
liver of mice. However, liposomal encapsulation did result in increased levels of MTPPE in 
spleen and lungs (68). An improved therapeutic efficacy due to liposomal encapsulation of 
MTPPE was also observed in experimental infections in mice caused by herpes simplex virus 
(112), influenza virus (76), Rift Valley fever virus and Friend leukemia virus (51). Izbicki 
et al. (97) also found a protective effect of liposome-encapsulated MTPPE against 
Streptococcus pneumoniae infection in pigs, but the effect of free MTPPE was not in-
vestigated. For several hydrophilic MDP-derivatives, it was demonstrated that liposomal 
encapsulation led to a 20- to 1000-fold increase in efficacy in experimental infections or in 
monolayers of infected macrophages (7 ,54,68) as well as in in vivo and in vitro models of 
tumorcytotoxicity ( 41, 172). 
The protective effect of liposome-encapsulated MTPPE observed in our study was also 
dependent on the time of administration with regards to the appearance of bacteria in the 
blood. Administration of liposome-encapsulated MTPPE, as well as MTPPE in the free form, 
at 24 h before bacterial inoculation appeared to be most effective. This is in agreement with 
the findings of Ausobsky et al. (3) who demonstrated that, administration of muramyl 
dipeptide (MDP) at 24 h before inoculation with K. pneumoniae was more effective than 
administration at 2 h, at 4 h or at 6 h after inoculation. Otani et al. (158) also found that the 
highest efficacy of MDP, as well as the lipophilic MDP-derivatives Ll8-MDP and MDP-
Lys(Ll8), was achieved when administered at 24 h before bacterial inoculation. 
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Administration of these agents at the time of bacterial inoculation had no effect anymore. In 
our study, administration of MTPPE at 1 h after bacterial inoculation was effective for only 
part of the animals: 50% of the mice survived. Administration of liposome-encapsulated 
MTPPE at 1 h after bacterial inoculation was not effective. The dose of free MTPPE that was 
effective when administered at 24 h before inoculation, was not effective when given at 48 
h before bacterial inoculation. However, administration of liposome-encapsulated MTPPE at 
48 h before inoculation was still effective for part of the animals, 33% of the mice surviving. 
Probably MTPPE is slowly released from the liposomes and some time is needed to 
appropriately stimulate macrophages. Fogler and others (66) showed that when, encapsulated 
in the same liposomes as were used in our study and i. v. administered to mice, MTPPE did 
not leak out of the liposomes before 4 h after administration and at 24 h after injection only 
part of MTPPE was released from the liposomes. 
Repeated administration of liposome-encapsulated MTPPE in our K. pneumoniae infec-
tion model seems to be only beneficial when the second dose is administered not later than 
72 h after the first dose (given 48 h before bacterial inoculation). When the second dose of 
liposome-encapsulated MTPPE was administered 96 h after the first dose there was no 
increase in the survival rate. This was not due to high numbers of bacteria in the organs and 
blood at the time of administration of the second dose but was probably due to the time 
needed for MTPPE to be released from the liposomes and stimulate macrophages properly. 
Our study shows that administration of MTPPE in the free, or liposome-encapsulated 
form, led to significantly increased numbers of granulocytes, monocytes and lymphocytes in 
the blood. Only at 1 h and 24 h after zero time were the numbers of granulocytes 
significantly decreased. Wachsmuth (213) also found that administration of free MTPPE to 
rabbits resulted in an initial decrease followed by an increase in the numbers of granulocytes 
and lymphocytes in the blood. Yamaguchi et al. (218) also showed this effect in the numbers 
of granulocytes, monocytes and lymphocytes at 24 h after administration of MDP-Lys(L18) 
to mice. The increased numbers of granuluocytes, monocytes and lymphocytes are probably 
due to increased levels of colony stimulating factor (CSF), a lymphokine which enhances the 
proliferation and differentiation of cells in the bone marrow (34). This correlation was 
confirmed by Yamaguchi et al. (218) who found that administration of the lipophilic MDP-
derivative MDP-Lys(Ll8) to mice resulted in increased levels of CSF and increased numbers 
of leukocytes in the blood. The rise in numbers of leukocytes due to administration of lipo-
some-encapsulated MTPPE in our study was later than that observed with MTPPE in the free 
form. This also indicates that it takes time for MTPPE to be released from the liposomes. 
In PBS-treated infected mice a decrease of granulocytes, monocytes and lymphocytes 
in the blood was observed, which was probably due to migration of these cells to the infected 
organs. In infected mice treated with liposome-encapsulated MTPPE or MTPPE in the free 
form, the numbers of granulocytes and lymphocytes were not changed, which probably 
resulted from the increase in numbers due to treatment with MTPPE counteracting the 
decrease in numbers due to migration from the blood to the infected organs. The reason for 
the 10-fold increase in numbers of monocytes found in infected mice treated with free 
MTPPE remains obscure. 
In summary, antibacterial resistance against K. pneumoniae infection in terms of 
clearance of bacteria from the blood as well as bacterial killing in various organs is achieved 
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by administration of free MTPPE. The time of administration in relation to the time of 
appearance of bacteria in the blood is very important indicating that repeated administration 
is necessary to obtain protection for a prolonged period. In view of the reported toxicity of 
free MTPPE it is an important observation that repeated administration of lower doses of 
MTPPE in the liposome-encapsulated form also leads to antibacterial resistance. 
Administration of MTPPE in the free form or in the liposome-encapsulated form results in 
increased numbers of granulocytes, monocytes and lymphocytes in the blood. Future studies 
will elucidate the factors contributing to the MTPPE-induced antibacterial resistance, such as 
the increased numbers of leukocytes recruited from the bone marrow and the stimulation of 
resident macrophages in liver and spleen. 
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CHAPTERS 
ROLES OF PERIPHERAL LEUKOCYTES AND TISSUE 
MACROPHAGES IN ANTIBACTERIAL RESISTANCE INDUCED BY 
FREE OR LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE 
PHOSPHATIDYLETHANOLAMIDE 
Pernella M.B. Melissen, Wim van Vianen, and Irma A.J.M. Bakker-Woudenberg. 
Infection and Immunity 1992;60:4891-7. 
Abstract 
Administration of free muramyl tripeptide phosphatidylethanolamide (MTPPE) or 
liposome-encapsulated MTPPE (LE-MTPPE) in a twofold lower dose at 24 h before bacterial 
inoculation resulted in clearance of intravenously inoculated Klebsiella pneumoniae by tissue 
macrophages, whereas in control mice bacteria were not effectively cleared from the blood. 
In addition, MTPPE and LE-MTPPE led to increased numbers of leukocytes in the blood, 
which could compensate for the leukopenia in mice resulting from infection with K. pneumo-
niae. In an attempt to elucidate the relative contribution of the activation of tissue macropha-
ges and the recruitment of leukocytes to the antibacterial resistance induced by MTPPE and 
LE-MTPPE, mice were infected intraperitoneally with K.pneumoniae. In these MTPPE- and 
LE-MTPPE treated mice, intraperitoneal influx of leukocytes and phagocytic capacity of 
leukocytes were not higher than in untreated control mice. However, MTPPE- and LE-
MTPPE-treated mice survived much longer; eventually 33% of the LE-MTPPE-treated mice 
survived, whereas all untreated control mice died as a result of bacterial septicemia. This 
prevention of early death appeared to be the result of an increased clearance of bacteria from 
the blood by activated tissue macrophages. It was observed that depletion of these tissue 
macrophages in liver and spleen abrogates the effect of LE-MTPPE-treatment, indicating that 
tissue macrophages are of major importance in the by LE-MTPPE induced resistance against 
K. pneumoniae infection. 
Introduction 
Antibiotic therapy of infections, especially in the immunocompromised host, is not 
always effective. The failure of the host immune system to give adequate support to antibiotic 
treatment may contribute to this lack of success (150, 169). In this respect it would be of great 
value to stimulate the non-specific antimicrobial defense system of the host (50,169). 
Stimulation of the non-specific antimicrobial defenses, in particular the cells of the 
mononuclear phagocyte system, can be achieved with various compounds including 
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interferons, colony stimulating factors, bacterial lipopolysaccharides and muramylpeptides. 
Muramyl peptides have been found to be highly active in vitro and in vivo, in terms of 
inducing tumoricidal (172,174,181,196), antiviral (46,97,128,129) and bactericidal (97,136) 
activities. Encapsulation of muramyl peptides in liposomes led to improved therapeutic 
efficacy in in vitro and in vivo models of tumorcytotoxicity (41,172,196) as well as in 
experimental microbial infections in mice (51, 76,112, 136). The precise mechanisms by which 
muramylpeptides exert their protective effect remain incompletely understood. It is shown that 
muramyl peptides have many effects on macrophages in terms of several morphologic and 
biochemical changes, enzyme production and monokine production (19,96,120,134). In 
addition, it is shown that administration of several muramylpeptides, among which muramyl 
tripeptide phosphatidylethanolamide {N -acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-
2-[1 ,2-dipalmitoy 1-sn-gl ycero-3-(hydroxy-phosphoryloxy) ]ethanolamide (MTPPE)}, resulted 
in increased numbers of leukocytes in the blood of uninfected mice (136,213,218) which 
could compensate for the leukopenia in infected mice (97,136). 
The aim of this study was to elucidate the relative contribution of the recruitment of 
blood leukocytes and the activation of tissue macrophages in the antibacterial resistance 
against Klebsiella pneumoniae, effects induced by free MTPPE and liposome-encapsulated 
MTPPE (LE-MTPPE). This question was investigated in mice which were intraperitoneally 
inoculated with K. pneumoniae after treatment with MTPPE or LE-MTPPE. In these infected 
mice, it was possible to discriminate between the roles of recruited blood leukocytes and 
activated tissue macrophages, as numbers and activity of recruited leukocytes now could be 
quantitated. 
Materials and methods 
Animals. Specific pathogen free, 11- to 13-weeks old female C57BL!Ka mice were used 
(ITRI-TNO, Rijswijk, The Netherlands). 
Reagents. MTPPE was kindly provided by Ciba-Geigy Ltd. (Basel, Switzerland). 
Liposomes were prepared from a dry lyophilisate composed of 250 mg phosphatidylcholine 
and phosphatidylserine in a molar ratio of 7:3 with or without I mg MTPPE by shaking with 
2.5 ml of phosphate buffered saline (PBS) (CGP 19835A lipid). All MTPPE was encapsulated 
in the liposomes (205). The average diameter of the constituted liposomes was between 2.0 
and 3.5 I'm and at least 80% of the liposomes were larger than 1.5 I'm (205). Liposome-
encapsulated dichloromethylene diphosphonate (LE-DMP) was a kind gift of Dr N. van 
Rooijen (Free University, Amsterdam, The Netherlands). 
Bacteria. A strain of K. pneumoniae capsular serotype 2 (ATCC 43816) was used. 
Bacteria were grown for 16 h at 37"C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, 
England) and preserved on ice. Directly before the inoculation of mice the bacteria were 
washed three times with PBS. 
Experimental infections caused by K. pneumoniae. Intravenous (i.v.) infections were 
induced by i.v. inoculation of 104 CFU K. pneumoniae into C57BL!Ka mice. At different 
intervals after inoculation, blood samples were taken from the retroorbital plexus and 
collected in polypropylene tubes containing 1 mg dried EDTA (BDH Chemical Ltd, Poole, 
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England). Serial tenfold dilutions were prepared and volumes of 0.2 ml of each dilution were 
spread on tryptone soya agar (TSA) plates (Oxoid Ltd, Basingstoke, England). Then groups 
of six mice per time point were sacrificed. Spleen, lung, kidney and liver were removed and 
each was homogenized in 20 ml of PBS for 30 sat 10,000 rpm in a VirTis homogenizer (The 
VirTis Co Inc Gardiner, New York). Serial 10-fold dilutions of homogenate in PBS were 
prepared. Volumes of 0.2 ml of each dilution and 2 ml volumes of the undiluted homogenate 
were spread on TSA plates. The remainder of the homogenate together with an equal volume 
of2 times concentrated TSA was poured in plastic plates. All plates were incubated at 26°C. 
The number of viable bacteria recovered from liver, spleen, lung, kidney and blood was used 
as a parameter for therapeutic efficacy. 
Intraperitoneal (i.p.) infections were induced by i.p. inoculation of 1o3 CFU K. 
pneumoniae into C57Bl!Ka mice. At different intervals after inoculation blood samples were 
taken from the retroorbital plexus and collected in polypropylene tubes containing 1 mg dried 
EDTA. Serial tenfold dilutions in PBS were prepared and volumes of 0.2 ml of each dilution 
were spread on TSA plates. Then groups of six mice per time point were sacrificed and 4 ml 
of peritoneal cell suspension was collected after i.p. injection of 5 ml PBS containing 10 U 
heparin (Organon Teknika B.V., Boxtel, The Netherlands) per ml. To determine the total 
numbers of peritoneal bacteria, cells were lysed by 10-fold dilution in distilled water, 
followed by 1 min vigorously mixing. Serial 10-fold dilutions of peritoneal cell suspension 
in PBS were prepared. Volumes of 0.2 ml of each dilution was spread on TSA plates. In 
order to quantitate only the intracellular bacteria, peritoneal cells were washed 3 times with 
PBS (10 min at 110 x g). Thereafter cells were lysed and 10-fold dilutions in PBS were 
spread on TSA plates, as described above. 
Treatment of mice. Mice were treated i.v. with 50 J.!g MTPPE in the free form or 25 
J.!g liposome-encapsulated MTPPE (LE-MTPPE) at 24 h before i.v. or i.p. bacterial 
inoculation. These doses appeared most effective in an earlier study in which different doses 
of free and LE-MTPPE were compared in the model of i.v. infection with K. pneumoniae 
(136). 
Quantitation of leukocytes in blood and peritoneal cell suspension. For total leukocyte 
counts blood or peritoneal cell suspension from groups of six mice per time point was diluted 
1:10 with Turk solution (0.1% crystal violet in 1% acetic acid) and numbers of leukocytes 
were determined in duplicate in a Blirkers hemocytometer. The numbers of lymphocytes, 
granulocytes and monocytes were calculated from the total number of leukocytes and 
differential counts of 500 leukocytes in cytocentrifuge preparations ofbuffycoats obtained by 
centrifugation of blood samples for 30 min at 1500 x g in hematocrit tubes (Tamson B.V., 
Zoetermeer, The Netherlands). 
Elimination of spleen and liver macrophages. Intravenous injection of liposome-
encapsulated dichloromethylene diphosphonate (LE-DMP) resulted in depletion of macropha-
ges in spleen and liver of mice within I day after treatment as described by Van Rooijen and 
others (209) From 1 week after injection macrophages reappeared in the liver and spleen 
(210,211). This is confirmed for C57Bl/Ka mice used in this study. In brief, cryostat sections 
of liver and spleen were made at 1 day, 3 days, 5 days, 7 days, and 14 days after i.v. 
injection ofLE-DMP. These sections were stained with monoclonal rat anti-mouse antibodies 
directed to different subsets of macrophages which were kindly provided by Dr P.L. Leenen 
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(Department of Cell Biology II, Erasmus University Rotterdam, The Netherlands). 
Statistical analysis. Statistical evaluation of differences in numbers of bacteria as well 
as numbers of peritoneal leukocytes between MTPPE-treated, LE-MTPPE-treated, PBS-
treated, and empty liposome-treated groups of animals was performed by using the Mann-
Whitney test. Analysis of variance followed by Bonferroni !-test was used for evaluation of 
differences in the numbers ofleukocytes between MTPPE-treated, LE-MTPPE-treated, PBS-
treated and empty liposome-treated groups of uninfected and infected animals. 
Results 
Effects of MTPPE and LE-MTPPE on the course of K. pneumoniae infection. Within 30 
min after i.v. inoculation of K. pneumoniae, 80% of the bacteria were trapped in liver and 
spleen; thereafter, bacterial numbers in liver, spleen, kidney and lung increased until mice 
died at 72 h after bacterial inoculation (Figure 5.1). Although initially 80% of the bacteria 
were cleared from the blood, they were not effectively cleared and bacterial numbers 
increased resulting in death of mice. From a twofold dose range, 50 l'g of MTPPE or 25 l'g 
of LE-MTPPE administered at 24 h before bacterial inoculation, was the minimal effective 
dose resulting in significantly lower bacterial numbers in the organs from 8 h after inoculati-
on, compared with the numbers in control mice and all mice survived (135). Treatment of 
mice with MTPPE or LE-MTPPE also led to significant lower numbers of bacteria in the 
blood from 8 h after bacterial inoculation, compared with numbers in control mice. Empty 
liposomes had no effect on the course of K. pneumoniae infection in the organs and in the 
blood. 
Effects of MTPPE and LE-MTPPE on the number of leukocytes in the blood. Table 5.1 
shows that administration of 50 l'g of MTPPE or 25 l'g of LE-MTPPE at 24 h before 
bacterial inoculation resulted in 1.5-fold-increased numbers of leukocytes in the blood of 
uninfected mice from 24 h (MTPPE) or 48 h (LE-MTPPE) after zero time. In mice i. v. 
infected with K. pneumoniae, treatment with MTPPE or LE-MTPPE led to a slight increase 
in blood leukocyte numbers, whereas in PBS- or empty liposome-treated mice the numbers 
decreased to 40% of the numbers in uninfected mice at 48 h after bacterial inoculation. 
Effects of MTPPE and LE-MTPPE on numbers of peritoneal leukocytes and bacteria 
after an i.p. challenge with K. pneumoniae. Figure 5.2 shows that after i.p. inoculation of 
K. pneumoniae, numbers of leukocytes in the peritoneal cavity sharply increased within 24 
h. Between 24 and 48 h after bacterial inoculation, numbers of peritoneal leukocytes remained 
unchanged. Administration of MTPPE and LE-MTPPE at 24 h before bacterial inoculation 
had no effect on the number of peritoneal leukocytes compared with the numbers in mice 
treated with PBS or empty liposomes, except for a significant higher number of peritoneal 
leukocytes at 24 h after bacterial inoculation in mice treated with MTPPE. There were no 
differences in the relative numbers of peritoneal monocytes, granulocytes or lymphocytes 
between MTPPE- or LE-MTPPE-treated infected mice and infected mice treated with PBS 
or empty liposomes at 48 h after bacterial inoculation, except for a decreased number of 
granulocytes and an increased number of lymphocytes in LE-MTPPE-treated mice (Table 
5.2). 
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FIGURE 5.1 Effects ofMTPPE and LE-MTPPE on the numbers of K. pneumoniae in liver, spleen, 
kidney, lung and blood of mice. Mice i.v. infected with 104 CFU K. pneumoniae at zero time were 
treated i.v. at 24 h before bacterial inoculation with 50 ~g MTPPE (A A), 25 ~g LE-MTPPE 
(I:J..----6), PBS (e.--e) or empty liposomes (o----o). Each point represents the geometric mean 
for six mice. If mice died a geometric mean was not calculated. Significance: *p ::;0.05 or **p S:O.Ol 
versus PBS-treated mice. 
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TABLE 5.1 Effects of MTPPE and liposome-encapsulated MTPPE (LE-MTPPE) on the numbers of 
leukocytes in blood of uninfected and infected mice 
Numbers of leukocytes at times after zero timeb 
Treatmenta I h 24 h 48 h 72h 96h 
Uninfected mice 
MTPPE 3283±370 5100±233* 5866±274** 5366±369** 4616±282 
LE-MTPPE 3482±242 3966±423 5100±194* 5533±145** 4350±111 
PBS 3633±240 3783±164 3466±257 3566±362 3916±314 
EL 3983±380 4383±674 3683±666 3900±176 4400±215 
Infected mice 
MTPPE 3183±135 3048±177 4648±227** 4665±723 3811±234 
LE-MTPPE 2873±101* 3566±341* 4150±790** 3850±337 5200±171 
PBS 3466±98 2503±369 1471 ±314 c -d 
EL 2698±183** 2020±103 1758±178 -c _d 
a Mice (six per group) were treated i.v. at 24 h before zero time with 50 J.l-g MTPPE, 25 p,g LE-
MTPPE, PBS or empty liposomes (EL). 
b At zero time, part of the mice were injected with PBS (uninfected mice) and part of the mice were 
inoculated with 104 CFU K. pneumoniae (infected mice). Significance: *p :::;0.05, **p ::;;Q.Ol 
versus PBS-treated mice. 
c Only part of the mice survived, and a mean was not calculated. 
d All mice died. 
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FIGURE 5.2 Effects of MTPPE and LE-MTPPE on numbers of leukocytes in the peritoneal cavity 
of mice. Mice i.p. infected with 103 CFU K. pneumoniae at zero time were treated i.v. at 24 h before 
bacterial inoculation with 50 l'g MTPPE ( ~ ), 25 l'g LE-MTPPE ( .. ), PBS ( c::J ) 
or empty liposomes { !:·:.:·:·>>) ). Each point represents the geometric mean for six mice ± SEM. If 
mice died a geometric mean was not calculated. Significance: *pS0.05 versus PBS-treated mice. 
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Figure 5.3 shows that after i.p. inoculation of K. pneumoniae, bacterial numbers in the 
peritoneal cavity sharply increased, and between 48 h and 96 h, all PBS-treated mice died. 
Administration of MTPPE and LE-MTPPE at 24 h before bacterial inoculation had no effect 
on the total numbers of bacteria from 1 h until 48 h after inoculation. Thereafter, numbers 
of intraperitoneal bacteria in LE-MTPPE-treated mice were slightly decreased at 72 h and 
increased again until to about 108 CPU per 4 ml washing at 120 h. In the surviving MTPPE-
treated mice (some mice died between 48 h and 72 h) numbers of intraperitoneal bacteria also 
increased until 108 CPU per 4 ml washing at 120 h. In addition, intracellular bacterial 
numbers were not affected (data not shown). However, MTPPE- and LE-MTPPE-treated 
mice survived much longer than did the PBS-treated mice. MTPPE-treated mice died between 
48 and 264 h. After treatment with LE-MTPPE some mice died after 120 h; eventually, 33% 
of the mice survived. 
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FIGURE 5.3 Effects of MTPPE and LE-MTPPE on bacterial numbers in the peritoneal cavity of 
mice. Mice i.p. infected with 103 CFU K. pneumoniae at zero time were treated i.v. at 24 h before 
bacterial inoculation with 50 l'g MTPPE ( ~ ), 25 l'g LE-MTPPE ( - ), PBS ( C=::J ) 
or empty liposomes ( 1:-:-:-:-:1 ). Each point represents the geometric mean for six mice ± SEM. If 
mice died a geometric mean was not calculated. 
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TABLE 5.2 Numbers of total leukocytes and the percentage of monocytes, granulocytes and 
lymphocytes in peritoneal washing at 48 h after bacterial inoculation 
Determination (mean ± SEM) 
Treatment" Totalleukocytesb Monocytes(%) Granulocytes(%) Lymphocytes(%) 
MTPPE 7.48±0.07 42.3±1.5 54.6±1.7 3.2±0.4 
LE-MTPPE 7.47±0.02 45.7±2.3 48.5±2.4** 5.9±0.9** 
PBS 7.23±0.08 39.4±2.5 57.9±2.9 2.7±0.4 
EL 7.13±0.03 39.9±1.8 57.8±2.0 2.3±0.3 
a Mice (six per group) were treated i.v. at 24 h before i.p. inoculation with 103 K. pneumoniae with 
50 Mg MTPPE, 25 Mg LE-MTPPE, PBS or empty liposomes (EL). Significance: **p ,;Q.Ol versus 
PBS-treated mice. 
b Log number of leukocytes in 4 ml peritoneal wash fluid. 
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FIGURE 5.4 Effects of MTPPE and LE-MTPPE on numbers of K. pneumoniae in blood of mice. 
Mice i.p. infected with 103 CFU K. pneumoniae at zero time were treated i.v. at 24 h before bacterial 
inoculation with 50 l'g MTPPE ( ~ ), 25 l'g LE-MTPPE ( - ), PBS ( c:::::::J ) or empty 
liposomes ( 1:·:-:-:·:1). Each point represents the geometric mean for six mice ± SEM. If mice died 
a geometric mean was not calculated. Significance: **p :;;;:0.01 versus PBS-treated mice. 
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Effects of MTPPE and LE-MTPPE on bacterial numbers in the blood after i.p. challenge 
with K. pneumoniae. Figure 5.4 shows that after i.p. inoculation of K. pneumoniae, bacterial 
numbers in the blood sharply increased until all mice died. Administration of MTPPE and 
LE-MTPPE resulted in a slower increase in bacterial numbers in the blood, and in LE-
MTPPE-treated mice, bacterial numbers remained stable from 24 until 96 h after bacterial 
inoculation; thereafter, numbers decreased. In the surviving MTPPE-treated mice bacterial 
numbers in the blood further increased to 2x!05 bacteria per ml blood at 120 h. 
Effect of LE-MTPPE on bacterial numbers in the blood after i.p. challenge with K. 
pneumoniae in mice depleted of tissue macrophages in liver and spleen by LE-DMP. Figure 
5.5 shows that LE-DMP treatment at 48 h before i.p. inoculation with K. pneumoniae 
resulted in a much faster increase in bacterial numbers in the blood, compared with the 
increase in control mice, and mice died between 24 and 48 h after bacterial inoculation. 
When LE-MTPPE was given to LE-DMP-treated mice at 24 h before bacterial inoculation, 
numbers of bacteria in the blood sharply increased in the same way. The numbers of 
leukocytes in the blood of control mice decreased 1.5-fold between I and 24 h after bacterial 
inoculation. After administration of LE-DMP leukocyte numbers in the blood decreased in 
the same way as in control mice. 
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FIGURE 5.5 Effect of liposome-encapsulated MTPPE (LE-MTPPE) on numbers of K. pneumoniae 
in the blood of mice after elimination of tissue macrophages from liver and spleen. Mice were i.v. 
treated with liposome-encapsulated dichloromethylene diphosphonate (LE-DMP) or PBS at 48 h before 
i.p. inoculation with 103 CPU K. pneumoniae. To LE-DMP-treated mice at 24 h before bacterial 
inoculation 25 l'g LE-MTPPE (b--- -A) or PBS (0--- --o) was administered. To PBS-treated mice 
at 24 h before bacterial inoculation 25 )tg LE-MTPPE (~) or PBS (.,....___.,) was administered. 
Each point represents the geometric mean of six mice. Significance: *p:::::; 0.05, **p:::::; 0.01 versus PBS-
treated mice. 
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Discussion 
Increased resistance against experimental K. pneumoniae infection due to treatment with 
muramyl dipeptide (MDP) or derivatives was observed by several investigators 
(3,29,73,35,165,177,178). The precise mechanisms by which muramyl peptides exert their 
protective effects remain incompletely understood. In this study it was observed that in mice 
treated with free MTPPE or liposome-encapsulated MTPPE at a twofold lower dose, the 
clearance of i. v. inoculated K. pneumoniae from the blood by tissue macrophages was 
observed. In control mice, however, bacteria were not effectively cleared from the blood and 
bacterial numbers increased again, resulting in death of mice. This finding is in agreement 
with data of lzbicki et a!. (97) who also found an increased clearance of bacteria from the 
blood of LE-MTPPE-treated minipigs during the first 2 h after i.v. inoculation with 
Streptococcus pneumoniae. In our study differences in clearance of bacteria between mice 
treated with free MTPPE or LE-MTPPE and control mice were at first seen at 8 h after 
bacterial inoculation and from that time also bacteria in the organs were killed. Bacterial 
numbers in blood and organs were positively correlated. This finding is in agreement with 
the study of Polk et a!. (178), who also found this positive correlation between bacterial 
numbers in blood, liver, lungs and spleen in MDP-treated mice intramuscularly inoculated 
with K. pneumoniae. 
Our study also shows that treatment of mice with free MTPPE or LE-MTPPE resulted 
in increased numbers of leukocytes in the blood. This result is in agreement with those of 
other investigators who also found increased numbers of leukocytes in the blood after 
treatment of uninfected rabbits or mice with MTPPE or MDP-Lys(Ll8), respectively 
(213,218). To elucidate the relative contributions of the recruitment of blood leukocytes and 
the activation of tissue macrophages to resistance against K. pneumoniae infection, induced 
by MTPPE and LE-MTPPE, we used mice which were i.p. inoculated with K. pneumoniae. 
In these mice, it was possible to discriminate between both effects of treatment with MTPPE 
or LE-MTPPE, since recruited leukocytes now could be quantitated. It was shown that after 
the i.p. bacterial challenge, numbers of peritoneal leukocytes in MTPPE and LE-MTPPE-
treated mice were not significantly greater than numbers in control mice. These observations 
suggest that the leukocytes recruited by MTPPE and LE-MTPPE do not have increased 
potency to respond to a bacterial challenge. In addition, peritoneal leukocytes did not show 
an enhanced phagocytic capacity. These observations are in agreement with our in vitro data 
showing that exposure of peritoneal macrophages to various concentrations of MTPPE had 
no effect on the uptake or killing of K. pneumoniae (unpublished observations). Ozaki eta!. 
(160) showed that i.v. administration of the lipophilic MDP derivative, MDP-Lys(Ll8), led 
to increased numbers of granulocytes but not of macrophages in bronchoalveolar lavage fluid 
(BAL) of rats, intratracheal inoculated with Pseudomonas aeruginosa. These granulocytes and 
macrophages had an increased phagocytic activity for P. aeruginosa in vitro. Lamont et al 
(119) also found increased numbers of granulocytes around an intramuscular suture, 
impregnated with K. pneumoniae, in mice subcutaneously pretreated with MDP. These 
granulocytes had an increased phagocytic capacity. 
Although in our study, numbers of peritoneal leukocytes and their phagocytic capacities 
did not differ between MTPPE- or LE-MTPPE-treated mice and control mice, LE-MTPPE-
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treated mice survived, whereas only some of the MTPPE-treated mice survived and all 
control mice died. The increased efficacy of LE-MTPPE compared to MTPPE in the free 
form found in the i.p. infection may be explained as follows. After i.p. infection, there is a 
constant influx of bacteria from the peritoneal cavity into the blood. Resident macrophages 
have to be activated for a prolonged period of time, which may be achieved by administration 
of MTPPE in the liposome-encapsulated form. In the i.v. infection, in which the doses of 
MTPPE and LE-MTPPE used appear to be equally effective, bacteria stay in the blood for 
only a short time period and in this case it is not necessary that macrophages be activated for 
a prolonged period of time. The prevention of early death from bacterial septicemia and the 
increased survival time in LE-MTPPE treated and i.p. infected mice appeared to be the result 
of an increased clearance of bacteria from the blood by tissue macrophages following 
treatment with LE-MTPPE. Polk et al. (178) also found lower numbers of bacteria in the 
blood of MOP-treated mice implanted with a K. pneumoniae-infected suture in an extremity 
than in the blood of control mice. When one compares the results of both studies, it must be 
borne in mind that because of regional anatomical differences between the peritoneal cavity 
and the extremities, recruitment of different defence mechanisms may be involved. In 
addition, Polk et al. (178) concluded that because ofMDP-treatment, lymphatic filtration, but 
not the clearance of bacteria from the blood by tissue macrophages, was improved. To obtain 
more insight into the role of the tissue macophages, mice were treated with LE-DMP, an 
agent which caused elimination of macrophages in the liver and the red pulp and of marginal 
zone and metallophylic marophages in the spleen within l day (209). Numbers of peritoneal 
macrophages were not affected after i.v. administration of LE-DMP (210). The first 
macrophages reappeared at 1 week after treatment with LE-DMP. The effect of LE-DMP on 
numbers of granulocytes in liver and spleen was assumed to be very limited, since before 
injection of LE-DMP, there are only few numbers of granulocytes in liver and spleen. In 
addition, numbers of granulocytes in the blood are not changed after injection of LE-DMP 
and therefore it is very likely that an influx of granulocytes in reponse to infection in LE-
DMP-treated mice is not drastically changed. In mice depleted of tissue macrophages in the 
liver and spleen, bacterial numbers in the blood increased rapidly and mice died between 24 
h and 48 h after bacterial inoculation. Administration of LE-MTPPE to these mice had no 
effect anymore on the antibacterial resistance, numbers of bacteria in the blood increased and 
subsequently all mice died. This increased mortality was not due to decreased numbers of 
leukocytes in the blood. These observations clearly show that the tissue macrophages in liver 
and spleen are of major importance in LE-MTPPE induced resistance against K. pneumoniae. 
Whether other cell types are also involved in the induced activation of macrophages remains 
to be elucidated. 
In summary, treatment of mice with MTPPE or LE-MTPPE results in efficient 
clearance and killing of K. pneumoniae in liver, spleen, kidney, and lung. The data suggest 
that increased numbers of leukocytes in the blood due to MTPPE or LE-MTPPE do not 
contribute significantly to this induced antibacterial resistance. However, tissue macrophages 
appear to be of major importance in this phenomenon, since depletion of tissue macrophages 
abrogates the effect of LE-MTPPE treatment. 
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CHAPTER 6 
TREATMENT OF KLEBSIELLA PNEUMONIA£ SEPTICEMIA IN 
NORMAL AND LEUKOPENIC MICE BY LIPOSOME-ENCAPSULATED 
MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMIDE 
Pernella M. B. Melissen, Wim van Vianen, and Irma A. J. M. Bakker-Woudenberg 
This study is submitted for publication. 
Abstract 
The effect of muramyl tripeptide phosphatidylethanolamide (MTPPE), in the free form 
or in the less toxic liposome-encapsulated form (LE-MTPPE), on Klebsiella pneumoniae 
septicemia resulting from intraperitoneal bacterial inoculation was investigated in mice. When 
administering a single dose at 24 h before bacterial inoculation, 50 f'g MTPPE and 25 f'g LE-
MTPPE appeared to be most effective doses from a twofold dose range. The percentage 
survival was 55% and 40%, respectively, whereas all control mice died. The efficacy of 
repeated administration of LE-MTPPE at various intervals was investigated. After administra-
tion of additional therapeutic doses the percentage survival did not exceed 40%. An increased 
percentage survival was obtained when prophylactic treatment with LE-MTPPE was started 
7 days before bacterial inoculation, percentage survival increased up to 85%. This prophylac-
tic treatment schedule was not dependent on increased. leukocyte numbers in the blood 
following administration of LE-MTPPE, since this treatment schedule was effective in 
cyclophosphamide-treated leukopenic mice. 
Introduction 
Administration of agents that activate the nonspecific antimicrobial host defense may be 
of great value in treatment of severe infections particularly in the immunocompromised host. 
From clinical experience it is well known that these infections are difficult to treat with 
antibiotics. One of the factors that contribute to this lack of success of antibiotic treatment 
is the failure of the host defense to give adequate support to antibiotic treatment. In this 
respect it is of great importance to stimulate the nonspecific host defense, in particular the 
mononuclear phagocyte system. This can be effectuated by the immunomodulating agent 
muramyl tripeptide phosphatidylethanolamide (MTPPE). 
MTPPE is a lipophilic derivative of muramyl dipeptide. Muramyl peptides stimulate 
macrophages to morphological and biochemical changes, increased production of monokines 
and enzymes as well as enhanced tumoricidal activity (61,65,134,172,181). In addition, 
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muramyl peptides have been proven to be effective in stimulating the nonspecific host defense 
against several bacterial infections (158,167). In a previous study we observed that 
administration of a single dose of MTPPE at 24 h before intravenous (i.v.) inoculation with 
Klebsiella pneumoniae led to increased antibacterial resistance of mice against infection in 
terms of decreased numbers of bacteria in blood, liver, spleen, lung and kidney (136). K. 
pneumoniae is an important cause of infection and mortality of hospitalized patients and is 
a serious complication of patients with malignancies (36). Since mostly these 
immunocompromised patients are prone to infections during a prolonged period of time it is 
expected that repeated administration of immunornodulating agents is needed. However, 
repeated administration ofMTPPE has been shown to result in toxic side effects (18,58,188). 
Encapsulation of MTPPE in liposomes may therefore be of importance, since in this form a 
reduction in MTPPE toxicity has been demonstrated (58, 188). In addition, due to liposomal 
encapsulation MTPPE is targeted to the cells of the mononuclear phagocyte system (124) 
which have been shown to be of major importance in the antibacterial resistance. In the model 
of i. v. induced K. pneumoniae infection administration of a single dose of liposome-
encapsulated MTPPE (LE-MTPPE) at 24 h before bacterial inoculation was also effective 
even in a two-fold lower dose as MTPPE in the free form (137). In the present study we used 
an infection model in which K. pnewnoniae was inoculated intraperitoneally resulting in 
appearance of K. pneumoniae in the blood at regular intervals eventually leading to 
septicemia. This model has a clinical relevance as immunocompromised patients are also 
prone to develop septicemia from a local infection. The efficacy of several prophylactic and 
therapeutic treatment schedules with free MTPPE or LE-MTPPE was investigated. 
Materials and methods 
Animals. Specific pathogen free, II to 13 weeks old male C57Bl!Ka mice were used 
(ITRI-TNO, Rijswijk, The Netherlands). 
Reagents. N-acetyl-muramyl-L-alany 1-D-isoglutaminyl-L-alanine-2-[ I ,2-dipalmitoyl-sn-
glycero-3-(hydroxy-phosphoryloxy)]ethanolamide was kindly provided by Ciba-Geigy 
(Basel,Switzerland). Liposomes containing MTPPE and placebo liposomes were a generous 
gift of Ciba-Geigy Ltd. (Basel, Switzerland). Liposomes were prepared from a dry 
lyophilisate composed of 250 mg phosphatidylcholine and phosphatidylserine in a molar ratio 
of 7:3 (with or without I mg MTPPE) and shaken with 2.5 ml of phosphate buffered saline 
(PBS) (CGP 19835A lipid). The average diameter of the constituted liposomes was between 
2.0 and 3.5 I'm and at least 80% of the liposomes were larger than 1.5 I'm (205). 
Bacteria. A strain of K. pneumoniae capsular serotype 2 (ATCC 43816) was used. 
Bacteria were grown for 16 h at 37'C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, En-
gland) and preserved on ice. Directly before the inoculation of mice the bacteria were washed 
three times in PBS. 
Induction of leukopenia. Leukopenia was induced by i.p. injections with 
cyclophosphamide (Sigma Diagnostics, StLouis, Missouri, USA), a first dose of 120 mglkg 
at eleven days before bacterial inoculation followed by doses of 80 mglkg at every third day 
thereafter. At 7 days before bacterial inoculation i.v. treatment with LE-MTPPE started. 
Quantitation of blood leukocytes. Blood samples (0.8 ml) were taken from the 
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retroorbital plexus and collected in polypropylene tubes containing 1 mg dried EDTA (BDH 
Chemicals Ltd, Poole, England). For total leukocyte counts, blood was diluted 1:10 with 
Turk solution (0.1% crystal violet in 1% acetic acid) and the number of leukocytes was 
determined in duplicate in a Biirkers hemocytometer. 
Experimental irifection caused by K. pneumoniae. Infections were induced by i.p. 
inoculation of 103 CFU of K. pneumoniae into C57Bl/Ka mice. Then mice were housed in 
seperate cages and every day the survival of mice was examined until 21 days after bacterial 
inoculation. From dead mice only K. pneumoniae was recovered from the blood. 
Quantitation of bacterial numbers in the blood. At different intervals after i. v. 
inoculation with 104 K. pneumoniae blood samples (0.8 ml) were taken from the retroorbital 
plexus and collected in polypropylene tubes containing 1 mg dried EDTA (BDH). Serial 
tenfold dilutions were prepared and volumes of 0.2 ml of each dilution were spread on trypto-
ne soya agar (TSA) plates (Oxoid Ltd, Basingstoke, England). All plates were incubated 
overnight at 26°C. 
Statistical analysis. Statistical evaluation of the differences in the survival curves 
between MTPPE-treated, LE-MTPPE-treated and PBS-treated groups of animals was 
performed by using the log rank test. This test examines the decrease in survival with time 
as well as the eventual percentage of survival. The Mann-Whitney test was used for 
evaluation of the differences in the numbers of leukocytes and bacteria between LE-MTPPE-
treated and PBS-treated groups of animals. 
Results 
Effect of a single (prophylactic) dose of free MTPPE or LE-MTPPE on the survival of 
mice from K. pneumoniae irifection. After i.p. inoculation of mice with 103 CFU of K. 
pneumoniae, bacteria appeared in the blood and reached levels of lo3 to 104 CFU of K. 
pneumoniae per ml blood within 4 hours and 106 CFU per ml blood after 2 days, eventually 
leading to the death of mice (Figure 6.1). Figure 6.2 shows that all mice died within 6 days 
after bacterial inoculation. Most mice died between day 3 and day 4. Only K. pneumoniae 
was recovered from the blood of all dead mice. Administration of 50 l"g MTPPE per mouse 
at 24 h before bacterial inoculation resulted in survival of 55% of the mice. When a twofold 
higher dose was given, 100 !J.g MTPPE per mouse, survival rate and percentage survival was 
not increased. Administration of 6.3 l"g MTPPE per mouse at 24 h before bacterial 
inoculation appeared to be the lowest dose from a twofold dose range that resulted in a 
significantly increased survival rate compared to PBS-treated mice. A dose of 3.1JLg had no 
significant effect (data not shown). 
Figure 6.3 shows that administration of 25 l"g LE-MTPPE per mouse at 24 h before 
bacterial inoculation resulted in survival of 40% of the mice. A dose of 6.3 mg placebo 
liposomes, which is equivalent to the amount of lipid in which 25 l"g MTPPE is encapsulated, 
had no effect. A dose of 25 JLg LE-MTPPE was the maximum dose that could be 
administered, since at higher doses the equivalent amount of placebo liposomes had toxic 
effects. Administration of 3.1 JLg of LE-MTPPE per mouse at 24 h before bacterial 
inoculation appeared to be the lowest dose from a twofold dose range that resulted in a 
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FIGURE 6.1 Numbers of K. pneumoniae in the blood of mice after i.p. inoculation. At 24 h before 
i.p. inoculation with 103 CPU K. pneumoniae, mice were i.v. treated with PBS. Each point represents 
the geometric mean for six mice ± SEM. 
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FIGURE 6.2 Effect of administration (prophylactic) of a single dose of free MTPPE on survival of 
mice from K. pneumoniae infection. At 24 h before i.p. inoculation with 103 CFU K. pneumoniae, 
mice were i.v. treated with a single dose of free MTPPE from a twofold dose range (100-6.3 p.g per 
mouse) or with PBS. Groups of twenty mice were used. Significance: *p~O.OS, **p:s;O.Ol, 
***p :::;0.001 versus PBS-treated mice. 
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significantly increased survival rate compared to PBS-treated control mice. A dose of 1.5 p.g 
had no significant effect (data not shown). 
Effect of repeated administration (prophylactic and therapeutic) of LE-MTPPE on the 
survival of mice from K. pnewnoniae infection. Compared to administration of a single dose 
of 25 p.g LE-MTPPE at 24 h before bacterial inoculation, which treatment resulted in 40% 
survival of the mice (Figure 6.3), administration of a second dose of 25 p.g LE-MTPPE at 
24 h after bacterial inoculation and a third dose at 72 h after bacterial inoculation did not 
further enhance the survival rate and percentage survival significantly (Figure 6.4). Repeated 
administration of 6.3 mg placebo liposomes had no effect. 
Whereas administration of 3.1 p.g LE-MTPPE at 24 h before bacterial inoculation 
resulted in a significantly increased survival compared to that in PBS-treated mice (percentage 
survival was 5%) (Figure 6.3), administration of a second dose at 24 h after bacterial 
inoculation led to a survival percentage of 30% (Figure 6.5). When a third dose was given 
at 72 h after bacterial inoculation survival was not significantly further enhanced. Changing 
the interval of administration of doses of 3.1 p.g LE-MTPPE into 24 h (instead of 48 h) 
effected a further increase in survival rate, percentages being 5%, 45%, and 55%, 
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FIGURE 6.3 Effect of administration (prophylactic) of a single dose of liposome-encapsulated 
MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. At 24 h before i.p. 
inoculation with 103 CFU K. pneumoniae, mice were i.v. treated with a single dose of LE-MTPPE 
from a twofold dose range (25-3.1 J.Lg per mouse), or with placebo liposomes (---·--)or with PBS 
( ). Groups of twenty mice were used. Significance: *p ~0.05, **p ~0.01, ***p ~0.001 
versus PBS-treated mice. 
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FIGURE 6.4 Effect of repeated administration (prophylactic and therapeutic) of 25 p.g liposome-
encapsulated MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. Mice were i.p. 
inoculated with 103 CFU K. pneumoniae at zero time. Mice were i. v. treated with 25 p.g LE-MTPPE 
at 24 h before bacterial inoculation (- - ), or at 24 h before and at 24 h after inoculation 
( ... -- .. ), or at 24 h before and at 24 h after and at 72 h after inoculation (- -- -). Control mice 
were i. v. treated with placebo liposomes at 24 h before and at 24 h after and at 72 h after bacterial 
inoculation ( ----- ) or with PBS at 24 h before inoculation ( ). Groups of twenty mice 
were used. Significance: ***p :::;;Q.OOI versus PBS-treated mice. 
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FIGURE 6.5 Effect of repeated administration (prophylactic and therapeutic) of 3.1 J-Lg liposome-
encapsulated MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. Mice were i.p. 
inoculated with 103 CPU K. pneumoniae at zero time. Mice were i.v. treated with 3.1 J.Lg LE-
MTPPE at 24 h before bacterial inoculation (- - ), or at 24 h before and at 24 h after inoculation 
( ....... ), or at 24 h before and at 24 h after and at 72 h after inoculation(-----). Control mice 
were i.v. treated with placebo liposomes at 24 h before and at 24 h after and at 72 h after bacterial 
inoculation (----- ) or with PBS at 24 h before inoculation ( ). Groups of twenty mice 
were used. Significance: **p:;:;; 0.01, ***p:::;; 0.001 versus PBS-treated mice. 
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a further increase in survival rate, the percentages being 5%, 45%, and 55%, respectively 
(Figure 6.6). Repeated administration of 0.8 mg placebo liposomes, equivalent to the amount 
of lipid in which 3.1 l'g MTPPE was encapsulated, had no effect. 
Effect of repeated administration (prophylactic) of LE-MTPPE on the survival of mice 
from K. pneumoniae infection. Doses of 3.lftg LE-MTPPE were administered, the last dose 
being given at 24 h before bacterial inoculation. Administration at a 48 h interval, of two 
doses resulted in a survival of 40%, of three doses resulted in 70% survival and of four doses 
in 85% survival (Figure 6. 7). Repeated administration of 0.8 mg placebo liposomes with an 
interval of 48 h had no effect. Changing the interval of administration of doses of 3.lf'g LE-
MTPPE into 24 h (instead of 48 h) resulted in a survival of 40% when two doses were 
given, and in 75 % survival after three doses (Figure 6.8). When a fourth dose was given the 
survival rate and percentage survival did not change anymore. Repeated administration of 0. 8 
mg placebo liposomes with an interval of 24 h also resulted in a significantly increased 
survival compared to PBS-treated mice (p=0.04). 
Effect of repeated administration (prophylactic) of LE-MTPPE on the survival of 
leukopenic mice from K. pneumoniae infection. Figure 6.9 shows that leukopenic mice i.p. 
infected with 103 CFU K. pneumoniae all died within 3 days after bacterial inoculation. Most 
mice died at day 2. Prophylactic administration of 4 doses of 3.1 l'g LE-MTPPE to leuko-
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FIGURE 6.6 Effect of repeated administration (prophylactic and therapeutic) of 3.1 p.g liposome-
encapsulated MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. Mice were i.p. 
inoculated with 103 CFU K. pneumoniae at zero time. Mice were i. v. treated with 3.1 p.g LE-MTPPE 
at 24 h before bacterial inoculation (- -), or at 24 h before and at zero time ( ........ ·), or at 
24 h before and at zero time and at 24 h after inoculation(-·~-). Control mice were i.v. treated 
with placebo liposomes at 24 h before and at zero time and at 24 h after bacterial inoculation 
(------ ) or with PBS at 24 h before inoculation ( ). Groups of twenty mice were used. 
Significance: **p :5:0.01, ***p s; 0.001 versus PBS-treated mice. 
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FIGURE 6.7 Effect of repeated administration (prophylactic) of 3.1 p,g liposome-encapsulated 
MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. Mice were i.p. inoculated 
with 1o3 CFU K. pneumoniae at zero time. Mice were i.v. treated with 3.1 p,g LE-MTPPE at 24 h 
before bacterial inoculation(- - ), or at 24 h and 72 h before inoculation ( - . - ... ), or at 24 
hand 72 hand 120 h before inoculation(----), or at 24 hand 72 hand 120 hand 168 h before 
bacterial inoculation (- - -). Control mice were i. v. treated with placebo liposomes at 24 h and 
72 h and 120 h and 168 h before bacterial inoculation (-- - - - -) or with PBS at 24 h before 
inoculation ( ). Groups of twenty mice were used. Significance: *p:::;0.05, **p:::;O.Ol, 
***p :5:0.001 versus PBS-treated mice. 
TABLE 6.1 Clearance of K. pneumoniae from the blood of normal and leukopenic micea 
Mice Log numbersb of K. pneumoniae per ml blood at several 
times after i. v. bacterial inoculation 
normal 
leukopenic 
1 min 
3.80±0.05 
3.80±0.05 
15 min 
3.15±0.05 
3.29±0.08 
30 min 
3.01±0.14 
3.25±0.14 
60 min 
3.05±0.10 
3.06±0.13 
a Normal and leukopenic mice were i. v. inoculated with 104 CPU K. pneumoniae. Leukopenia was 
induced by i.p. injections with cyclophosphamide, a first dose of 120 mg/kg at eleven days before 
bacterial inoculation followed by doses of 80 mg/kg at every third day thereafter. 
b Geometric mean ± SEM for six mice. 
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FIGURE 6.8 Effect of repeated administration (prophylactic) of 3.1 J.lg liposome-encapsulated 
MTPPE (LE-MTPPE) on survival of mice from K. pneumoniae infection. Mice were i.p. inoculated 
with 103 CPU K. pneumoniae at zero time. Mice were i.v. treated with 3.1 f.lg LE-MTPPE at 24 h 
before bacterial inoculation(- -),or at 24 hand 48 h before inoculation (-. - ... ), or at 24 
h and 48 h and 72 h before inoculation (- - - - ), or at 24 h and 48 h and 72 h and 96 h before 
bacterial inoculation (-- -). Control mice were i.v. treated with placebo liposomes at 24 hand 
48 h and 72 h and 96 h before bacterial inoculation (------) or with PBS at 24 h before inoculation 
( --- ). Groups of twenty mice were used. Significance: **p SO.Ol, ***p sO.OOl versus PBS-
treated mice. 
penic mice with an interval of 48 h (the treatment schedule which was most effective in 
immunocompetent mice) led to an increased survival rate compared to that in PBS-treated 
leukopenic mice. Numbers of leukocytes in the blood ofLE-MTPPE-treated leukopenic mice 
did not differ from numbers in PBS-treated leukopenic mice. They were 670±25 and 687±26 
per 1'1 blood (mean±SEM for six mice), respectively. Treatment of mice with 
cyclophosphamide did not lead to a decreased MPS capacity to clear K. pneumoniae from 
the blood compared to the clearance capacity of PBS-treated normal mice (Table 6.1). 
Discussion 
This study shows that administration of a single dose of MTPPE resulted in resistance 
against K. pneumoniae septicemia resulting from i. p. bacterial inoculation in terms of an 
increased percentage survival and an increased survival time. Administration of a single dose 
of LE-MTPPE was also effective but at a twofold lower dose. This is in agreement with our 
earlier observations in K. pneumoniae septicemia induced by i. v. inoculation where bacterial 
numbers in the organs and blood were used as parameter of therapeutic efficacy (136). 
However in the i. v _ induced infection administration of a single dose of MTPPE or LE-
MTPPE resulted in survival of all mice, whereas in the present model of i.p. induced 
infection only 55% or 40% of the infected mice survived after administration of a single dose 
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FIGURE 6.9 Effect of repeated administration (prophylactic) of 3.1 J.l.g liposome-encapsulated 
MTPPE (LE-MTPPE) on survival of leukopenic mice from K. pneumoniae infection. Leukopenic mice 
were i.p. inoculated with 103 CFU K. pneumoniae infection at zero time. Mice were i.v. treated with 
3.1 l'g LE-MTPPE at 24 hand 72 hand 120 hand 168 h before bacterial inoculation(---). 
Control mice were i.v. treated with placebo liposomes at 24 hand 72 hand 120 hand 168 h before 
bacterial inoculation (- - - - - - ) or with PBS at 24 h before inoculation ( ). Groups of 
twenty mice were used. Significance: ***p 50.001 versus PBS-treated mice. 
of MTPPE or LE-MTPPE, respectively. The increased efficacy of a single dose of MTPPE 
and LE-MTPPE in the i.v. induced infection may be explained as follows. After i.v. 
inoculation bacteria are present in the blood for only a short period of time and activation of 
macrophages is only needed for a rather short period of time, whereas after i. p. inoculation 
influx of bacteria from the peritoneal cavity into the blood occurs at regular intervals and 
macrophages have to be activated for a prolonged period of time by repeated doses LE-
MTPPE. An increased resistance against experimental K. pneumoniae infection due to 
administration of muramyl dipeptide (MDP) or its derivatives was also observed by other 
investigators using either systemic infections or wound infection models with the survival of 
animals (30,75,169,178), or the decrease in bacterial numbers in the infected organs (3,178) 
used as parameters for therapeutic efficacy. Administration of a single dose of MTPPE, LE-
MTPPE, MDP or other MDP-derivatives seemed to be most effective when given at 24 h 
before bacterial inoculation (3,136,158). The results obtained with repeated administration 
of MDP derivatives were in discrepancy (46,67, 109,112,151, 167). Various microorganisms 
were used (viruses, bacteria or parasites) and in most studies only few treatment schedules 
were tested. However, a detailed study related to the effects of prophylactic or therapeutic 
treatment schedules of MDP derivatives was not performed before. 
Investigations on the efficacy of repeated administration of immunomodulating agents 
are of clinical relevance since immunocompromised patients are prone to infections during 
a prolonged period of time. It is known that repeated administration of MTPPE in the free 
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form results in toxic side effects (18,58, 188). By encapsulation of MTPPE in liposomes this 
toxicity can be reduced, in addition, targeting of MTPPE to the cells of the mononuclear 
phagocyte system can be achieved (124,188). The present study shows that the survival of 
mice treated at 24 h before bacterial inoculation with the maximum tolerated dose of LE-
MTPPE (25 l'g per mouse) could not be further increased by additional doses of LE-MTPPE 
at a 48-h interval. Since LE-MTPPE had to be given repeatedly, it was preferred to 
administer the lowest possible doses of LE-MTPPE to exclude any toxic side effects. A single 
dose of 3.1 l'g LE-MTPPE was the lowest dose from the two-fold dose range that 
significantly improved survival of mice. Additional doses of 3.1 l'g LE-MTPPE could 
enhance the percentage survival up to 55%. Administration of three doses of 3.1 l'g LE-
MTPPE led to a better survival than administation of three doses of 25 l'g LE-MTFFE. These 
results suggest that for the degree of macrophage activation by LE-MTFFE the total 
administered dose is of less importance. The highest therapeutic effect was obtained when all 
doses of LE-MTPFE were given prophylactically with an interval of 48 h, the percentage 
survival of infected mice was increased to 85%. The number of doses as well as the time of 
administration of LE-MTFFE are of major importance. It can be concluded that time is 
needed for macrophages to become maximally activated. This may be the result of the direct 
stimulation by LE-MTFFE but also by products released by activated macrophages such as 
interleukin-1 or tumor necrosis factor. In addition more macrophages may be activated during 
this period of prophylactic administration. Studies about efficacy of treatment schedules using 
MDF derivatives are rare. Farant et al. (169) found an increased efficacy of the lipophilic 
MDP derivative, murabutide, when it was i.p. administered once a day at 3, 2, and 1 day 
before i.v. inoculation of K. pneumoniae. However, they compared this effect only with the 
efficacy of administration of a single dose either at 3 or 1 day before inoculation and not with 
other treatment schedules. 
It is known from clinical experience that particularly immunocompromised patients often 
suffer from severe infections which can not always be treated successfully with antibiotics. 
One factor which contributes to this lack of success is the failure of the host defense system 
to give adequate support to antibiotic treatment. Therefore, stimulation of nonspecific host 
defenses may be very important in these patients. In the present study we have investigated 
the effect of stimulating host defenses in leukopenic mice. These mice were 
immunocompromised due to treatment with cyclophosphamide resulting in a 85% decrease 
in numbers of peripheral leukocytes. The effects of repeated prophylactic administration of 
LE-MTPPE we found in immunocompetent mice: increased survival rate and increased 
percentage survival we also observed in leukopenic mice. By others only the effect of single 
doses of MDP derivative, administered at 24 h before bacterial inoculation, was assessed 
(73,74,167,178). Galland et al. (73,74) found an increased survival time of starved, 
cyclophosphamide-treated or hydrocortison-treated mice infected with a K. pneumoniae leaden 
suture after a single s.c. dose of MDF. Farant (167) observed an increased survival of 7 day 
old mice from an intragastric K. pneumoniae infection after a single intragastric dose of 
murabutide. Polk et a!. (178) demonstrated an increased survival and decreased bacterial 
numbers in the blood of starved mice infected with an K. pneumoniae loaden suture after 
administration of a single dose of MDP. 
Whereas in immunocompetent mice we found increased numbers of leukocytes in the 
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blood due to LE-MTPPE treatment (136), the present study demonstrated that in leukopenic 
mice after repeated administration of LE-MTPPE, numbers of leukocytes in the blood were 
not increased. This was due to the cyclophosphamide induced blockade of the recruitment of 
leukocytes. Therefore it may be concluded that activation of tissue macrophages by LE-
MTPPE is of major importance in the induced antibacterial resistance in leukopenic mice. In 
immunocompetent mice we have also found that activation of tissue rnacrophages is of great 
importance in the increased resistance against K. pneumoniae infection (135). Our results are 
in agreement with findings of Nakajima et a!. (145) that leukocyte numbers in the blood of 
cyclophosphamide-treated mice were not increased after treatment with the lipophilic MDP-
Lys(Ll8). 
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CHAPTER 7 
TISSUE DISTRIBUTION AND CELLULAR DISTRIBUTION OF 
LIPOSOMES ENCAPSULATING MURAMYLTRIPEPTIDE 
PHOSPHATIDYL ETHANOLAMinE 
Pernella M.B. Melissen, Wim van Vianen, Pieter J.M. Leenen, and I.A.J.M. Bakker-
Woudenberg 
This study is submitted for publication. 
Abstract 
In a previous study it was shown that administration of liposome-encapsulated MTPPE 
(LE-MTPPE) led to resistance against Klebsiella pneumoniae infection. To gel more insight 
into the cell types that are involved in this induced antibacterial resistance by LE-MTPPE, 
the tissue distribution of liposomes encapsulating MTPPE and the cellular distribution in the 
main target organs were investigated. After intravenous injection of the liposomes in mice a 
substantial amount was recovered from liver and spleen and a smaller amount from the lung. 
In the liver 83% of the liposomes was taken up by the Kupffer cells. In the spleen also most 
liposomes were taken up by macrophages of the red and white pulp as well as by dendrocy-
tes. The liver and spleen were also the organs in whichj after intravenous inoculation, K. 
pneumoniae was trapped. It was observed that a great part of the cells containing LE-MTPPE 
had not taken up bacteria. Most bacteria, about 73%, were found in cells not containing 
liposomes. The capacity of the liposome-containing cells to take up bacteria did not change 
with time. This suggests that the by LE-MTPPE immunostimulating effect is due to the 
production of cytokines by the cells that take up LE-MTPPE. These cytokines might stimulate 
other cells to the killing of bacteria. 
Introduction 
Stimulation of the nonspecific host defense, in particular the mononuclear phagocyte 
system can be effected by immunomodulators either from bacterial origin, such as LPS or 
muramyl peptides or by cytokines such as interleukin-1, colony stimulating factor or 
interferon--y. In previous studies we showed that administration of the lipophilic muramyl 
peptide derivative, muramyl tripeptide phosphatidylethanolamide (MTPPE) to mice led to 
resistance against Klebsiella pneumoniae infection (135, 136). From these studies it appeared 
that for effective treatment the nonspecific host defense has to be stimulated for a prolonged 
period of time and repeated administration of MTPPE is needed. It has been shown that 
repeated administration of MTPPE has toxic side effects (58, 188). Encapsulation of MTPPE 
in liposomes (LE-MTPPE) has been proven to reduce this toxicity (58,188). The liposomes 
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encapsulating MTPPE are rather large (diameter of 2.0-3.5,um, 205) and are consisting of 
phosphatidylcholine and phosphatidylserine rendering them negatively charged. It is expected 
that these liposomes are preferentially taken up by cells of the mononuclear phagocyte system 
(MPS) in the liver and spleen (124,200). 
In a previous study we observed that administration of LE-MTPPE resulted in an 
increased antimicrobial resistance against K. pneumoniae infection compared to administration 
of MTPPE in the free form (135,136). An improved efficacy of MTPPE after liposomal 
encapsulation was also found in studies investigating the stimulation of the nonspecific 
defenses against several viruses (51,76,!12). To get more insight into the cell types that are 
involved in the by LE-MTPPE induced enhancement of the nonspecific resistance, in the 
present study the tissue distribution of LE-MTPPE and the distribution of LE-MTPPE over 
the cells in the main target organs was investigated. In addition, the capacity of cells 
containing LE-MTPPE to take up K. pneumoniae was examined. 
Materials and methods 
Animals. Specific pathogen free, !1 to 13 weeks old female C57Bl!Ka mice were used 
(ITR!-TNO, Rijswijk, The Netherlands). 
Reagents. Liposomes containing MTPPE were a generous gift of Ciba-Geigy Ltd. 
(Basel, Switzerland). Liposomes were prepared from a dry lyophilisate composed of 250 mg 
phosphatidylcholine and phosphatidylserine in a molar ratio of 7:3 (with or without 1 mg 
MTPPE) and shaken with 2.5 ml of phosphate buffered saline (PBS) (COP 19835A lipid). 
The average diameter of the constituted liposomes was between 2.0 and 3.5 ,urn and at least 
80% of the liposomes were larger than 1.5 I'm (205). Rhodamine phosphatidylethanolamine 
(Rho-PE) was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Tetramethyl-
rhodamine isothiocyanate (Trite) and fluorescein isothiocyanate (Fitc) were obtained from 
Sigma (St. Louis, Missouri, USA). 67Gallium-citrate and 111Indium-chloride were from 
Frosst (Quebec, Canada). Deferoxamine mesylate (DF) was from Ciba-Geigy Ltd (Basel, 
Switzerland). 
Radiolabeling ofliposomes. Liposomes were radiolabeled with 67Gallium-deferoxamine 
c67oa-DF) as described by Gabizon et al. (71). The labeling resulted in formation of a 67oa-
DF complex in the aqueous interior of liposomes. Non-entrapped 67Ga-oxine was removed 
by two times centrifugation for 1 hat 48,000xg at 4°C. 
Fluorescent labeling of liposomes. Liposomes were passively labeled with 0.03 mol 
percent of Rho-PE, a marker of the lipid bilayers, or with 1 mg Trite per ml PBS, a marker 
of the aquous phase. Non-encapsulated Trite was removed by two times centrifugation for I 
h at 48,000xg at 4 °C. 
Biodistribution of liposomes. A dose of 6.25 mg of liposomes encapsulating 25 ,ug 
MTPPE and labeled with 67 Ga-DF was intravenously injected. At several times after 
administration samples of 0.2 ml blood were obtained by retroorbital bleeding under COz 
anesthesia. Then mice were sacrificed (six mice per time point) and liver, spleen, kidney and 
lung were removed. Radioactivity was quantitated in a y-counter (Minaxy 5530, Packard 
Instruments, Downers Grove, USA). 
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Immunohistochemical staining of sections from liver and spleen. At 1 h after injection 
of liposomes, passively labeled with Rho-PE in the lipid bilayers or with Trite in the aqueous 
phase, mice were sacrificed. Spleen, lung and liver were removed and embedded in Tissue-
Tek 11 (Miles laboratories Inc, Kankakee, USA) on a specimen stub and frozen immediately. 
Five I'm sections were cut on a cryostat (model 1720, Leitz, Germany) and collected on 
micoscope slides precoated with a solution containing 0.1% gelatin and 0.01% chromium 
potassium sulphate. Slides were air-dried and used immediately or stored at -20°C. Prior to 
use sections were fixed for 10 min in acetone and air-dried. After fixation sections were 
incubated for 1 hat 37"C with PBS supplemented with 0.05% bovine serum albumin (Sigma, 
St Louis, Missouri, USA) (PBS-BSA). Then sections were incubated for 30 min at room 
temperature with monoclonal antibodies directed to different subsets of macrophages. The 
monoclonal antibody BM8 was used to identify Kupffer cells in the liver and red pulp 
macrophages in the spleen. MOMA-1 binds to marginal metallophilic macrophages, ER-TR9 
to marginal zone macrophages, NLDC-145 to dendritic cells, CD3 toT-cells, and RA3 6B2 
to B-cells (122). After rinsing the sections with PBS-BSA, the sections were incubated for 
30 min at room temperature with a 1:60 dilution of File-conjugated rabbit-anti-(rat lgG) 
(Cappel, Organon Teknika Corp, Boxtel, The Netherlands) in PBS-BSA containing 2% 
normal mouse serum. Sections were rinsed with PBS-BSA and embedded in PBS with 10% 
glycerol (Merck, Darmstadt, Germany) and 0.1% phenylene diamine (BDH Chemicals Ltd, 
Poole, England). 
Labeling of bacteria. An overnight culture of K. pneumoniae was washed three times 
with PBS. Then the pellet of bacteria was incubated with 100 l'g Fitc/ml PBS for I h at 
37°C. The nonbinding Fitc molecules were removed by washing three times with PBS 
containing I% fetal bovine serum (HyClone Laboratories Inc., Logan, Utah, USA). 
Results 
Tissue distribution of liposomes encapsulating MTPPE. Mice were injected i.v. with 
6.25 mg of 67Ga-DF labeled liposomes encapsulating 25 l'g MTPPE being the lowest 
effective dose from a twofold dose range that resulted in enhanced resistance against K. 
pneumoniae infection (136). In Table 7.1 it is shown that at 5 min after injection 96.9% of 
the initially injected liposomes was recovered from blood and several organs: 55.1% of the 
liposomes was recovered from the blood, the remainder was distributed over several organs, 
particularly in the liver. During the first 30 min the total recovery of the injected liposomes 
decreased substantially to 65.2% of the injected dose. From 30 min after injection the 
recovery ofliposomes from spleen, lung and blood slowly decreased with time, whereas from 
the liver remained stable. Incubation of liposomes containing MTPPE in mouse serum for 24 
h at 37°C in vitro did not affect the stability of the liposomes (data not shown). 
Cellular distribution of liposomes encapsulating MTPPE in the liver, spleen and lung. 
It was investigated among which cell types in the liver, spleen and lung liposomes 
encapsulating MTPPE, labeled with Rho-PE, were distributed after i.v. injection (Figure 7.1). 
In addition, the cells of a certain cell type that had taken up liposomes encapsulating MTPPE 
were quantitated (Table 7.2). It was found that at I h after i.v. injection 83.2% of the 
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TABLE 7.1 Biodistribution of liposomes encapsulating MTPPE labeled with 67 Ga-DF in mice at 
various time intervals after injection a 
Tissue radioactivity (% of injected dose)b 
5 min 30 min 60 min 120 min 
liver 25.0±0.5 29.1±1.4 31.7±0.7 29.9±0.8 
spleen 6.6±0.7 18.1±1.6 17.0±0.6 14.2±0.4 
lung 8.4±0.3 5.6±0.2 4.8±0.1 4.0±0.3 
kidney 1.2±0.3 1.6±0.1 1.3±0.1 1.2±0.1 
bloodc _?5.1+1.5 10.8+0.6 7.4+0.6 5.4+0.4 
recovery 96.9±1.5 65.2±1.3 62.2±1.3 54.6±1.0 
a Mice were injected at zero time with 6.25 mg 67 Ga-DF labeled liposomes in which 25 Jlg MTPPE 
was encapsulated. At several times distribution of radio labeled liposomes in blood and organs was 
shown as percentage radioactivity of the total injected amount of radioactivity. Values were 
corrected for the blood content in the tissues, which was determined after i. v. injection of 
111Indium labeled syngeneic erythrocytes in a seperate group of twelve mice. Labeling of 
erythrocytes was performed as described by Heaton et al. (85). 
b Percentages are the mean ± SEM for six mice. 
c Per total amount of blood. 
TABLE 7.2 
organ 
liver 
spleen 
Percentage of cell types in liver and spleen containing liposomes encapsulating 
MTPPE" 
cell type 
macrophages 
RP macrophages 
MM macrophages 
MZ macrophages 
dendritic cells 
T-cells 
B-cells 
percentage positive cellsb 
11.2-13.0 
23.6-25.4 
13.6-15.2 
10.2-12.4 
3.8-6.0 
1.0-1.4 
0.8-1.1 
a Mice were i. v. injected with 6.25 mg liposomes encapsulating 25 Jlg MTPPE and labeled with Rho-
PE. At 1 h thereafter mice were sacrificed and spleen and liver were removed and slides were 
prepared as described in the materials and methods section. Each slide was stained with a different 
Fitc-conjugated monoclonal antibody directed against the cell type mentioned. RP macrophages, red 
pulp macrophages. MM macrophages, marginal metallophilic macrophages. MZ macrophages, 
marginal zone marcophages. 
b The percentage of 500 monoclonal antibody positive cells that had taken up liposomes. Values of 
two mice are shown. 
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Cell type Cellular distribution of liposomes 
LIVER 
macrophages 83.2% 
SPLEEN 
RP macrophages 111.3% 
MM macrophages f:::=========::::;~---------- 15.2% 
1 7.5% MZ macrophages 
dendritic cells 18.8% ~=::::::;----
1 3.6% T-cells 
B-cells 1-----1 4.4% 
FIGURE 7.1 Cellular distribution of liposomes encapsulating MTPPE in liver and spleen. Mice 
were i.v. injected with 6.25 mg liposomes encapsulating 25 J.Lg MTPPE and labeled with Rho-PE. 
After 1 h mice were sacrificed and liver and spleen were removed. Slides were prepared and each of 
them was stained with a different monoclonal antibody. On each slide the percentage of 500 liposome-
containing cells that were positive for the monoclonal antibody ( c::J. ) was determined. The mean 
and range was given for the values of two mice. RP macrophages, red pulp macrophages. MM 
macrophages, marginal metallophilic macrophages. MZ macrophages, marginal zone macrophages. 
liposomes that were recovered from the liver were taken up by macrophages. Of all Kupffer 
cells 12.1% contained liposomes. At 1 h after i.v. injection 79.5% of the liposomes were 
recovered from the white pulp in the spleen. Most liposomes were found in macrophages and 
in dendritic cells, percentages being 34.0% and 8.8% of the l;posomes that were recovered 
from the spleen, respectively. T- and B-cells had taken up 8.0% of the liposomes. In 
addition, 41.0% of the injected liposomes were adhered to these T- and B-cells. From the cell 
types in the spleen the BM8 positive macrophages contained relatively the most 1iposomes: 
24.5% of these cells had taken up liposomes. In slides of the lung only few liposomes were 
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observed. Liver and spleen contained a small number of granulocytes which had not taken 
up liposomes (data not shown). 
Distribution of K. pneumoniae in the liver and spleen of mice treated with liposomes 
encapsulating MTPPE. At various times after i.v. injection of 6.25 mg Trite-labeled 
liposomes containing 25 l'g MTPPE, mice were i.v. inoculated with 107 Fitc-labeled K. 
pneumoniae. The cellular distribution of liposomes labeled with Trite was the same as that 
of liposomes labeled with Rho-PE. Thirty minutes after inoculation when most bacteria were 
cleared from the blood (data not shown), distribution of K. pneumoniae was investigated in 
the spleen. In Table 7.3 it is shown that about 27% of the inoculated bacteria were taken up 
by cells that contained liposomes, whereas about 73% of the bacteria were found in the cells 
that had not ingested liposomes. With time no significant change was observed in this 
distribution. With respect to the liposome-containing cells: about 20% had taken up one or 
more bacteria (Table 7.4). This percentage also did not change significantly with time. The 
total number of cells that contained liposomes did not change until 24 h after injection (data 
not shown). 
TABLE 7.3 Uptake of bacteria by cells in the spleen a 
Number of 
bacteria per cell 
cells containing liposomes 
I 
2-5 
>5 
cells not containing liposomes 
I 
2-5 
>5 
Number of cells containing bacteria at various 
intervals after injection of liposomesb 
I h 4 h 8 h 24 h 
108-143 121-158 116-161 101-133 
7-14 4-6 2-3 8-9 
0 0 0 0 
343-370 336-366 333-379 349-384 
7-8 2-7 2-5 6-10 
0 0 0 0 
a At several times after i.v. injection of 6.25 mg of Trite-labeled liposomes encapsulating 25 J.Lg 
MTPPE, mice were i.v. injected with 107 Fitc-labeled K. pneumoniae. Thirty minutes after 
bacterial inoculation mice were sacrificed and spleen was removed. Slides were prepared as 
described in the materials and methods section. 
b On each slide 500 cells which contained bacteria were microscopically screened for the uptake of 
liposomes. Values of two mice are shown. 
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TABLE 7.4 Uptake of bacteria by liposome containing cells in the spleen. a 
Numbers of 
bacteria per cell 
0 
1 
2-5 
>5 
Number of cells containing bacteria at various intef'lals 
after injection of liposomesb 
1 h 4h 8 h 24 h 
372-398 400-416 408-431 419-422 
91-116 73-92 58-83 67-68 
11-12 8-11 9-11 11-13 
0 0 0 0 
a At several times after i.v. injection of 6.25 mg of Trite-labeled liposomes encapsulating 25 p.g 
MTPPE, mice were i.v. injected with 107 Fitc-labeled K. pneumoniae. Thirty minutes after 
bacterial inoculation mice were sacrificed and spleen was removed. Slides were prepared as 
described in the materials and methods section. 
b On each slide 500 liposome-containing cells were microscopically screened for the numbers of 
intracellular bacteria. Values of two mice are shown. 
Discussion 
In a previous study we showed that administration of the liposome-encapsulated 
immunomodulator MTPPE resulted in increased resistance against K. pnewnoniae in mice 
(135,136). MTPPE encapsulated in liposomes (LE-MTPPE) appeared to be effective in a 
twofold lower dose compared to MTPPE in the free form (135). Since it is expected that in 
patients with impaired host defense MTPPE has to be given at regular intervals, 
administration of the liposome-encapsulated form is preferred because of its reduced toxicity 
(58,188). The mechanism by which LE-MTPPE exerts its antibacterial resistance enhancing 
effects, particularly which cell types are involved, is not fully understood. To get more 
insight into this we studied the tissue distribution of LE-MTPPE and its distribution over the 
cells in those organs from which the most liposomes were recovered. 
To study the tissue distribution of liposomes we used the radioactive marker 67Ga-DF. 
This complex is located in the aqueous phase of the liposome. Gabizon et al. (71) showed that 
there is a minimal translocation of the radioactive label to plasma proteins as well as a rapid 
renal clearance rate when the label is released from the liposomes. Since a high amount of 
liposomes was still in the blood during the first 30 min, we corrected the percentage of 
liposomal recovery from a certain organ for the blood content in that organ. 
It appeared that a substantial amount of the liposomes injected was recovered from liver 
and spleen. This distribution was as expected when injecting large (diameter between 2.0 I'm 
and 3.5 I'm) negatively charged liposomes consisting of phosphatidylcholine and 
phosphatidylserine (molar ratio 7:3) (124,200). In the lung, liposomes are probably trapped 
in the capillaries of the lung rather than taken up by macrophages, since in sections of lung 
only few liposomes were observed. Between 5 and 30 min after injection, recovery of the 
liposomes from the blood decreased substantially. Since we found in in vitro studies that the 
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aqueous marker was not released from the liposomes after 24 h incubation in mouse serum, 
it is not likely that the observed decrease in recovery of liposomes was the result of 
degradation of the liposomes in serum. Probably most of the liposomes are taken up from the 
blood by liver and spleen within 30 min after injection, followed by rapid degradation of 
liposomes and release ot67Ga-DF. 
The tissue distribution of LE-MTPPE has also been studied in rats by Schumann et a!. 
(188) using 14C-phosphatidylcholine (14C-PC) as marker for LE-MTPPE. In these studies it 
was shown that at 30 min after injection of the liposomes almost 100% was recovered: 54% 
from the liver, 14% from the spleen, 19% from the lung and 12% from the blood. At 6 h 
after injection of the liposomes still 60% was recovered: a decrease was only observed in 
liver,lung and blood. This discrepancy between these data and our observations may be 
explained by the liposomal marker used: Partial degradation of the liposomes results in a 
rapid loss of a marker of the aqueous phase ("7Ga-DF), whereas a marker of the lipid bilayer 
(14C-PC) will be only partly released. In addition, after degradation of liposomes the 
breakdown products of 14C-PC are used by the cell for de novo synthesis of phospholipids, 
with the radioactive label remaining inside the cell (7). 
In the liver almost allliposomes were taken up by the macrophages. Most liposomes in 
the spleen were also taken up by macrophages: either red pulp macrophages or white pulp 
macrophages such as marginal metallophilic macrophages and marginal zone macrophages. 
In addition, a substantial part of the liposomes was taken up in the dendrocytes in the white 
pulp. Most liposomes were found in or associated with cells of the white pulp, the areas of 
lymphoid tissue in the spleen. The cells of the red pulp contained a higher percentage 
liposomes compared to the percentage found in each cell type in the white pulp. This might 
be explained by the localization of the red pulp macrophages. When liposomes in the 
bloodstream enter the spleen, they first reach the cells of the red pulp and thereafter the cells 
of the white pulp. 
Although the organs primarily involved in the uptake of liposomes, liver and spleen, 
were also the organs in which most of K. pneumoniae are trapped after i.v. inoculation (136), 
a great part of the cells in the spleen containing liposomes had not taken up K. pneumoniae. 
Most bacteria, about 73%, were found in cells not containing liposomes. In agreement with 
our observations, Phillips eta!. (173) did not find a positive correlation between uptake of 
liposome-encapsulated MDP-GDP and tumoricidal activity of murine alveolar macrophages. 
More specifically, the macrophages that did not contain liposomes were tumoricidal. In 
addition, in studies of Daemen eta!. (42) rat Kupffer cells that had taken up most of the 
liposomes encapsulating MDP appeared to be the least tumoricidal. These in vivo data and 
our observations that murine peritoneal macrophages in vitro could not be stimulated by LE-
MTPPE to an increased uptake and killing of K. pneumoniae (data not shown) suggest that 
other cell types besides the macrophages that have taken up LE-MTPPE are involved in the 
induced resistance. Since it is known that MOP-derivatives are able to stimulate macrophages 
to produce M-CSF, TNF, IL-l and IL-6 (1,70,187), it seems likely that LE-MTPPE 
stimulates macrophages to produce cytokines which stimulate other macrophages to take up 
and kill the bacteria. In future studies it will be investigated which cytokines and celltypes 
are involved in the by LE-MTPPE induced resistance against K. pneumoniae. 
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Abstract 
The effect of free and liposome-encapsulated muramyl tripeptide phosphatidylethanola-
mide (MTPPE) and interferon-y (IFN-y) on the resistance against Listeria monocytogenes 
infection in mice was investigated. It was shown that administration of MTPPE or IFN-'Y at 
24 h before bacterial inoculation led to increased resistance against L. monocytogenes 
infection in terms of a decrease in bacterial numbers in liver and spleen. Encapsulation of 
MTPPE and IFN-y in liposomes increased their efficacy 33- or 66-fold, respectively. In 
addition, liposomal encapsulation led to a more rapid decrease in bacterial numbers. The 
immunmodulator to lipid ratio appeared to be very important in the antibacterial effect of LE-
MTPPE and LE-IFN-y. When non therapeutic doses of liposome-encapsulated MTPPE or 
IFN-y were administered in a larger amount of lipid (so at higher lipid:immunomodulator 
ratio), these doses became effective. Exposure of macrophages in monolayer infected with 
L. monocytogenes in vitro to MTPPE had no effect, whereas exposure to IFN-y only led to 
growth inhibition of the intracellular bacteria. However, incubation of macrophages with a 
combination of MTPPE and IFN-y resulted in killing of the intracellular bacteria. Exposure 
of macrophages in vivo to both immunomodulators in combination can be effected by using 
liposomes as carrriers. It was observed that administration of MTPPE and !FN-y co-
encapsulated in liposomes resulted in a synergistic enhanced antibacterial resistance against 
L. monocytogenes. Both reactive oxygen and nitrogen intermediates seemed to play a role in 
the killing of L. monocytogenes by macrophages activated with a combination of MTPPE and 
!FN-y. 
Introduction 
Antibiotic treatment of infections in the immunocompromised host does not always have 
a satisfactory therapeutic effect. The failure of the host system to give adequate support to 
antibiotic treatment may contribute to this lack of success. In this respect it would be of great 
value to activate the nonspecific antimicrobial defenses of the host, particularly, the 
mononuclear phagocyte system (MPS). The cells of the MPS can be activated by 
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immunomodulators, either from bacterial ongm, such as LPS or muramyl peptides, or 
cytokines such as interleukin-1, colony stimulating factor, tumor necrosis factor or interferon-
"( (IFN--y). 
Muramyl peptides stimulate macrophages to morphological and biochemical changes, 
increased production of monokines and enzymes as well as enhanced tumoricidal activity 
(61,65,134,172,180). In addition, muramyl peptides have been proved to be effective in 
stimulating the host defense against several bacterial infections (158,167). However, reports 
about the efficacy of muramyl peptides in experimental infections with Listeria 
monocytogenes, an intracellular bacterium which is able to survive in macrophages, are 
contradictory (65,92,154,158). We observed that exposure of macrophages infected with L. 
monocytogenes to MTPPE in vitro had no effect on intracellular survival of the bacteria. 
However, administration of MTPPE to mice infected with L. monocytogenes led to increased 
antibacterial resistance. 
The macrophage is also one of the main target cells for !FN--y. IFN--y stimulates 
macrophages to increased production of enzymes, monokines as well as enhanced tumoricidal 
activity (13,95). In addition, it is shown that !FN--y increased the antibacterial defenses 
against several infections (87,132). With respect to L. monocytogenes again the reports about 
the efficacy of IFN--y in stimulating host defenses are contradictory (31,108,117,203,204). 
We observed that exposure of macrophages infected with L. monocytogenes to !FN--y in vitro 
led to growth inhibition of intracellular bacteria, whereas administration of IFN--y to mice 
infected with L. monocytogenes led to bacterial killing and increased antibacterial resistance. 
Since our previous studies showed that treatment with MTPPE or IFN--y in the free form 
resulted in increased antibacterial resistance against L. monocytogenes, in the present study 
the effect of liposomal encapsulation of MTPPE (LE-MTPPE) or IFN--y (LE-IFN--y) on the 
therapeutic effect was investigated. Since, immunocompromised patients are prone to 
infections during a prolonged period of time, repeated administration of immunomodulating 
agents is expected to be needed. Repeated administration of MTPPE or IFN--y has been 
shown to result in toxic side effects (18,49,58, 118,188). Encapsulation of MTPPE or IFN--y 
in liposomes may therefore be of importance since, in the liposomal form, a reduction in 
MTPPE toxicity (118, 188) or IFN--y toxicity (90) has been demonstrated. In addition, due to 
liposomal encapsulation MTPPE or IFN--y can be effectively targeted to the cells of the MPS 
(123). 
The influence of the immunomodulator to liposomal lipid ratio on the antibacterial 
efficacy of LE-MTPPE or LE-IFN--y is also investigated in the present study. In 
tumorcytotoxicity experiments it was found that this ratio in the liposomal formulation used 
was an important determinant in the degree of induced tumorcytotoxicity (41,186). 
In the last part of the present study the effect of MTPPE and IFN--y co-encapsulated in 
liposomes on L. monocytogenes infection was investigated. With the use of liposomes as 
carrriers is possible to target two different immunomodulators to the same cell, probably 
resulting in maximum activation in terms of antibacterial effect. Data from tumorcytotoxicity 
studies suggest that co-encapsulation of MTPPE and IFN--y in liposomes led to an increased 
effect compared to the that obtained with MTPPE and IFN--y encapsulated in separate 
liposomes (144, 186). 
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Materials and methods 
Animals. Specific pathogen free, 11 to 13 weeks old female C57Bl/Ka mice were used 
(ITRI-TNO, Rijswijk, The Netherlands). 
Reagents. N-acety 1-muramy 1-L-alany 1-D-isoglu taminy 1-L-alanine-2-[1, 2-dipalmitoy 1-sn-
glycero-3-(hydroxy-phosphoryloxy)]ethanolamide (MTPPE) was kindly provided by Ciba-
Geigy Ltd. (Basel, Switzerland). Recombinant rat IFN--y with a specific activity of 4.4xldi 
U!mg protein was kindly provided by Dr P. van der Meide (ITRI-TNO, Rijswijk, The 
Netherlands) based on collaboration between the two laboratories. Superoxide dismutase 
(SOD), catalase (CA1), and dimethyl sulfoxide (DMSO) were purchased from Sigma 
Diagnostics (StLouis, Missouri, USA), sodiumazide (SA) from Brithish Drug Houses Ltd 
(Poole, England) and W-monomethyl-arginine acetate (NMMA) from ICN Biomedicals Inc. 
(Cleveland, Ohio, USA) 
Preparation of liposomes. Liposomes were prepared from a dry lyophilisate composed 
of 250 mg phosphatidylcholine and phosphatidylserine in a molar ratio of7:3 with or without 
MTPPE. Preparation of LE-MTPPE by shaking the lyophilisate with MTPPE in 2.5 ml of 
phosphate buffered saline (PBS). Preparationof LE-IFN--y by shaking the lipid lyophilisate 
without MTPPE in PBS containing !FN--y. Free IFN--y was removed by washing with PBS 
at 44,000xg for 1 h at 4 'C. By means of trace amounts of 125!-labeled !FN--y, 22% of the 
IFN--y added was appeared to be encapsulated in the liposomes. The average diameter of the 
constituted liposomes was between 2.0 and 3.5 I'm and at least 80% of the liposomes were 
larger than 1.5 I'm (205). 
Bacteria. A strain of Listeria monocytogenes type 1/2 was used. Bacteria were grown 
for 16 h at 37'C in Todd-Hewitt broth (Oxoid Ltd, Basingstoke, England) and preserved on 
ice. Directly before the inoculation of mice, the bacteria were washed twice with PBS. 
Experimental infection caused by L. monocytogenes. Infections were induced by 
intravenous inoculation of 5x!04 CFU L. monocytogenes into C57Bl/Ka mice. At different 
intervals after inoculation, blood samples were taken from the retroorbital plexus and twofold 
diluted in 3.8% sodium citrate (BDH Chemicals Ltd, Poole, England). Serial !0-fold dilutions 
in PBS were prepared and volumes of 0. 2 ml of each dilution were spread on tryptone soya 
agar (TSA) plates (Oxoid Ltd, Basingstoke, England). Mice were then sacrificed and spleen 
and liver were removed and each was homogenized in 20 ml of PBS for 30 sat 10,000 rpm 
in a VirTis homogenizer (The VirTis Co. Inc., Gardiner, New York). SeriallO-fold dilutions 
of homogenate in PBS were prepared. Volumes of 0.2 ml of each dilution and 2 ml volumes 
of the undiluted homogenate were spread on TSA plates. The remainder of the homogenate 
together with an equal volume of double concentrated TSA was poured in plastic plates. All 
plates were incubated for 48 hat 37°C. The number of viable bacteria recovered from liver, 
spleen and blood was used as a parameter of therapeutic efficacy. 
Mono/ayers of peritoneal macro phages infected with L. monocytogenes. Monolayers of 
peritoneal macrophages from C57Bl/Ka mice were cultured at 37'C in chamber-slides (Miles 
laboratories Inc., Naperville, Illinois) in an humidified atmosphere of 7.5% C~ in air in 
culture medium containing Dulbecco modified Eagle medium (D-MEM, Flow Laboratories, 
Irvine, Scotland) with 1% glutamine and 15% fetal bovine serum (FBS, HyClone 
Laboratories Inc., Logan, Utah, USA) for 48 h before incubation with bacteria. After the first 
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2 h of incubation fresh culture medium was added to the monolayer. The cells were exposed 
24 h before incubation with bacteria to MTPPE or IFN-)', or to PBS. At zero time bacteria 
were added in a ratio of 16 bacteria per macrophage. After an uptake period of 30 min the 
noningested bacteria were removed by washing the monolayer three times with culture 
medium. The macrophages were reincubated for 6 h. In some experiments scavengers of 
reactive oxygen and nitrogen intermediates were added during the uptake of bacteria and the 
reincubation of the macrophages. At different time intervals during the period of reincubation, 
monolayers were washed with icy-cold culture medium and the macrophages were disrupted 
by quickly freezing and thawing and vigorously mixing of the cell suspension. The 
intracellular numbers of viable bacteria were determined by preparing tenfold serial dilutions. 
Volumes of 0.2 ml of each dilution were spread on TSA plates. All plates were incubated for 
48 h at 37°C. 
Statistical analysis. Statistical evaluation of differences in numbers of bacteria between 
MTPPE-treated, LE-MTPPE-treated, IFN-)'-treated, LE-IFN-)'-treated and PBS-treated 
groups of animals was performed by using the Mann-Whitney test. 
Results 
Effect of free MTPPE and liposome-encapsulated MTPPE (LE-MTPPE) on L. 
monocytogenes infection. After intravenous injection of 5x104 CFU L. monocytogenes, most 
bacteria are taken up by liver and spleen. Numbers increased rapidly until 72 h after bacterial 
inoculation. Thereafter, bacterial numbers in the liver remained stable until 120 h after 
bacterial inoculation, and numbers in the spleen slightly decreased. Figure 8.1 shows that 
administration of a dose of 100 p.g free MTPPE at 24 h before bacterial inoculation resulted 
in significantly decreased bacterial numbers in liver and spleen at 120 h after inoculation. 
Administration of a dose of 50 p.g was only effective in the spleen not in the liver, and a dose 
of 25 p.g had no effect anymore on bacterial numbers in liver and spleen. However, when a 
dose of 25 l'g MTPPE was given in the liposome-encapsulated form, bacterial numbers in 
liver and spleen were significantly decreased. From a twofold dose range, 3.1 l'g LE-
MTPPE was the lowest dose that resulted in decreased bacterial numbers in liver and spleen. 
Administration of a dose of 1.6 p.g LE-MTPPE or lower was not effective anymore. In 
addition, a dose of 6.3 mg placebo liposomes (the equivalent of the amount of lipid in which 
25 p.g MTPPE was encapsulated) had no effect on bacterial numbers (data not shown). 
Administration of the doses of LE-MTPPE that resulted in significant lower numbers 
of bacteria in liver and spleen at 120 h after bacterial inoculation (25 p.g, 6.3 p.g or 3.1 p.g 
LE-MTPPE) also led to decreased bacterial numbers at 72 h (Figure 8.2). Administration of 
free MTPPE (100 p.g) only resulted in decreased bacterial numbers at 120 h, not at 72 h. 
Effect of free IFN-)' and liposome-encapsulated IFN-)' (LE-IFN-)') on L. monocytogenes 
infection. Figure 8.3 shows that administration of a dose of 12500 U IFN-1' at 24 h before 
bacterial inoculation resulted in significantly decreased bacterial numbers in liver and spleen 
at 120 h after bacterial inoculation. From a twofold dose range this appeared to be the lowest 
effective dose, since administration of a dose of 6250 U IFN-)' or lower was not 
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FIGURE 8.1 Effect of free MTPPE and Jiposome-encapsulated MTPPE (LE-MTPPE) on numbers 
of L. monocytogenes in liver and spleen. At 24 h before i.v. inoculation with 5xlo4 CFU L. 
monocytogenes, mice were i.v. treated with one dose from a twofold dose range (25 p,g- 100 J..Lg) of 
free MTPPE, or with one dose from a twofold dose range (0.8 p,g - 25 J..Lg) of LE-MTPPE, or with 
PBS. Each point represents the geometric mean for six mice ± SEM at 120 h after bacterial 
inoculation. Significance *p~O.OS **p:::;;0.02 ***ps;0.002 versus PBS-treated mice. 
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FIGURE 8.2 Effect of free MTPPE and Jiposome-encapsulated MTPPE (LE-MTPPE) on numbers 
of L. monocytogenes in liver and spleen. At 24 h before i.v. inoculation with 5xlo4 CFU L. 
monocytogenes, mice were i.v. treated with 100 J.Lg of free MTPPE (8--- ---$),or with 3.1 J.Lg 
(o----o), 6.3Jtg (0-- -o), or 25Jtg (o· ·· · ·· o) ofLE-MTPPE per mouse, or with PBS 
(&-----e). Each point represents the geometric mean for six mice. Significance *p 5:0.05 **p 5:0.02 
***p 5:0.002 versus PBS-treated mice. 
93 
liVER SPLEEN 
' 
6,---------------------------, 
.. 
I ... I ]* 
' 
6 
• 2500 6250 3125 390 195 97 48 
' 
... 
. .. 
f ~ • ' ' 
3125 390 ,,, 
" 
48 0 
4 
0 3 12500 6250 
IFN , I c.l __ _;l::Ec_-':_:FN.:_-_:Y ___ _JII PBS I lE 'FN 'l t t Pest IFN-y IIL_ ____ =_::_:;c_.:_ ______ _j 
FIGURE 8,3 Effect of free lFN-r and liposome-encapsulated JFN-r (LE-JFN-')') on numbers of L. 
monocytogenes in liver and spleen. At 24 h before i. v. inoculation with 5x 104 CFU L. monocytogenes, 
mice were i.v. treated with one dose from a twofold dose range (6250 U- 12500 U) of free IFN-y, 
or with one dose from a twofold dose range (48 U- 3125 U) ofLE-IFN-y, or with PBS. Each point 
represents the geometric mean for six mice ± SEM at 120 h after bacterial inoculation. Significance 
*p s0.05 **p s0.02 ***p s0.002 versus PBS-treated mice. 
not effective anymore. However, when a dose of 3120 U IFN-y was given in the liposome-
encapsulated form, bacterial numbers in liver and spleen were significantly decreased. From 
a twofold dose range 195 U LE-IFN--y was the lowest dose that resulted in decreased bacterial 
numbers in liver and spleen. Administration of a dose of 97 U LE-IFN--y or lower was not 
effective anymore. 
Administration of the doses of LE-IFN-r that resulted in significant lower numbers of 
bacteria in liver and spleen at 120 h after bacterial inoculation (3120 U, 390 U or 195 U LE-
IFN--y) also led to decreased bacterial numbers at 72 h (Figure 8.4). Administration of free 
IFN--y (12500 U) only resulted in decreased bacterial numbers at 120 h, not at 72 h. 
Influence of the MTPPE to lipid ratio an the antibacterial resistance against L. 
monocytogenes. Administration ofnontherapeutic doses ofLE-MTPPE became effective when 
encapsulated in increasing amounts of lipid (Table 8.1). Administration of 0.8 l'g MTPPE 
in 1.6 mg lipid had no effect on bacterial numbers in liver and spleen atl20 h after bacterial 
inoculation, compared to numbers in PBS-treated mice as shown in Figure 8.1. Increasing 
the amount of encapsulating lipid led to significantly decreased numbers of bacteria in liver 
and spleen. The same results were found for 1.6 l'g MTPPE encapsulated in increasing 
amounts of lipid. 
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FIGURE 8.4 Effect of free IFN-1 and !iposome-encapsulated IFN-1 (LE-IFN-1) on numbers of L. 
monocytogenes in liver and spleen. At 24 h before i.v. inoculation with 5xHt CFU L. monocytogenes, 
mice were i.v. treated with 12500 U of free IFN-1 (- - •), or with 195 U (0-- - -0) or 390 
U (O· ····· · o) or 3125 U ofLE-IFN-1 (o--- --o), or with PBS (6 e). Each point represents 
the geometric mean for six mice. Significance *p s;:0.05 **p s: 0.02 ***p s; 0.002 versus PBS-treated 
mice. 
TABLE 8.1 Influence of the MTPPE to lipid ratio on the antibacterial resistance against L. 
monocytogenel-
Dose of Dose of lipid (mg)b 
MTPPE (pg)3 0.8 1.6 3.1 6.3 
a 
0 _CI_d -I-
0.4 -I- -I-
0.8 -I- -1+ +I+ 
1.6 -I- +I- +I+ 
3.1 +I+ +I+ 
At 24 h before i.v. inoculation with 5x104 CFU L. monocytogenes, mice were treated with one 
dose from a twofold dose range of MTPPE encapsulated in liposomes. 
b 
c/d 
The amount of lipid in which MTPPE was encapsulated. 
Numbers of bacteria in the liver/spleen of mice treated with LE-MTPPE (n=6) compared to 
bacterial numbers in the liver/spleen of PBS-treated mice (n= 12) at 120 h after bacterial 
inoculation. Significance:+ = p:::;O.OS,- =not significant. 
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Influence of the IFN-y to lipid ratio on the antibacterial resistance against L. 
monocytogenes. Administration of non therapeutic doses of LE-IFN-y became effective when 
encapsulated in increasing amounts of lipid (Table 8.2). Administration of 48 U !FN-yin 0.2 
mg lipid had no effect on bacterial numbers in liver and spleen at 120 h after bacterial 
inoculation, compared to numbers in PBS-treated mice as shown in Figure 8.3. Increasing 
the amount of encapsulating lipid led to significantly decreased numbers of bacteria in liver 
and spleen. The same results were found for 97 U IFN-'Y encapsulated in increasing amounts 
of lipid. 
TABLE 8.2 Influence of the IFN-r to lipid ratio on the antibacterial resistance against L. 
monocytogenes2 
Dose of Dose of lipid (mg)b 
IFN-y (U)a 0.2 0.4 0.8 1.6 3.1 6.3 
0 _cl_d -1-
24 -I- -I- -I- -I-
48 -1- -1+ -I- +I+ +I+ +I+ 
97 -I- -1+ +I+ 
195 +I+ 
a At 24 h before i.v. inoculation with 5xl04 CFU L. monocytogenes, mice were treated with one 
dose from a twofold dose range of IFN-'Y encapsulated in liposomes. 
b The amount of lipid in which IFN-r was encapsulated. 
c/d Numbers of bacteria in the liver/spleen of mice treated with LE-IFN-y (n=6) compared to 
bacterial numbers in the liver/spleen of PBS-treated mice (n= 12) at 120 h after bacterial 
inoculation. Significance:+ = p~0.05,- =not significant. 
Effect of MTPPE and IFN-y co-encapsulated in liposomes on L. monocytogenes 
ilifection. Administration of 1.6 p.g MTPPE and 97 U IFN-r co-encapsulated in 0.2 mg of 
liposomallipid led to significantly decreased bacterial numbers in liver and spleen at 120 h 
after bacterial inoculation (Table 8.3). A dose of 1.6p.g LE-MTPPE alone, or 97 U LE-IFN-
'Y alone had no effect on bacterial numbers when administered in 0.2 mg of liposomallipid. 
Also twofold lower doses of MTPPE and IFN-y, 0. 8 p.g and 48 U, respectively, co-
encapsulated in liposomes resulted in significantly decreased numbers of bacteria. 
Effect of MTPPE and IFN-y on the uptake and intracellular survival of L. 
monocytogenes in macrophages in monolayer. Table 8.4 shows that in macrophages not 
exposed to MTPPE or !FN--y numbers of intracellular bacteria increased 7-fold within 6 hours 
after bacterial uptake. In macrophages exposed for 16 h to MTPPE at a concentration from 
a fourfold dose range, ranging from 0.1-100 p.glml, bacterial numbers increased in the same 
way as in untreated macrophages, (the data obtained at 1.6p.glml are shown). Incubation of 
the macrophages with a dose of IFN-y from a fourfold dose range, ranging from 15 U- 1000 
Ulml, led to inhibition of bacterial growth (the data obtained at the lowest effective dose of 
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TABLE 8.3 Effect of a combination of MTPPE and IFN--y co-encapsulated in liposomes on 
antibacterial resistance against L. monocytogenesa 
Dose of Dose of MTPPE (!'g)• 
IFN-y (U)a · 0 0.8 1.6 
0 
48 
97 
a 
ND _bj_C -1-
-/- +I+ ND 
-1- ND +I+ 
At 24 h before i.v. inoculation with 5x104 CFU L. monocytogenes, mice were treated with 0.2 
mg liposomal lipid per mouse in which IFN-y or MTPPE or both IFN-y and MTPPE were 
encapsulated. 
b/c Numbers of bacteria in the liver/spleen of mice treated with LE-MTPPE (n=6) compared to 
bacterial numbers in the liver/spleen of PBS-treated mice (n= 12) at 120 h after bacterial 
inoculation. Significance: + = p ::;;0.05,- = not significant. 
250 U/ml are shown). Incubation of the macrophages with a combination of 1.6 l'g 
MTPPE/ml and 250 U IFN-y/mlled to killing of the intracellular bacteria from 4 h after 
bacterial uptake. 
Effect of scavengers of reactive oxygen and nitrogen metabolites on the killing of L. 
monocytogenes. Table 8.5 shows that incubation of macrophages, previously activated with 
a combination of 1.6 l'g MTPPE/ml and 250 U IFN-y/ml, in the presence of scavengers of 
reactive oxygen metabolites: SOD (300 U/ml) or SA (1 l'mol/ml) or CAT (15000 U/ml) or 
DMSO (300 l'mol/ml), or with scavengers of reactive nitrogen metabolites (NMMA, 100 
l'g/ml) led to inhibition of the killing of intracellular L. monocytogenes. 
TABLE 8.4 Effect of MTPPE and IFN·y on uptake and intracellular survival of L. monocytogenes 
in peritoneal macrophage& in monolaye~ 
Treatment 
MTPPE 
IFN-y 
MTPPE+ IFN--y 
PBS 
Log CFU L.monocyrogenes per 106 macrophages at times (h) after 
bacterial uptakeb 
0 4 6 
5.84±0.15 5.86±0.17 6.32±0.16 
5.72±0.07 5.64±0.07* 5.72±0.08** 
5.43±0.09 5.18±0.08** 4.82±0.06** 
5.55±0.05 5.97±0.08 6.34±0.05 
a 
b 
Before incubation with bacteria, macrophages in monolayer culture were exposed for 16 h to 
MTPPE (1.61'glml), IFN-y (250 Ulml), or MTPPE (1.61'glml) plus IFN-y (250 U/ml) or PBS. 
Data represent the geometric mean ± SEM for six observations or sixteen observations (control). 
Significance: *p ::;;9.05 **p ::;;0.02 vs PBS. 
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TABLE 8.5 Effect of scavengers of reactive oxygen intermediates and reactive nitrogen intermediates 
on the intracellular survival of L. monocytogenes in peritoneal macrophages in monolayer 
exposed to a combination of MTPPE and IFN-')'a 
Treatmenta 
MTPPE+IFN-'Y+SOD 
MTPPE+ IFN-'Y+SA 
MTPPE+IFN-'Y+CAT 
MTPPE+ IFN-'Y+ DMSO 
MTPPE + IFN-'Y+ NMMA 
MTPPE+ IFN-'Y 
PBS 
Log CFU L. monocytogenes per Jcfi macrophages at 
times (h) after bacterial uptakeb 
0 4 6 
5.73±0.09 6.16±0.04 6.32±0.09 
5.42±0.12 6.14±0.22 5.60±0.10 
5.37±0.09 6.08±0.17 6.55±0.07 
5.24±0.13 6.03±0.02 5.59±0.20 
5.71±0.05 5.84±0.10 6.10±0.08 
5.43±0.09 5 .18±0.08** 4.82±0.06*** 
5.55±0.05 5.97±0.08 6.34±0.05 
a Before incubation with bacteria, macrophages in monolayer culture were exposed for 16 h to 
MTPPE (1.6 fg/ml) plus IFN-'Y (250 U/ml) or PBS. Uptake and intracellular survival of bacteria 
was studied in the presence of scavengers: superoxide dismutase (SOD, 300 U/ml), sodiumazide 
(SA, I fiDOl/ml), catalase (CAT, 15000 U/ml), dimethyl sulfoxide (DMSO, 300 fiDOI/ml) or rfl-
monomethyl-arginine acetate (NMMA, lOO fg/ml). 
b Data represent the geometric mean ± SEM for sixteen observations (control) or twelve obser-
vations (MTPPE+IFN-y) or six observations (all other treatments). Significance: **p::;:0.02 
***p ::;:Q.002 versus PBS. 
Discussion 
An increased resistance against various bacterial infections due to administration of 
muramyl peptide derivatives was found by several investigators (158, 167). However, the 
reports about the effects of administration of muramyl peptides on resistance against L. 
monocytogenes infection are contradictory. Some investigators (92, 154,65, !58) found an 
increased resistance, whereas others (65,158) concluded that muramyl peptide derivatives 
were not effective in enhancing the host resistance against L. monocytogenes infection. This 
study shows that administration of MTPPE led to increased antibacterial resistance against 
L. monocytogenes infection in mice, in terms of killing of bacteria in liver and spleen. Due 
to liposomal encapsulation the efficacy of MTPPE was 33-fold increased. These observations 
are in agreement with those of other investigators who found that the resistance against K. 
pneumoniae infection in mice (136), and herpes simplex virus type 2 infection in mice (!12) 
was increased after encapsulation of MTPPE in liposomes. In tumorcytotoxicity studies it was 
often found that liposome-encapsulated muramyl peptide derivatives had increased efficacy 
compared to compounds in the free form (42,172). 
This study also shows that administration of another immunomodulator, IFN-'Y, led to 
increased antibacterial resistance against L. monocytogenes infection. This effect was 66-fold 
increased due to liposomal encapsulation. An increased resistance due to administration of 
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IFN-I' against various bacterial infections was also found by other investigators (95, 132, 142). 
However, the reports about the effects of administration of IFN -)' on resistance against L. 
monocytogenes infection show great discrepancy (31,108,203,204). Mellors et al. observed 
an increased efficacy of IFN-I' after it was encapsulated in liposomes, the efficacy of LE-
IFN-1' was 10-fo1d higher as that of free IFN-I' in in vitro growth inhibition of Toxoplasma 
gondii in macrophages (135). In addition, Smith et al. (194) found an increased efficacy of 
LE-IFN-1' compared to free IFN-I' in stimulating macrophages to tumorcytotoxic activity. 
Liposomal encapsulation of MTPPE or IFN-I' not only allowed a 33- to 66-fold decrease 
in the dose to obtain the same effects of the immunomodulator in the free form, but it also 
led to a more rapid decrease in numbers of L. monocytogenes in liver and spleen. Probably 
this is the result of higher MTPPE and IFN-I' concentrations in the liver and spleen, since as 
a result of liposomal encapsulation the irnmunomodulators have been targeted to these organs. 
Liposomes can interact with cells in several ways. Important is the phagocytosis of liposomes 
by the cells of the MPS, resulting in high intracellular concentrations (156). With respect to 
this Fidler et al. (59,60) showed that liposomal encapsulation allowed IFN-I' and MTPPE to 
bind to intracellular receptors of macrophages. It is also expected that liposomes can be 
adsorbed to cells so that the immunomodulator can slowly leak out, resulting in high local 
concentrations (156). 
We have also shown in this study that the immunomodulator to lipid ratio seemed to be 
of relevance in the by LE-MTPPE and LE-IFN-1' induced antibacterial resistance. When 
nontherapeutic doses of LE-MTPPE or LE-IFN-1' were administered in a larger amount of 
encapsulating lipid (so at a higher lipid:immunomodulator ratio), these doses became 
effective. Future studies will be necessary to elucidate whether encapsulating a certain amount 
of immunomodulator in increasing amounts of lipid results in activation of macrophages more 
efficiently or activation of higher numbers of macrophages. The influence of the 
immunomodulator:lipid ratio upon the efficacy was also described by other investigators 
(41,186), who showed a higher level of tumorcytoxicity when a same dose of rnuramyl 
dipeptide was administered in more encapsulating lipid. 
When macrophages in monolayer were exposed to MTPPE and IFN-I' in combination 
we have found a synergistic effect of MTPPE and IFN-I' on the bactericidal activity of the 
macrophages. Incubation of macrophages in vitro with MTPPE alone had no effect on the 
intracellular growth of L. monocytogenes, incubation with IFN-I' alone resulted in growth 
inhibition, whereas incubation with a combination of MTPPE and IFN-I' led to killing of the 
intracellular bacteria. Other investigators found that incubation of macrophages with IFN-I' 
alone resulted in an increased bactericidal (104,179), antifungal (21,138) and antiparasitic 
(12,48) activity. A synergistic antiparasitic activity of macrophages in vitro against 
Leishmania donovani was shown by Hockertz et a!. (89) after incubating the macrophages 
with a combination of MTPPE and IFN-)'. Exposure of macrophages in vivo to MTPPE and 
IFN-I' in combination may be realized by injection of liposomes in which both 
immunomodulators were co-encapsulated. It was shown that co-encapsulation of IFN-')' and 
MTPPE in liposomes was synergistic in enhancing the antibacterial resistance against L. 
monocytogenes infection. Synergism due to co-encapsulation of muramyl peptide derivatives 
and IFN-I' was demonstrated in vitro in tumorcytotoxicity studies by Saiki et al. (186) and 
Fidler et al. (57). They found synergistic effects of MDP and IFN-I' in activating 
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macrophages in vitro to tumorcytotoxicity. Hockertz et a!. (89) found synergistic effects of 
!FN--y and MTPPE co-encapsulated in liposomes in stimulating the resistance of mice against 
Leishmania donovani infection. 
We found that reactive oxygen as well as nitrogen metabolites seem to play a role in the 
by MTPPE and IFN--y induced bacterial killing. Other investigators only have studied the 
antimicrobial mechanisms of macrophages activated with IFN--y alone. In these studies 
reactive oxygen metabolites or reactive nitrogen metabolites played a role in the killing or 
growth inhibition of microorganisms by IFN--y activated macrophages. They have 
demonstrated this by finding an increased production of the metabolites themselves: 0 2-, 
H2o 2 (47,101,104) or No2- (47,64) or by showing a prevention of killing of growth 
inhibition of microorganisms due to incubation of the IFN--y activated macrophages with 
scavengers of the metabolites (21 ,64, 170). 
In summary, this study shows that administration of MTPPE and IFN--y led to increased 
resistance againstL. monocytogenes infection in terms of decreased bacterial numbers in liver 
and spleen. Encapsulation of MTPPE or IFN--y in liposomes increased their efficacy and in 
addition resulted in a more rapid decrease in bacterial numbers. Exposure of macrophages 
in vitro to a combination of MTPPE and IFN--y resulted in a synergistic antibacterial activity. 
By using liposomes as carriers in which MTPPE and IFN-')' were co-encapsulated also in vivo 
cells could be exposed to both immunomodulators in combination, resulting in a synergistic 
antibacterial effect. 
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CHAPTER9 
GENERAL DISCUSSION 
Infections in immunocompromised patients are often treated unsuccessfully as a result 
of insufficient support from the host defense system to antibiotic treatment (8, 164). The cells 
of the MPS play a major role in the defense against infections. With respect to this, stimulati-
on of these cells might be of great importance for the potentiation of treatment of severe 
infections. To this aim immunomodulators can be applied. Various experimental studies in 
animals were performed to investigate the efficacy of immunomodulators to enhance 
antimicrobial resistance. Models of bacterial infection (83,151,158,207), fungal infection 
(51,54,100,104,212), viral infection (51,93,112,175), as well as protozoal infection 
(5 ,25 ,45, 109, 120) were used. The immunomodulators were in most cases administered in the 
free form via several routes (subcutaneously, intraperitoneally, intravenously or intranasally) 
and usually a single dose was given. In most studies the resistance against microbial 
infections was enhanced in terms of increased survival of infected animals. Some 
immunomodulators, among which MTPPE and IFN-')' are at present under investigation in 
clinical studies in cancer patients to stimulate cells of the MPS in the removal of metastases 
(56,70,125). In addition, IFN--y is successfully used in patients with chronic granulomatous 
disease, in which the microbial infections could not be cured with antibiotics (11,189). 
The aim of this thesis was to gain insight into the possibilities and restrictions of 
clinical application of immunomodulators in the free form as well as in the less toxic 
liposome-encapsulated form (90,118,188) in order to enhance resistance against bacterial 
infections. To illustrate this, different models of infection in mice were used. 
In one experimental model, infections were induced with L. monocytogenes. This 
bacterium is easily taken up by cells of the MPS and is able to resist killing by these cells. 
In other experimental models, infections were induced with K. pneumoniae, a bacterium 
that, when it is not opsonized by specific antibodies, is poorly taken up by cells of the MPS. 
When K. pneumoniae infection was induced by i.v. inoculation, about 80% of the bacteria 
were cleared from the blood by liver and spleen, resulting in death of all mice due to 
septicemia (artificially-induced septicemia). In a more clinically relevant model of infection 
K. pneumoniae was inoculated i.p. In this model multiplication of bacteria i.p. resulted in 
appearance of bacteria in the blood at regular intervals. Eventually all mice died due to 
septicemia (naturally-induced septicemia). As a parameter for efficacy of treatment, survival 
of animals was used as well as significant decreases in the numbers of bacteria in the infected 
organs and blood. 
In the first studies, the efficacy of MTPPE and IFN--y in the free form to induce 
nonspecific resistance in relation to the genetically determined antimicrobial resistance was 
investigated. It appeared that the MTPPE induced resistance against L. monocytogenes 
infection depended on the genetically determined innate resistance to this infection. For 
the efficacy of IFN--y no such relationship was observed (Chapter 2, Chapter 3). Since 
in man genetic factors also contribute to the susceptibility to intracellular infections caused 
by Mycobacterium spp (22, 193) usefulness of MTPPE may be restricted in this type of 
infection. The MTPPE induced antibacterial resistance seemed to be correlated with the 
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capacity of MTPPE to recruit leukocytes from the bone marrow. These increased numbers 
of leukocytes (monocytes, granulocytes, lymphocytes) in the blood after treatment with 
MTPPE are probably the result of increased levels of CSF, a lymphokine which enhances the 
proliferation and differentiation of these cells in the bone marrow (34). Increased levels of 
CSF and increased numbers of leukocytes in the blood were found after administration of 
another lipophilic muramyl peptide derivative, MDP-Lys(Ll8) (218). These recruited 
leukocytes are expected to migrate to the infected organs. The IFN-'Y induced resistance 
against L. monocytogenes was not related to the capacity of IFN-')' to recruit leukocytes. The 
usefulness of IFN-')' to enhance resistance against bacterial infections in man, differing in 
susceptibility to intracellular infections, has to be investigated. 
In the MTPPE and !FN-'Y induced resistance against L. monocytogenes infection other 
cell types besides the macrophage are involved. This conclusion derives from our observati-
ons that in vitro exposure of macrophages to MTPPE did not result in killing of intracellular 
L. monocytogenes. After exposure of macrophages to IFN-'Y intracellular growth was only 
inhibited. Our in vivo and in vitro observations suggest that the induced antibacterial resistan-
ce by MTPPE or IFN-')' is mediated by different mechanisms. 
Studies were continued with MTPPE in the free form or in the liposome-encapsulated 
form in the two models of K. pneumoniae infection. The artificially-induced K. pneumoniae 
septicemia could be prevented by administration of a single dose ofMTPPE (Chapter 4). LE-
MTPPE was also effective even at a 2-fold lower dose. Bacterial numbers were decreased not 
only in liver and spleen, organs rich in cells of the MPS and primarily important in the 
clearance of bacteria from the blood, but also in lung and kidney, organs containing fewer 
cells of the MPS. Whether the decrease in bacterial numbers in these organs is the result of 
the activation of the macrophages locally, or by a decreased presence of bacteria in the blood 
due to an increased removal of bacteria from the blood by activated macrophages in liver and 
spleen, is not yet clear. 
To obtain a therapeutic effect in the models of K. pneumoniae infection, MTPPE and 
LE-MTPPE had to be given prophylactically. In the model of naturally-induced K. 
pneumoniae septicemia a single dose of MTPPE or LE-MTPPE was only partially 
effective (Chapter 6). Repeated prophylactic administration of LE-MTPPE led to 
improvement in efficacy. This emphasizes the importance of liposomal encapsulation, 
resulting in a less toxic formulation and allowing repeated administration (58,188). As 
observed in the model of L. monocytogenes infection, treatment with MTPPE and LE-MTPPE 
also resulted in the recruitment of leukocytes in the models of K. pneumoniae infection. 
However, it appeared that, in these infection models, the recruitment of leukocytes did not 
contribute significantly in the resistance against the infection locally. A discrepancy was 
observed between the K. pneumoniae model and the L. monocytogenes model, since in the 
latter model the MTPPE induced recruitment of leukocytes correlated with the therapeutic 
effect. In L. monocytogenes infection a great influx of monocytes, granulocytes, NX cells and 
T-cells in the infected liver was observed by other investigators (80), indicating an important 
role for these cells in the host defense against this infection. In the MTPPE or LE-MTPPE 
induced resistance against K. pneumoniae infection, the recruitment of leukocytes seemed 
to be of minor importance. However, the activation of tissue macrophages in liver and 
spleen by MTPPE or LE-MTPPE was of major importance in the induced resistance 
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against this infection (Chapter 5), The clinical relevance of this observation is that, 
immunocompromised patients, which are often leukopenic, may benifit from treatment with 
LE-MTPPE. In leukopenic patients, development of septicemia from a local infection occurs 
at an early stage, and maximal blood clearance capacity of the MPS is of great importance. 
A substantial amount of liposomes encapsulating MTPPE was distributed over liver and 
spleen, the organs which are of primary importance in the uptake of bacteria from the blood 
(Chapter 7). It was shown that the cells that had taken up K. pneumoniae often did not 
contain LE-MTPPE. Taken also into account the observation that exposure of macrophages 
to LE-MTPPE in vitro did not result in increased uptake or killing of the intracellular 
bacteria, it is suggested that LE-MTPPE does not stimulate macrophages directly to 
increased uptake or killing of bacteria. Other cell types besides the macrophages are 
probably involved and communication between the cells by means of cytokines seems 
necessary (Chapter 7). Future studies are needed to elucidate which cell types and which 
cytokines are involved. Such studies will provide further insight into the usefulness of 
immunomodulators in patients, immunocomprornised in different ways. 
Administration of MTPPE or IFN-1' in the liposome-encapsulated form also led to 
resistance against L. monocytogenes infection (Chapter 8). The liposomal formulation being 
effective at a 33-fold or 66-fold lower dose, respectively, compared to the agents in the free 
form. In this induced antibacterial resistance, the immunomodulator to lipid ratio appeared 
to be of importance (Chapter 8). When non therapeutic doses of MTPPE or IFN-"Y in the 
liposome-encapsulated form were administered in a larger amount of encapsulating lipid (ie. 
a lower immunomodulator to lipid ratio), these doses became effective. A possible 
explanation for this may be that macrophages are more efficiently activated when exposed to 
more liposomes containing MTPPE or IFN-'Y, or that greater numbers of macrophages are 
activated. 
It remains to be elucidated why the liposome-encapsulated form is effective at a lower 
dose than the agent in the free form. With respect to LE-MTPPE, other investigators have 
shown that the increased therapeutic efficacy was related to increased levels in lung and 
spleen, as well as to a much longer presence of relatively high MTPPE concentrations in the 
liver (66). With respect to LE-IFN-1', it was shown by others (89) that after liposomal 
encapsulation more than 60% of the administered IFN-1' was accumulated in liver and spleen, 
whereas free IFN-')' was distributed equally among all compartments. 
It was shown that, exposure of macrophages infected with L. monocytogenes in vitro 
to both MTPPE and IFN-1' at the same time resulted in a synergistic antibacterial effect with 
the intracellular killing of the bacteria. Reactive oxygen as well as reactive nitrogen 
metabolites seemed to play a role in the MTPPE plus IFN-1' induced bacterial killing. The 
value of this synergistic effect for treatment of infections is questionable since exposure of 
macrophages in vivo to both immunomodulators simultaneously after i.v. administration of 
the agents is expected to be minimal. However, the synergistic effect in vivo could be 
realized by administration of the immunomodulators co-encapsulated in the same liposome. 
Doses of MTPPE and IFN-1' that were not effective when administered in separate 
liposomes, resulted in antibacterial resistance against L. monocytogenes infection, when 
administered after co-encapsulation in liposomes (Chapter 8). 
In conclusion, in this thesis it is shown that treatment with MTPPE and IFN-1' in the 
103 
liposome-encapsulated form appeared to be useful for enhancing the resistance against 
bacterial infections. Possibilities as well as restrictions of treatment with MTPPE and lFN--y, 
in the free form or in the liposome-encapsulated form, are indicated. For understanding the 
precise mode of action of LE-MTPPE or LE-IFN--y more studies have to be performed in the 
future. In this respect knowledge about which cells and cytokines are involved in the LE-
MTPPE and LE-IFN-y induced enhanced antibacterial resistance is needed. This will lead to 
insight in the usefulness of LE-MTPPE and LE-IFN--y for treatment of infections in patients, 
immunocompromised in various ways. 
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SUMMARY 
From clinical experience it is known that in immunocompromised patients severe 
infections frequently occur and are a continuing threat to patients. Antimicrobial treatment 
of these infections is not always successful, despite the use of new and potent antibiotics. 
Several factors may contribute to the failure of antibiotic treatment. One factor is an impaired 
host defense, unable to provide adequate support for antibiotic therapy. For the potentiation 
of treatment of severe infections stimulation of the nonspecific resistance of the host, 
particularly the cells of the MPS, may be of great value. It is expected that stimulation of the 
MPS not only leads to an increased resistance against infections involving the MPS but also 
to infections in general. Immunocompromised patients are often leukopenic, resulting in 
development of septicemia from a local infection at an early stage. For these patients maximal 
blood clearance capacity of the MPS is of great importance. 
The cells of the MPS can be stimulated by immunomodulators, either from bacterial 
origin, such as muramyl tripeptide phosphatidylethanolamide (MTPPE), or cytokines, such 
as interferon--y (IFN--y). Since immunocompromised patients are prone to infections for a 
prolonged period of time, repeated administration of immunomodulators is anticipated. This 
may result in toxic side effects. To reduce the toxicity the immunomodulating agents can be 
encapsulated in liposomes. These are microscopic vesicles consisting of one or more lipid 
bilayers, surrounding an internal aqueous compartment. In liposomes a variety of agents can 
be entrapped. 
In this thesis MTPPE and IFN--y in the free form or in the liposome-encapsulated form 
were studied for their efficacy to enhance the nonspecific resistance to bacterial infections. 
The aim was to obtain an insight in the possibilities and restrictions of treatment with these 
immunomodulators. This was investigated in experimental bacterial infections in mice. 
In one experimental model, infections were induced with Listeria monocytogenes after 
intravenous inoculation. This bacterium is easily taken up by cells of the MPS and is able to 
resist killing by these cells. It is investigated whether the cells of the MPS, when stimulated 
by MTPPE or IFN--y are able to kill L. monocytogenes. In other experimental models 
infections were induced with Klebsiella pneumoniae, a bacterium that, when it is not 
opsonized by specific antibodies, is poorly taken up by cells of the MPS. It is investigated 
whether in the non-immune host the cells of the MPS, when stimulated by MTPPE are able 
to effectively phagocytose K. pneumonioe. When K. pneumoniae infection was induced by 
intravenous inoculation, about 80% of the bacteria were cleared from the blood by liver and 
spleen, resulting in death of all mice due to septicemia ('artificially-induced septicemia'). In 
a more clinically relevant model of infection K. pneumoniae was inoculated intraperitoneally. 
In this model multiplication of bacteria in the peritoneal cavity resulted in appearance of 
bacteria in the blood at regular intervals. Eventually all mice died due to septicemia ('natural-
ly-induced septicemia'). 
It is known that genetic factors contribute to the susceptibility of man to infections. 
Therefore it was investigated whether the difference in susceptibility is a restrictive factor in 
the usefulness of MTPPE and IFN--y to induce resistance against L. monocytogenes infection 
(Chapter 2, Chapter 3). For this, mouse strains differing in their genetically determined innate 
resistance to L. monocytogenes were used. It appeared that administration of MTPPE to mice 
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relatively resistant to L. monocytogenes infection resulted in an increased resistance to this 
infection, whereas in mice, relatively susceptible, a decrease in resistance was observed. 
These effects appeared to be correlated with the capacity of MTPPE to recruit leukocytes 
from the bone marrow. In contrast, the IFN-'Y induced resistance against L. monocytogenes 
infection seemed not to be related to the genetically determined innate resistance. 
Administration of JFN-')' led in both mouse strains to an increased antibacterial resistance and 
was not related to the capacity of IFN-')' to recruit leukocytes. 
In the MTPPE and IFN-1' induced resistance to L. monocytogenes infection other cell 
types besides the macrophage are probably involved. This conclusion derives from our 
observation that in vitro exposure of macrophages to MTPPE had no effect on the 
intracellular multiplication of L. monocytogenes. After exposure of macrophages to IFN-')', 
intracellular growth of L. moncytogenes was only inhibited. Our in vivo and in vitro 
observations suggest that the induced antibacterial resistance by MTPPE and lFN-1' is 
mediated by different mechanisms. 
Since in the immunocompromised host protection against infections is needed for a 
prolonged period of time, it was investigated what the effects were of administration of 
MTPPE in the less toxic liposome-encapsulated form (LE-MTPPE). This was studied in the 
models of K. pneumoniae infection. The artificially-induced K. pneumoniae septicemia could 
be prevented by a single dose of MTPPE (Chapter 4). LE-MTPPE was also effective even 
at a 2-fold lower dose. Bacterial numbers were decreased not only in liver and spleen, organs 
rich in cells of the MPS, but also in lung and kidney, organs containing fewer cells of the 
MPS. In the naturally-induced K. pneumoniae septicemia, administration of a single dose of 
MTPPE and LE-MTPPE was only partially effective (Chapter 6). The therapeutic efficacy 
in this model of infection was improved after repeated prophylactic administration of LE-
MTPPE. This emphasizes the importance of liposomal encapsulation, resulting in a less toxic 
formulation and allowing repeated administration. 
Particularly in immunocompromised patients, the enhancement of nonspecific resistance 
against infections by administration of immunomodulators may be of importance. These 
patients are often leukopenic. It was investigated what the relative roles were of the 
recruitment of leukocytes, on the one hand, and the activation of tissue macrophages, on the 
other hand, both of which are induced by MTPPE or LE-MTPPE. In the model of naturally-
induced K. pneumoniae septicemia it was possible to discriminate between both effects of 
treatment with MTPPE or LE-MTPPE, since recruitment of leukocytes and their phagocytic 
capacity now could be quantitated. The recruitment of leukocytes appeared to be of minor 
importance in the MTPPE or LE-MTPPE induced resistance against K. pnewnoniae infection 
(Chapter 5). However, the activation of tissue macrophages in liver and spleen by MTPPE 
or LE-MTPPE was of major importance. The clinical relevance of this observation is that 
immunocompromised patients, which are often leukopenic may benefit from treatment with 
LE-MTPPE. 
The observation that the MTPPE and LE-MTPPE induced recruitment of leukocytes in 
the model of K. pnewnoniae infection did not contribute significantly to the resistance against 
the infection locally, is in contrast with findings in the L. monocytogenes model in which the 
MTPPE induced recruitment of leukocytes correlated with the therapeutic effect. 
A substantial amount of liposomes encapsulating MTPPE was distributed over liver and 
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spleen, the organs which are of primary importance in the uptake of bacteria from the blood 
(Chapter 7). It was shown that the cells that had taken up K. pneumoniae often did not 
contain LE-MTPPE. This indicates that LE-MTPPE does not stimulate macrophages directly 
to an increased uptake or killing of bacteria. Taken also into account the observation that 
exposure of the macrophages to LE-MTPPE in vitro did not result in an increased uptake or 
killing of K. pneumoniae, it may be concluded that other cell types besides macrophages 
appear to be involved and communication between various cells by means of cytokines seems 
necessary. 
Administration of MTPPE or IFN-'Y in the liposome-encapsulated form also led to 
resistance against L. monocytogenes infection (Chapter 8). The liposomal formulation was 
effective at a 33- or 66-fold lower dose, respectively, compared to agents in the free form. 
In this induced antibacterial resistance the immunomodulator to lipid ratio appeared to be of 
importance. Nontherapeutic doses of MTPPE or IFN-'Y in the liposome-encapsulated form 
became effective when administered in a larger amount of encapsulating lipid. 
Exposure of macrophages infected with L. monocytogenes in vitro to both MTPPE and 
IFN-'Y at the same time led to a synergistic antibacterial effect with intracellular bacterial 
killing. Reactive oxygen as well as reactive nitrogen metabolites seemed to play a role in the 
MTPPE plus IFN-'Y induced bacterial killing. The value of this synergistic effect for treatment 
of infections is questionable since exposure of macrophages in vivo to both 
immunomodulators simultaneously after intravenous administration of the agents is expected 
to be minimal. Therefore it was investigated whether this synergistic effect could be realized 
by intravenous administration of MTPPE and IFN-'Y co-encapsulated in liposomes. Doses of 
MTPPE or IFN-'Y that were not effective when administered in separate liposomes, resulted 
in antibacterial resistance against L. monocytogenes infection, when administered after co-
encapsulation in liposomes. 
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SAMENV ATTING 
Uit klinische ervaring blijkt dat bij patienten met een verminderde weerstand emstige 
infecties regelmatig voorkomen en een voortdurende bedreiging zijn. Ondanks de toepassing 
van recent ontwikkelde en in vitro goed werkzame antimicrobiele middelen is de behandeling 
niet altijd succesvol. Verschillende factoren dragen bij tot het falen van de therapie. Ben 
ervan is het feit dat de afweer van de gastheer verminderd is en onvoldoende ondersteuning 
kan geven aan de antibioticumbehandeling. Ten behoeve van een verbetering van de 
behandeling van emstige infecties zou stimulatie van de niet-specifieke afweer, met name van 
de cellen van het mononucleaire phagocyten systeem (MPS), van grate waarde kunnen zijn. 
De verwachting is dat door stimulatie van het MPS zowel de afweer tegen infecties in het 
MPS zelf, als de afweer tegen infecties in het algemeen versterkt wordt. Patienten met een 
verminderde weerstand zijn immers vaak leukopenis.ch, waardoor een lokale infectie 
gemakkelijk tot een sepsis kan leiden. Voor deze patienten is het dan oak van groot belang 
dat het vermogen van het MPS om bacterien uit het bloed weg te vangen, maximaal is. 
De cellen van het MPS kunnen gestimuleerd worden door immunomodulatoren, hetzij 
stoffen van bacteriele oorsprong, bijvoorbeeld muramyl tripeptide phosphatidylethanolamide 
(MTPPE), hetzij cytokinen, bijvoorbeeld interferon-)' (IFN-)'). Omdat patienten met een 
verminderde weerstand gedurende een langere periode verhoogd gevoelig zijn voor infecties, 
zullen naar verwachting de immunomodulatoren herhaalde mal en moeten worden toegediend. 
Dit kan echter toxische neveneffecten tot gevolg hebben. Om de toxiciteit te verminderen 
kunnen immunomodulerende middelen in liposomen worden ingekapseld. Liposomen zijn 
microscopisch kleine bolletjes, bestaande uit een of meerdere lipide bilagen die waterige 
compartimenten omsluiten. In liposomen kunnen allerlei stoffen van verschillende aard 
worden ingebouwd. 
In dit proefschrift wordt beschreven in hoeverre MTPPE en IFN-)', in vrije vorm of in-
gekapseld in liposomen (LE-MTPPE, LE-IFN)'), in staat zijn de niet-specifieke afweer tegen 
bacteriele infecties te versterken. Het doel was om inzicht te krijgen in de mogelijkheden en 
beperkingen van de behandeling met de twee genoemde immunomodulatoren. Dit werd 
onderzocht in modellen van bacteriele infecties in muizen. 
In een experimenteel model werden infecties geinduceerd door intraveneuze inoculatie 
van Listeria monocytogenes. Deze bacterie wordt weliswaar gemakkelijk opgenomen door 
cellen van het MPS, maar kan de intracellulaire killing weerstaan. Onderzocht werd of cellen 
van het MPS, wanneer gestimu!eerd door MTPPE of lFN-)', de bacterie kunnen doden. In 
andere experimentele modellen werden infecties geinduceerd door Klebsiella pneumoniae. Dit 
is een bacterie die, wanneer niet geopsoniseerd door specifieke antilichamen, moeilijk wordt 
opgenomen door cellen van het MPS. Onderzocht werd of in de niet-immune gastheer 
stimulatie van de cellen van het MPS door MTPPE, leidde tot effectieve opname en killing 
van de bacterie. In de K. pneumoniae infectie gei'nduceerd door intraveneuze inoculatie, werd 
ongeveer 80% van de bacterien door de lever en milt uit het bloed weggevangen, hetgeen 
resulteerde in de dood van aile muizen als gevolg van sepsis ('artificieel-geinduceerde 
sepsis'). In een ander klinisch meer relevant infectiemodel, werd K. pneumoniae 
intraperitoneaal geinoculeerd. Vermenigvuldiging van bacterien in de peritoneale holte leidde 
tot een regelmatige strooiing van bacterien in het bloed. Uiteindelijk stierven aile muizen ten 
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gevolge van sepsis ('natuurlijk-ge!nduceerde sepsis'). 
Bij de mens word! de gevoeligheid voor infecties mede bepaald door genetische 
factoren. In dit proefschrift werd onderzocht of dit verschil in infectiegevoeligheid een 
beperkende factor is in de bruikbaarheid van MTPPE en IFN--y om de afweer tegen deL. 
monocytogenes infectie te verhogen (Hoofdstuk 2, Hoofdstuk 3). Hiervoor werden 
muizestammen gebruikt, met een verschillende genetisch bepaalde weerstand tegen L. 
monocytogenes infectie. Toediening van MTPPE aan muizen die relatief infectieresistent 
waren, leidde bij deze muizen tot een versterking van de afweer. Daarentegen leidde MTPPE 
behandeling van muizen die relatief infectiegevoelig waren tot een vermindering van de 
afweer. Deze effecten bleken te correleren met het vermogen van MTPPE om leukocyten uit 
het beenmerg te recruteren. In tegenstelling tot de effecten verkregen met MTPPE, bleeker 
bij de IFN--y gelnduceerde afweer tegen L. monocytogenes infectie geen relatie te zijn met de 
genetisch bepaalde infectiegevoeligheid. Toediening van IFN--y leidde in beide 
muizenstamrnen, tot een verhoogde antibacteriele bescherming, en was niet gerelateerd aan 
het vermogen van IFN-')' om leukocyten uit het beenmerg te recruteren. 
In de door MTPPE en IFN--y gelnduceerde afweer tegen L. monocytogenes infectie zijn 
behalve de macrofaag waarschijnlijk ook andere celtypen betrokken. Dit kan geconcludeerd 
worden uit de waarneming dat blootstelling van macrofagen in vitro aan MTPPE geen effect 
heeft op de intracellulaire vermenigvuldiging van L. monocytogenes. Blootstelling van de 
macrofagen aan IFN--y resulteerde slechts in verhindering van de intracellulaire bacteriele 
vermeerdering. Onze in vivo en in vitro bevindingen suggereren dat de door MTPPE en IFN-
'Y gelnduceerde verhoogde antibacteriele bescherming tot stand komt via verschillende 
mechanisrnen. 
Omdat de infectiebescherming in patienten met verminderde weerstand voor een langere 
periode noodzakelijk is, werd onderzocht wat de effecten waren van MTPPE in de minder 
toxische, liposomaal-ingekapselde vorm (LE-MTPPE). De studies werden verricht in de 
modellen van K. pneumoniae infectie. De artificieel-gei'nduceerde sepsis kon worden 
voork6men middels een enkelvoudige dosis van MTPPE (Hoofdstuk 4). LE-MTPPE was 
eveneens effectief, zelfs bij een 2-voudig lagere dosis. Niet aileen in de lever en de milt, 
organen rijk aan cellen van het MPS, werd killing waargenomen, ook in de long en denier, 
organen die vee! minder cellen van het MPS bevatten. In de natuurlijk-gelnduceerde K. 
pnewnoniae sepsis bleek een enkelvoudige dosis MTPPE of LE-MTPPE slechts ten dele 
effectief (Hoofdstuk 6). Het therapeutisch effect van LE-MTPPE kon worden verhoogd door 
de stof herhaaldelijk prophylactisch toe te dienen. Dit onderstreept het belang van liposomale 
inkapseling van MTPPE, aangezien deze minder toxische formulering herhaaldelijk toedienen 
mogelijk maakt. 
Vooral voor patienten met verminderde weerstand is versterking van de niet-specifieke 
afweer door toediening van immunomodulatoren van groat belang. Deze patienten zijn vaak 
leukopenisch. Onderzocht werd wat de relatieve bijdrage was van enerzijds het recruteren van 
leukocyten, anderzijds het aktiveren van weefselmacrofagen, beide effecten ge!nduceerd door 
MTPPE of LE-MTPPE. In het model van natuurlijk-ge!nduceerde K. pneumoniae sepsis 
waarin bacterien intraperitoneaal gelnoculeerd worden, was het mogelijk een onderscheid te 
maken tussen de twee genoemde effecten, omdat de recrutering van leukocyten en het 
fagocyterend vermogen van deze leukocyten konden worden gekwantificeerd. Het recruteren 
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van leukocyten bleek van ondergeschikt belang in de door MTPPE- of LE-MTPPE-
gelnduceerde bescherming tegen K. pneumoniae infectie (Hoofdstuk 5). Daarentegen bleek 
de activatie van weefselmacrofagen in lever en milt door MTPPE of LE-MTPPE wei van 
groat belang. De klinische relevantie van deze bevinding is, dat patienten met een 
verminderde weerstand die leukopenisch zijn, ook voordeel zouden kunnen hebben van 
behandeling met LE-MTPPE. 
De waarneming dat de door MTPPE- en LE-MTPPE-gelnduceerde recrutering van 
leukocyten in het model van K. pneumoniae infectie niet significant bijdroeg aan de afweer 
tegen een lokale infectie is tegengesteld aan de bevindingen in het L. monocytogenes model, 
waarin wei een correlatie tussen de door MTPPE-ge'induceerde recrutering van leukocyten 
en het therapeutisch effect bestond. 
Een groot dee! van de liposomen die MTPPE bevatten bleek terecht te komen in de 
lever en de milt, organen die belangrijk zijn voor het wegvangen van bacterien uit het bleed 
(Hoofdstuk 7). Aangetoond werd dat cellen die K. pneumoniae hadden opgenomen meestal 
geen LE-MTPPE bevatten. Geconcludeerd kan worden dat LE-MTPPE niet rechtstreeks 
macrofagen stimuleert tot een verhoogde opname of killing van bacterien. Mede gelet op het 
feit dat blootstelling van macrofagen in vitro aan LE-MTPPE niet leidt tot een verhoogde 
opname of tot killing van K. pneumoniae, lijkt het waarschijnlijk dat naast macrofagen ook 
andere celtypen hierbij betrokken zijn en dat cornmunicatie tussen de verschillende cellen door 
middel van cytokines daarbij noodzakelijk is. 
In het model van deL. monocytogenes infectie leidde toediening van MTPPE of IFN--y 
in de liposomaal-ingekapselde vorm eveneens tot verhoogde antibacteriele bescherming 
(Hoofdstuk 8). De liposomale formuleringen van MTPPE en IFN--y waren effectief bij een 
respectievelijk 33- en 66-voudig lagere dosis, vergeleken bij de stoffen in de vrije vorm. In 
deze gelnduceerde antibacteriele bescherming bleek de immunomodulator/lipid ratio van 
belang. Niet-therapeutische doses van MTPPE of IFN--y in de liposomaal-ingekapselde vorm 
hadden wei effect wanneer ze werden toegediend in een grotere hoeveelheid lipid. 
Het gelijktijdig blootstellen in vitro van L. moncytogenes geinfecteerde macrofagen aan 
zowel MTPPE als IFN--y, resulteerde in een synergistisch antibacterieel effect, namelijk 
killing van intracellulaire bacterien. Reactieve zuurstofmetabolieten en stikstofmetabolieten 
bleken een rol te spelen in de door MTPPE plus IFN--y ge!nduceerde bacteriele killing. De 
waarde van dit synergistisch effect voor de infectiebehandeling is onduidelijk, omdat 
gelijktijdige blootstelling van macrofagen aan beide immunomodulatoren na intraveneuze 
toediening naar verwachting zeer beperkt is. Daarom werd onderzocht of het synergistisch 
effect benut kan worden na toediening van liposomen waarin zowel MTPPE als IFN--y zijn 
ingekapseld. Doses vao MTPPE en IFN--y die niet effectief waren wanneer toegediend in 
afzonderlijke liposomen, bleken wei effectief in de bescherming tegen L. monocytogenes 
infectie wanneer toegediend na inkapseling in dezelfde liposomen. 
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